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Abstract 
Increased generation of reactive oxygen species (ROS) and an altered redox status have 
long been observed in several types of cancer. This biochemical property of cancer cells 
might be exploited for therapeutic benefits since it might be possible to preferentially 
eliminate these cells by pharmacological ROS insults. Compounds able to modulate the 
intracellular redox state of cells have been developed, which effectively, yet also selectively, 
appear to kill cancer cells. Among the various agents employed to modulate the intracellular 
redox state of cells, certain redox catalysts containing quinone and chalcogen moieties have 
shown considerable promise since they are non-toxic on their own yet develop an effective, 
often selective cytotoxicity. A simple synthetic method based on the Passerini and Ugi 
multicomponent reactions has been developed for the synthesis of multifunctional redox 
catalysts. This method allowed the synthesis of a representative set of agents combining two, 
three or even four redox centres in one molecule in a good yield. 
When incubated with cancer cells these multifunctional agents inhibited cell proliferation 
and induced both cell cycle delay and apoptotic cell death in low, often sub-micromolar 
concentrations. The cause was obviously OS, which was reflected by an enhanced ROS level 
together with a significant decrease in reduced glutathione. Interestingly, some of these redox 
active compounds showed quite low toxicity with normal human fibroblasts and endothelial 
cells, supporting the notion that such compounds might have a selective anticancer activity. 
Chemogenomic assays using a mutant library of Saccharomyces cerevisiae were used to look 
for chemical-genetic interactions. Analyzing the resulting chemical-genetic interaction 
profiles afforded a set of sensitive mutants. The corresponding knocked out genes of these 
mutants play a major role in the antioxidant defence system and are pivotal for the removal of 
toxic oxidants. Therefore, deletion of the respective genes might cause an OS sensitive 
phenotype of the mutant. These observations were in excellent agreement with the other cell-
based assay performed as a part of this study. Finally, some of these compounds showed a 
potent antimicrobial activity evaluated against different fungal and bacterial strains. 
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Kurzdarstellung 
Seit langem wird in mehreren Krebsarten eine erhöhte Generierung von reaktiven 
Sauerstoffspezies (ROS) und ein veränderter Redox-Status beobachtet. Diese biochemische 
Eigenschaft von Krebszellen könnte für therapeutische Zwecke genutzt werden, indem diese 
Zellen durch eine weitere Erhöhung des ROS-Levels eliminiert werden können. Wirkstoffe, 
die den intrazellulären Redox-Status der Zellen modulieren, wurden hier entwickelt. Diese 
können effektiv aber auch selektiv Krebszellen abtöten. Von den verschiedenen untersuchten 
Substanzen sind vor allem Redoxkatalysatoren, die Quinone- und Chalcogenreste enthalten, 
Erfolg versprechend. Sie sind an sich nicht toxisch, zeigen aber eine effektive und selektive 
Zytotoxizität. Für die Synthese von solchen multifunktionalen Redoxkatalysatoren wurde 
eine einfache synthetische Methode basierend auf den Passerini und Ugi Multikomponenten 
Reaktionen entwickelt.  Diese Methode ermöglicht die Synthese eines repräsentativen Satzes 
von Substanzen mit hoher Ausbeute. Diese Substanzen enthalten zwei, drei oder sogar vier 
Redox-Zentren in einem Molekül. 
Diese multifunktionalen Substanzen inhibieren die Zellproliferation in Krebszelllinien. 
Im niedrigen micromolaren Konzentrationsbereich hemmen sie den Zellzyklus und 
induzieren Apoptose. Diese Wirkung wurde durch oxidativen Stress (OS) vermittelt, was 
durch einen erhöhten ROS-Level zusammen mit einer deutlichen Abnahme von reduziertem 
Glutathion belegt werden konnte. Interessanterweise zeigen diese redox-aktiven Substanzen 
nur geringe toxische Effekte in primären humanen Fibroblasten sowie Endothelzellen, was 
die Annahme unterstützt, dass diese Substanzen einen selektiven Effekt auf Tumorzellen 
haben. Um chemo-genetische Wechselwirkungen dieser Stoffe zu identifizieren, wurden 
Experimente mit einer Bibliothek von Saccharomyces cerevisiae Mutanten durchgeführt. 
Dabei wurden mehrere Mutanten entdeckt, die sensitiv auf diese Stoffe reagieren. Die in 
diesen Mutanten deletierten Gene sind besonders bei der antioxidativen Kontrolle der Zellen 
von Bedeutung und spielen eine Schlüsselrolle bei der Beseitigung von toxischen Oxidantien. 
Die Deletion solcher Gene kann zu einem Phänotyp führen, der besonders empfindlich auf 
oxidativen Stress reagiert. Diese Ergebnisse stützen und bestärken die aus den zellbasierten 
Experimenten gewonnen Daten. Schließlich zeigen einige dieser Substanzen eine starke 
antimikrobielle Aktivität gegen verschiedene Pilz- und Bakterienstämme. 
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Abbreviations 
OS Oxidative stress 
ROS Reactive oxygen species 
MCR Multicomponent reactions 
P-3CR Passerini three component reactions 
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13
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NMR   Nuclear Magnetic Resonance 
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GSH  Glutathione (Reduced) 
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Chapter I: Introduction 
Therapeutic selectivity and drug resistance are two major issues in cancer chemotherapy. 
By targeting the genetic differences between normal and cancer cells, drugs like Gleevec and 
Herceptin show promising therapeutic activity and few side effects.1 These gene-targeting 
strategies however, are still facing problems because of genetic instability of cancer cells and 
acquired drug resistance.2 Recent studies suggest that targeting the particular biochemical 
changes in cancer cells might be a feasible approach to develop a cancer therapy that does not 
lead to the development of drug resistance.3
 
Many types of cancer cells exhibit a disturbed 
intracellular redox balance, making them different from their healthy counterparts. Some 
tumours, such as solid lung carcinoma, are hypoxic, i.e. their cells are more reducing than 
normal ones, while others, such as the cells of breast and prostate cancer are naturally under 
oxidative stress (OS), and when compared to healthy cells, their reactive oxygen species 
(ROS) levels are considerably closer to the critical redox threshold at which cell death is 
induced (Figure 1). These biochemical differences between healthy and malignant tissue are 
significant, and can be used to design selective, yet
 
effective redox drugs.4 
 
1.1. Reactive Oxygen Species and the Redox Balance 
Free oxygen radicals or, more generally, ROS, are broadly defined as chemically reactive 
molecules that have specific physiological functions in living organisms. There are two types 
of ROS, those of free radicals, such as superoxide (O2
·-
), nitric oxide and hydroxyl radicals 
(OH
.
), which contain one or more unpaired electros in their outer molecular orbitals, and non-
radical ROS, which do not have unpaired electrons, including hydrogen peroxide, ozone, and 
peroxynitrite.  
Cells control ROS levels by ROS-scavenging systems which could either be enzymatic 
(e.g., by catalase, glutathione peroxidase, superoxide dismutase) or nonenzymatic (e.g., by 
glutathione, some vitamins and metals, or phytochemicals such as isoflavones, polyphenols, 
and flavanoids). ROS can be found either in the environment, as pollutants, tobacco smoke, 
iron salts and radiation, or they can be generated inside cells.  
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The most common intracellular forms of ROS are listed in Table 1, together with their 
main cellular sources and the relevant enzymatic antioxidant systems scavenging these ROS 
molecules. Normal cells produce ROS through multiple mechanisms.  
 
 
 
 
 
 
 
 
 
 
Figure 1.Cancer redox biology: a basis for therapeutic selectivity 
Normal cells can tolerate a certain level of exogenous ROS stress owing to their „reserve‟ antioxidant capacity, 
which can be mobilized to prevent the ROS level from reaching the cell-death threshold (horizontal dotted line 
in figure). In cancer cells, the increase in ROS generation may trigger a redox adaptation response, leading to an 
upregulation of antioxidant capacity and a shift of redox dynamics with high ROS generation and elimination to 
maintain the ROS levels below the toxic threshold. A further increase of ROS stress in cancer cells (red bar) 
using exogenous ROS-modulating agents is likely to cause elevation of ROS above the threshold level, leading 
to cell death. 
(Nat. Rev. Drug Discov. 2009, 8, 579-591) 
 
Mitochondrial respiration is considered to be the major source of ROS in the cell. 
Electrons leaking from the mitochondrial respiratory chain may react with molecular oxygen, 
resulting in the formation of superoxide, which can subsequently be converted to other ROS. 
The increase in ROS in some cancer cells has several causes. On the one hand, the increase of 
NADPH oxidase activity in malignant cells can lead to an increase in hydrogen peroxide 
concentrations. NADPH oxidase is regulated by the GTPase Rac1, which is itself 
downstream of the protooncogene Ras, linking cancer to ROS-production.5 Similarly, in most 
breast cancers, thymidine phosphorylase has been found to be overexpressed and its activity 
has been linked to increased ROS concentrations in tumour cells in vitro.6  
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This enzyme converts thymidine to thymine and 2-deoxy-D-ribose-1-phosphate. The 
latter is a highly reducing sugar able to glycosylate proteins and to generate oxygen radicals.  
On the other hand, an increase in ROS can also occur because of the alteration in the 
activity of antioxidant enzymes.  
 
Table 1. The major ROS molecules and their metabolism 
ROS molecule Main sources Enzymatic defence systems Products 
Superoxide (O2
.-
) „Leakage‟ of electrons from the 
electron transport chain  
Activated phagocytes  
Xanthine oxidase  
Flavoenzymes 
Superoxide dismutase (SOD) H2O2 + O2 
Hydrogen peroxide (H2O2) From O2
.- via superoxide dismutase 
(SOD) 
NADPH-oxidase (neutrophils) 
Glucose oxidase 
Xanthine oxidase 
Glutathione peroxidase 
Catalases 
Peroxiredoxins (Prx) 
H2O+ GSSG 
H2O+ O2 
H2O+ GSSG 
Hydroxyl radical (
•
OH) From O2
.-  and H2O2 via transition 
metals (Fe or Cu) 
(Fenton's reaction) 
Fe
2+
 + H2O2 ----> Fe
3+
 + 
.
OH + OH
-
 
  
Nitric oxide (NO) Nitric oxide synthases  GSNO 
(Free Radical Biology and Medicine 2001, 31, 1287-1312) 
ROS are well recognised for playing a dual role both as defender and destroyer species, 
they act as a double edged sword, i.e., they can either be harmful or beneficial to living 
systems. Beneficial effects of ROS occur at low/moderate concentrations, for example in 
defence against infectious agents; as they are used by the immune system as a way to attack 
and kill pathogens, in the function of a number of cellular signalling systems, and in the 
induction of a mitogenic response. On the other hand, the overproduction of ROS on one side 
and a deficiency of enzymatic and/or non-enzymatic antioxidants on the other side, may 
cause potential biological damage, termed OS.  
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OS is considered to be a result of the disturbance in the equilibrium status of pro-oxidant/ 
antioxidant reactions in living organisms. The excess ROS can damage cellular lipids, 
proteins, or DNA thus inhibiting their normal function.7 
 Because of this, OS has been implicated in a number of human ailments that are 
associated with a disturbed redox balance, among them various types of cancer, 
neurodegenerative diseases, and bacterial and viral infections, as well as disorders which 
occurs in the ageing process.8  
 
A       B 
 
Figure 2. Redox balance and oxidative stress  
A) Under physiological conditions, normal cells maintain redox homeostasis with a low level of basal ROS by 
controlling the balance between ROS generation (pro-oxidants) and elimination (antioxidant 
capacity/defense). 
B) Oxidative stress could be found in biological systems when there is an overproduction of ROS on one side 
and a deficiency of enzymatic and non-enzymatic antioxidants on the other. 
(J. Cell. Biochem. 2008, 104, 657-667) 
 
The fine balance between beneficial and harmful effects of free radicals is an important 
aspect in living organisms and is achieved by mechanisms called “redox regulation” (Figure 
2). The process of “redox regulation” protects living organisms from various oxidative 
stresses and maintains “redox homeostasis” by controlling the redox status in vivo.9 
 
1.2. Assessment of Oxidative Stress 
Numerous methods have been used for estimating the oxidizing environment inside the 
cell. Among the most commonly used probes is 2`,7`-dichloro(dihydro)fluorescein diacetate 
(DCFH-DA) and  dihydroethidium (DHE) for the detection of intracellular ROS formation 
and 5,5'-dithiobis(2-nitrobenzoate) (DTNB) for the detection of intracellular reduced 
glutathione levels.10 
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OOO O O
Cl Cl
COOH
H
2`,7`-dichlorodihydrofluorescein diacetate (DCFH-DA)
(non fluorescent, cell permeable)
CELL MEMBRANE
OHO OH
Cl Cl
COOH
H
intracellular esterases
2`,7`-dichlorodihydrofluorescein (DCFH)
(non fluorescent)
OHO O
Cl Cl
COOH
2`,7`-dichlorofluorescein (DCF)
(fluorescent)
oxidation
a) Dichlorofluorescein assay (DCF) 
DCF assay is considered to be a general indicator of ROS, reacting with H2O2, ONOO
−
, 
and lipid hydroperoxides.11 It has been also used to implicate O2
.-
 production, as H2O2 is 
considered a secondary product of O2
.-
. DCFH-DA is cell permeable, and after uptake it is 
cleaved by intracellular esterases to the non-fluorescent 2′,7′-dichlorodihydrofluorescin 
(DCFH). The latter is trapped within the cells and oxidized to the fluorescent 2′,7′-
dichlorofluorescein (DCF) by a variety of ROS (Figure 3).12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.Detection of ROS with the DCFH-DA probe 
DCFH-DA is cleaved by intracellular esterases to DCFH and oxidized by ROS to the highly fluorescent 
molecule DCF.  
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Dihydroethidium (DHE)
(non fluorescent, lipophilic, cell permeable)
N
NH2H2N
H
O2
.-Oxidation by
N
NH2H2N
Dihydroethidium radical
N
NH2H2N
OH
2-Hydroxyethidium (2-OH-E+)
Highly fluorescent
CELL MEMBRANE
O2
.-
b) Dihydroethidium assay (DHE) 
DHE is a lipophilic probe and diffuses readily across cell membranes. Once inside the 
cell, it is rapidly oxidized by superoxide to the red fluorescent 2-hydroxyethidium (2-OH-E
+
), 
which can be detected with a fluorescence detector using an excitation wavelength of 480 nm 
and an emission wavelength of 580 nm (Figure 4).10 
Formerly, it was incorrectly thought that DHE reacts with O2
.-
 to form ethidium, a 
fluorescence probe which could be detected with a fluorescence detector using an excitation 
of 500-530 nm and an emission wavelength of 590-620 nm.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Detection of O2
•− 
by the DHE probe 
The reaction of O2
•−
 with DHE produces 2-hydroxyethidium (2-OH-E
+
).  
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c) DTNB assay 
Ellman's reagent or DTNB is a symmetrical aryl disulfide which readily undergoes the 
thiol-disulfide interchange reaction in the presence of a free thiol to give 2-nitro-5-
thiobenzoic acid (NTB). The latter is ionized in water at neutral and alkaline pH to the yellow 
NTB
2-
 dianion which has a relatively intense absorbance at 412 nm. Because the 
stoichiometry of protein thiol to NTB formed is 1:1, NTB formation can be used to assess the 
number of thiols present (Figure 5). 13 
 
 
Figure 5. Detection of GSH
 
by Ellman’s reagent 
The reaction of DTNB with a thiol to yield NTB. 
 
 
1.3. Effect of Oxidative Stress on Cellular Morphology and Cytoskeleton 
OS induces cellular injury by the production and accumulation of highly active free 
radicals, which may cause damage to all types of cellular biomolecules, including DNA, 
proteins, and lipids.14
 
In different mammalian cells, OS was reported to cause basically: free-
thiol oxidation and appearance of oxidized proteins, disassembly of cytoskeleton, elevation of 
Ca
2+
, increased plasma-membrane peroxidation and permeability, release of cytosolic 
components and breaking of DNA strands.15, 16 The eligible cellular targets of ROS are 
variable depending on many factors including: (i) cell-specific antioxidant pattern, (ii) 
intensity and nature of the stress imposed (e.g., radical versus non-radical oxidant), and (iii) 
site of generation (e.g., intra- versus extracellular).17
, 18  
Due to its structure, the cytoskeleton may represent one of the preferential targets of ROS 
whatever OS is applied; indeed, cytoskeletal proteins are particularly abundant within the 
cells and several protein constituents of the cytoskeleton display highly reactive residues that 
can be oxidized easily.18  
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The actin cytoskeleton is considered to be an early target of cellular OS. The latter causes 
disruption of the normal organization of microfilaments, essentially due to oxidative 
modifications of specific methionine and cysteine sulfhydryls of actin.18  
Although the interplay between the OS and endoplasmic reticulum (ER) stress is not 
clear, both of them have been implicated to participate in the pathogenesis of a wide variety 
of diseases such as neurodegenerative disorders, diabetes, and ischemia reperfusion heart 
disease.19 
ER is an extensive intracellular membranous network involved in Ca
2+
 storage, Ca
2+
 
signalling, glycosylation and trafficking of newly-synthesized membrane and secretory 
proteins. Perturbations of these processes cause a condition defined as ER stress.20 It was 
reported that severe OS associated with accumulation of ROS and glutathione depletion may 
lead to a flux of calcium ions from the ER to the mitochondria and thereby to an activation of 
the ER stress-mediated apoptotic pathway.19  
 
1.4. Oxidative Stress as a Mediator of Apoptosis 
Cell death can follow two distinct pathways, apoptosis or necrosis. The early biochemical 
events that dictate the mode of cell death, however, are still unclear. On the one hand, 
necrosis appears to be the result of acute cellular dysfunction in response to severe stress 
conditions or after exposure to toxic agents, and is a relatively passive process associated 
with rapid cellular ATP depletion. Morphologically, necrosis is characterized by a dramatic 
increase in cell volume and rupture of the plasma membrane, with spilling of the cellular 
contents into the intercellular milieu.21  
On the other hand, apoptosis is the process of programmed cell death (PCD) that may 
occur in multicellular organisms. Biochemical events lead to characteristic cell changes 
(morphology) and death. These changes include blebbing, loss of cell membrane integrity and 
attachment, cell shrinkage, nuclear fragmentation, chromatin condensation, and chromosomal 
DNA fragmentation. Several protease families are implicated in apoptosis, the most 
prominent being caspases. Caspases are cysteine-containing, aspartic acid-specific proteases 
which exist as zymogens in the soluble cytoplasm, mitochondrial intermembrane space, and 
nuclear matrix of virtually all cells.21  
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There are two types of apoptotic caspases: initiator and effector caspases. Initiator 
caspases (e.g., CASP2, CASP8, CASP9, and CASP10) cleave inactive pro-forms of effector 
caspases, thereby activating them. Effector caspases (e.g., CASP3, CASP6, and CASP7) in 
turn cleave other protein substrates within the cell, to trigger the apoptotic process. The 
initiation of this cascade reaction is regulated by caspase inhibitors. 
Up to now, three predominant apoptotic pathways, namely death receptor-mediated 
extrinsic pathway, mitochondria-mediated intrinsic pathway, and endoplasmic reticulum (ER) 
stress-mediated apoptotic pathway have been elucidated.22 
It has been reported that ROS are able to activate both the ER stress-mediated apoptotic 
pathway (discussed in section 1.3) and the mitochondrial-mediated apoptotic pathway. The 
latter is activated by inducing loss of mitochondrial transmembrane potential, cytochrome c 
release and caspase cascade activation.19
 
Indeed, it has also been shown that the increase in 
the cytosolic free calcium concentration due to ER stress coordinates with the opening of the 
mitochondrial permeability transition pores, which is substantial in the induction of 
mitochondria-mediated intrinsic apoptotic pathway.23
 
 
1.5. Connections between Oxidative Stress and Cell Cycle 
In fact, the examination of the current literature on the effect of OS on the cell cycle 
reveals that increases in ROS-induced DNA damage are correlated with cell cycle arrest.24 
However, whether ROS-exposed cells undergo growth arrest or apoptosis may depend in part 
on where the cell resides in the cell cycle when insulted. For example, human fibroblasts 
treated with H2O2 underwent either cell cycle arrest or apoptosis. The majority of the 
apoptotic fibroblasts were in the S phase of the cell cycle, whereas growth-arrested cells were 
predominantly in the G1 or the G2/M phase.
24, 25 
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1.6. Therapeutic Strategies against Cancer 
The role of OS in promoting cancer development and in causing oxidative damage 
provides two opposite therapeutic rationales against cancer.3 On the one hand, antioxidants 
could be used to increase reactive oxygen species (ROS) scavenging capacity, thereby 
nullifying ROS signalling and suppressing tumour growth.26 
 On the other hand, an opposite approach is to treat cancer cells with pharmacological 
agents that have pro-oxidant properties, which increase ROS generation or abrogate the 
cellular antioxidant systems.27  
The use of antioxidants for cancer prevention has become popular since the 1980s. The 
function of antioxidants in physiological systems is to prevent ROS concentrations from 
reaching a damaging level within a cell and also to attenuate metastatic progress.28 Although 
treating ROS-inducing tumours with antioxidants is reasonable, ironically, the mechanism 
underlying that many chemotherapeutic agents and ionizing radiation exert on tumour cell 
kill is not associated with the increase of antioxidants, but rather the production of more ROS 
leading to irreversible OS.
  
Recent studies have shown that supplementation with antioxidants, such as vitamin C or 
E, prevents some beneficial effects of exercise, such as adaptation to stress.29
 
Moreover, 
several antioxidants used in clinical trials were associated with increased cancer incidence.30 
This undesired effect of antioxidants might be related to the prevention of oxidative damage 
in tumours and the inhibition of ROS mediated apoptosis. Antioxidants may therefore 
promote tumour-cell survival.
 
Several attempts have therefore been made during the last 10 years to use the naturally 
occurring OS to selectively kill cancer cells. In preclinical models, ROS-generating agents 
showed selective toxicity towards malignant cells under OS, raising their endogenous ROS 
levels over the threshold of toxicity as antioxidant systems become overwhelmed.4, 31 Within 
this context, currently explored ROS-inducing strategies can be divided into three main lines 
of investigation (Figure 6):  
a) Agents that directly increase ROS in cancer cells to lethal levels. 
b) Agents that inhibit antioxidant enzymes and hence raise ROS concentrations to lethal levels. 
c) Catalysts that enhance the toxicity of ROS. 
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Figure 6. Redox modulation models 
A) Normal cells posses a redox homeostasis with a low level of basal ROS. 
B) ROS generating agents increase OS in cancer cells above the critical redox threshold and cause cell death. 
C) Agents inhibit the antioxidant enzymes, increase ROS concentrations by inhibiting ROS detoxification.  
D) Catalytic agents do not change the pre-existing redox balance or ROS composition, but facilitate the 
reaction of ROS with redox-sensitive pivotal proteins and enzymes. The rapid oxidation/modification of 
these potential enzymes subsequently triggers apoptotic processes in the cancer cells. 
Please note that this is a preliminary model, and issues such as differences in redox thresholds between normal 
and cancer cells or antioxidant activities associated with certain compounds in vitro require further exploration. 
(Antiox=antioxidants; Ox=oxidants.) 
(Chemistry - A European Journal 2010, 16, 10920-10928) 
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1.6.1. Agents which Increase Intracellular ROS Concentrations 
Agents investigated as a part of this strategy include arsenic trioxide, a compound able to 
increase superoxide levels by interfering with the mitochondrial respiratory chain; redox 
cycling quinones such as β-lapachone, emodin, daunorubicin and doxorubicin, compounds 
able to generate superoxide and hydrogen peroxide via a semiquinone intermediate; 
bortezomib, a proteasome inhibitor; as well as cisplatin and elesclomol (Figure 6, panel B and 
Figure 7).32
,
 33 
 
1.6.2. Agents that Inhibit Antioxidant Enzymes  
The redox balance is maintained by various enzymes that readily neutralize many types of 
disease-causing free radicals and toxic oxidants, ridding the organism of their harmful effects. 
Superoxide dismutases (SOD) catalyze the conversion of O2
·-
 to H2O2, which can then be 
converted to water by catalase (CAT) or glutathione peroxidase (GPx). Antioxidant enzyme 
inhibitors lead to OS by inhibiting ROS detoxification. Such agents include chemically 
diverse compounds, such as 2-methoxyestradiol (a SOD inhibitor), aminotriazol (a CAT 
inhibitor), and mercaptosuccinic acid (a GPx inhibitor) (Figure 6, panel C and Figure 7).34, 35  
 
1.6.3. Catalysts that Enhance the Toxicity of ROS 
ROS generators and inhibitors of antioxidant enzymes add an additional ROS burden 
without really discriminating directly between normal and sick cells (Figure 6, panel B and 
C).  These previously mentioned strategies rely only on the pre-existing differences in ROS 
levels between cancer and normal cells. Furthermore, the dosage of such agents is a serious 
problem.4, 31, 36 These compounds are not catalytic, and therefore need to be administered in 
rather large quantities, which might lead to serious side effects.  
Alternative approaches depending upon the usage of catalytic molecules that employ 
ROS as their substrates may not only raise ROS levels, but may also exhibit selectivity to 
cells rich in ROS, without exhibiting the same chemistry in normal cells (Figure 6, panel D). 
This delicate difference between ROS generators on one hand, and ROS users on the other, 
has significant implications for selective drug design. This leads to the area of sensor/effector 
agents and to metallo-organic, selenium, and tellurium chemistry. In principle, catalysts that 
enhance the toxicity of ROS could be divided into three classes.  
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Figure 7. Chemical structures of compounds that enhance OS. 
 Agents are grouped according to their likely mode of action. Agents able to generate oxidative stressors 
(including redox-cycling quinones), agents inhibiting antioxidant enzymes and catalytic agents 
generating/enhancing the cytotoxicity of oxidative stressors. 
 
The first class consists of compounds that are able to convert less reactive ROS to a 
cocktail of more damaging species. Such catalysts include various SOD mimics, which rely 
on pre-existing ROS in cancer cells and generate a different composition of ROS (Figure 8, 
panel A).  
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Kawakami et al.37 have shown that an iron-based porphyrin complex (cis- or trans-
FeMPy2P2P, Figure 7) with SOD activity is able to convert less reactive superoxide into a 
more reactive hydrogen peroxide and hydroxyl radical cocktail, since the latter is 
considerably more reactive towards proteins, DNA and membranes. Although metal-
porphyrin complexes are highly specific for cancer cells, and do not exert a major effect on 
healthy cells, the use of such compounds has one major drawback. These complexes contain 
a metal ion that might dissociate from the complex during cellular metabolism.  
The second class of ROS user consists of agents that are able to use ROS and speed up 
their reactions with redox-sensitive proteins and enzymes, ultimately causing malfunction 
and cell death. These compounds include organochalcogen-GPx mimics which do not 
generate any new ROS but rely on the pre-existing ROS in cancer cells.38, 39  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter I  Introduction 
15 
 
A 
SOD mimicO2
.-
H2O2
GPx
SOD mimic
CAT
. OH
H2O
H2O + O2
 
 
B 
 
 
C 
O2
.-
ROS user
ROS generator
+
H2O2
Modification Proteins
Enzymes
Oxidation
 
 
Figure 8. ROS enhancer catalyst models  
A) SOD mimics rely on pre-existing ROS in cancer cells; they are able to convert less reactive superoxide into 
a more reactive hydrogen peroxide and hydroxyl radicals leading to death of malignant cells. 
B) GPx mimics; 4,4`-dihydroxydiphenyltelluride catalyzes the oxidation of thiols in cells under (externally 
induced) H2O2 stress. 
C) Combinations of ROS-generating and ROS-using agents lead to the area of sensor/effector agents and to 
metallo-organic, selenium and tellurium chemistry, which could be a potent strategy to promote ROS 
accumulation in cells and enhance cytotoxicity against cancer cells. 
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Unlike iron, copper or manganese complexes, selenium (and tellurium) agents mimicking 
the activity of the selenium enzyme GPx are chemically and metabolically stable, the 
chalcogen being covalently attached to an alkyl or aryl group. A range of GPx mimics such 
as, 4,4`-dihydroxydiphenyltelluride (Figure 6), are known to exhibit some selectivity for cells 
under (externally induced) H2O2 stress. Such agents are able to catalyze the oxidation of 
thiols in the presence of hydrogen peroxide or peroxynitrite (Figure 8, panel B).40  
Since a disturbed redox balance is not just due to one chemical species but is the result of 
a combination of various ROS, reactive nitrogen species (RNS), metal ions and deficiencies 
in antioxidant defences, and to maximally exploit the ROS-mediated cell-death mechanism as 
a therapeutic strategy, it is possible to combine ROS-generating and ROS-using (GPx-mimic 
catalytic) agents.31 This approach has been adopted to increase the catalytic efficiency and 
might be particularly useful in cancer cells that have become adapted to stress and are 
therefore resistant to traditional anticancer agents.31, 36  
Tailor-made compounds combining more than one redox centre in one molecule were 
expected to increase efficiency and selectivity (Figure 8, panel C). For example, 2-
(phenyltelluryl)-3-methyl-(1,4)naphthoquinone (Figure 7), for the first time, could be 
employed effectively in sub-micromolar concentrations i.e., at low concentration compared to 
the first generation of Se and Te GPx-like catalysts.41 The quinone redox system was chosen 
as ROS generator because of its known activity in bioreductive anticancer agents. Like the 
chalcogen centre, quinone agents utilise several mechanisms to exert a cytotoxic effect. Of 
special interest is their ability to perform redox cycling processes with triplet oxygen, 
forming superoxide and peroxide.32 This is especially advantageous as the peroxide formed as 
a result of redox cycling of the quinone moiety has the potential to activate the chalcogen 
moiety of the catalyst. Although bioreductive agents act via a different mechanism (the 
prodrug is activated by cellular reductase enzymes whose expression varies widely between 
cell lines), the sensitivity towards the status of the cellular redox environment makes quinone 
redox systems interesting to both approaches. 
Quinones can undergo either one-electron or two-electron reductions. The first one might 
be mediated by microsomal NADPH P450 reductase, NADH cytochrome b5 reductase or 
mitochondrial NADH-oxidoreductase to form the corresponding semiquinone radical. 
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 Alternatively, a two electron reduction is mediated by NAD(P)H:quinone oxidoreductase 
(nqo1) (DT-diaphorase) to form the corresponding hydroquinone (Figure 9). The driving 
force is the formation of a fully aromatic system. Under aerobic conditions, the semiquinone 
radical and the hydroquinone can be oxidized to the parent quinone by molecular oxygen.42 
 This process, the reduction by a reductase followed by auto-oxidation, yields the toxic 
superoxide anion radicals (O2
·-) and is known as “quinone redox cycling". It is oxygen-
dependent and continues until the system becomes anaerobic. In general, the redox cycling of 
quinones in cells would quickly lead to conditions of OS via the formation of ROS capable of 
inflicting damage. Therefore, the redox cycling of quinonoid drugs and other related 
compounds has been implicated widely as a mechanism for their cytotoxicity.32  
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Figure 9. Redox cycling of quinones 
Quinones can be bioreduced to semiquinones via a one-electron process. In the presence of oxygen the quinone 
can be regenerated, forming superoxide. Alternatively, a two-electron bioreduction of quinones leads to the 
hydroquinone anion. 
(J. Am. Chem. Soc. 2010, 132, 5469-5478) 
 
1.7. Synthesis of Redox Modulator Agents 
The desire to increase the selectivity for cancer cells under OS has recently stimulated the 
synthesis of considerably more complicated multifunctional agents, which are tailored 
according to the biochemical redox signature of cancer cells and often combine two, three or 
even more functionalities (e.g. redox centres, metal binding sites) in one molecule.  
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Various synthetic avenues have been reported including: nucleophilic substitution, amino 
alkylation, and amide coupling. These avenues were used to generate a vast number of such 
multifunctional catalysts, which are chemically diverse and, depending on their structure, 
exhibit various interesting biological activities.43 
 
1.7.1.  Nucleophilic Substitution by Redox Active Chalcogen Moiety at Quinone Core 
Structure 
The direct attack of nucleophilic selenolate or tellurolate compounds at suitable 
bromoquinones was previously reported.44
,45 This approach enables the generation of 
compounds combining two to four redox centres relevant to OS (Figure 10). While this one-
step synthetic method is attractive because of its comparable simplicity, its scope appears to 
be limited by the chemical diversity, number of compounds achievable, and low yields 
especially in case of tellurium derivatives. In the case of compound 3n, for instance, yields of 
just 9% have been obtained.36
,39 
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Figure 10. Schematic overview of the synthesis of redox modulators by nucleophilic 
substitution  
NaBH4 was added to a solution of the appropriate dichalcogenide in ethanol (the thiophenol was used in case of 
sulfur analogues, NaBH4 was not required in this case) and the mixture was stirred until the solution turned 
colourless. A solution of the bromoquinone in ethanol was then added trough the rubber septum and the reaction 
mixture was further stirred at room temperature and monitored via thin layer chromatography for completion. 
 
1.7.2.  Aminoalkylation 
Aminoalkylation of the quinone by various chalcogen-containing amines was then 
explored to overcome the previous limitations.46, 47 This reaction proceeds via nucleophilic 
attack of the amine-based nucleophile at the quinone (Figure 11). Mechanistically it 
resembles the method described in section 1.7.1., with two significant differences: Firstly, 
aminoalkylation is a Michael addition reaction targeting quinones, and not bromoquinones. 
Secondly, the reactivity is controlled by the amine and not by the chalcogen (yet see below). 
 This method was employed successfully to synthesize compounds combining a 
naphthoquinone with one or two sulfur or selenium moieties in a yield of around 20 to 35%.  
Chapter I  Introduction 
20 
 
Although this method shows considerable promise for the synthesis of multifunctional 
sulfur  and selenium agents, it could not (yet) be used for the synthesis of the corresponding 
tellurium analogues. One may speculate that the long reaction time of three days, combined 
with the oxidizing conditions required to re-oxidize the semi- or hydroquinone to quinone 
(i.e. presence of air), may adversely affect the tellurium moiety.43 
 
 
Figure 11. The aminoalkylation method 
A solution of appropriate chalcogen-containing amine in ethanol was added dropwise to an ethanolic solution of 
quinone. The mixture was then stirred for three days on air and in the dark. The reaction was monitored via thin 
layer chromatography for completion. A selection of compounds synthesized according to this method is shown. 
(Org. Biomol. Chem. 2009, 7, 4753-4762) 
 
1.7.3.  Amide Coupling  
The amide coupling method is based on amide bond formation between acid and amine, a 
reaction used extensively in peptide synthesis and renowned for its wide applicability and 
mild conditions. This method is used to synthesize a range of compounds, some of which are 
shown in Figure 12. 
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Figure 12. The amide coupling method 
Individual components carrying different functional groups are synthesized first and then assembled in a final, 
straightforward step. This method employs „linkers‟, which attach to the quinone via a carbon or nitrogen atom 
(panel a and b, respectively). A selection of compounds synthesized according to this method is shown.  
(Org. Biomol. Chem. 2009, 7, 4753-4762) 
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In the first step, chalcogen-containing amines and quinone-containing carboxylic acid 
building blocks were obtained. It is possible, for instance, to attach a carbon chain to the 
quinone via oxidative decarboxylation of an acid, such as glutaric acid (Figure 12, panel a). 
Similarly, primary amines may be attached to quinones to form secondary amines (Figure 12, 
panel b).48, 49  
Amide coupling works well for sulfur, selenium and tellurium providing compounds in 
rather good yields of around 50 to 60% (Figure 12). The preparation of the individual 
building blocks and the coupling reaction itself can be performed under rather mild 
conditions. It is also possible to „switch‟ the acid and amine functions, i.e. to generate amine-
bearing quinones and chalcogen-containing acids. This method is suitable for the creation of 
a small library of agents, but is limited by the number of building blocks which can be 
assembled at one time.43 
 
1.8. Multicomponent Reactions (MCRs) 
Although amide coupling may be limited by the fact that just two building blocks (acid 
and amine) can be combined at a time, similar building blocks can be used in MCRs. MCRs 
are chemical transformations in which three or more reactants form a product derived from 
all of the inputs and they have been known for over 100 years. The development of MCRs is 
an efficient aspect in modern drug discovery for the preparation of so-called “substance 
libraries” from which pharmaceutical lead structures might be selected for the treatment of 
different diseases.  
Although it would be difficult to identify the first example of a MCR, the Hantzsch 
dihydropyridine (DHP) synthesis was reported in 1882,50
 
followed by the Biginelli 3CR in 
1893.51 The first isocyanide-based MCRs were disclosed by Passerini (3CR) and Ugi (4CR) 
in 1921 and 1959, respectively (Figure 13).52 Many subsequent variants of the Passerini and 
Ugi reactions that capitalize on the unique reactivity of isocyanides have subsequently been 
described. During this time, MCRs have also found wide application in the synthesis of 
natural products and other targets of interest.53  
 
Chapter I  Introduction 
23 
 
R1
O
CO2R2
R2 NH2
R3
O
H
N
R2
R1
CO2R2R2O2C
R1
R3
R1
O
CO2R2
NH2 R3
O
H
N
NH
H
O
R2O2C
R1
R3
H2N
O
R1
O
OH R3
O
H
N C
R4 R4
H
N
O
O
R3
R1
O
R1
O
OH R3
O
H
N
C
R4 R4
H
N
N
O
R3
R2
R1
O
R2 NH2
 
Figure 13. Timeline of discovery of multicomponent reactions (MCRs) 
The Hantzsch dihydropyridine (DHP) synthesis was reported in 1882, followed by the Biginelli 3CR in 1893. 
The first isocyanide based MCRs were disclosed by Passerini (3CR) and Ugi (4CR) in 1921 and 1959, 
respectively. 
(Curr. Opin. Chem. Biol. 2010, 14, 371-382) 
 
Generally, there are different classification schemes of MCRs possible, e.g. according to 
the reaction mechanisms, the components involved, or their intrinsic variability.54 Special 
subclasses are isocyanide based MCRs (IMCRs).55 They are particularly interesting because 
they are more versatile and diverse than the remaining MCRs. The great potential of 
isocyanides for the development of multicomponent reactions lies in the diversity of bond 
forming processes available, their functional group tolerance, and the high levels of chemo-, 
regio-, and stereoselectivity often observed.56  
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1.8.1.  Isocyanides 
Isocyanides, formerly known as isonitriles, are compounds, which contain a truly 
extraordinary functional group. They are the only class of organic compounds with a formally 
divalent carbon that could react with nucleophiles and electrophiles at the same atom, leading 
to the so-called α-adduct. In contrast other functional groups react typically at different atoms 
with either both nucleophiles or electrophiles.  
Almost all commercially available isocyanides are volatile and carry a repulsive odor. 
Other liquid isocynides do not smell and, in general, higher molecular weight isocyanides are 
often solid and odorless. 
 
1.8.2.  Histroy of isocyanides 
Isocyanides were first synthesized in 1859 by Lieke.57 The classical syntheses were then 
developed in 1867 by Gautier58 and Hoffmann.59  For a whole century, the chemistry of 
isocyanides stood out because of their unpleasant smell, which forced the chemist to work in 
outdoors space. In this period, the most interesting reactions were Passerini‟s introduction 
and investigation of his three component conversions in 1921-1931.60 The isocyanides 
became generally well available by 1958, and shortly after, Ugi et al.61 introduced the four-
component reaction of the isocyanides, which is, since 1962, referred to as the Ugi reaction 
(U-4CR).  
 
1.8.3.  Preparation of Isocyanides 
Isocyanides are relatively unavailable commercially and can be challenging to prepare. 
Even though dozens of methods for the preparation of isocyanides have been described,62 the 
most common method of isocyanide preparation is by dehydration of formamides, which is 
considered the method of choice regarding cost, yield, and execution in most cases.63, 64 
Depending on which further functionalities are present, many alternative production methods 
can be drawn upon (Table 2). 
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Table 2. Important methods for the preparation of isocyanides. 
Method Example
*
 Reference 
Lieke, 1859  
57
 
Meyer, 1866 
 
65
 
Hoffmann, 1867 
 
59
 
Hoffmann, 1870 
 
66
 
Ugi, 1958 
 
67
 
Appel, 1972 
 
68
 
SchÖllkopf, 1971 
 
69
 
Barton, 1988 
 
70
 
Gassman, 1982 
 
71
 
Baldwin, 1990 
 
72
 
Kitano, 1998 
 
73
 
*
 DABCO = 1,4-diazabicyclo[2.2.2]octane, TMS = Me3Si, Tol = tolyl. 
(Angew. Chem. Int. Ed Engl. 2000, 39, 3168-3210) 
 
Today most MCR chemistry performed with isocyanides relates to the classical reactions 
of Passerini and Ugi. Indeed, the large number of different scaffolds now available are mostly 
built on these two MCRs and their combination with other types of reactions. 
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1.8.4. The Passerini Reaction  
The Passerini reaction is a three-component condensation reaction of carboxylic acid, 
aldehyde and isocyanide with the concurrent generation of a stereogenic center to afford an 
α-acyloxyamide in a single step (Figure 14). This motif is present in the structures of many 
natural products, such as the pharmacologically active depsipeptides.74 The P-3CR reaction 
can also lead to interesting and potentially bioactive peptidomimetic compounds
 
and offers an 
inexpensive and rapid way to generate compound libraries. It is often a key step in the total 
synthesis of natural products.75
 
 
Figure 14. Passerini multicomponent reaction  
This three-component reaction between a carboxylic acid, a carbonyl compound such as a ketone or aldehyde, 
and an isocyanide, offers direct access to α-acyloxyamides. 
 
It was postulated that the reaction proceeds either via an ionic or via a concerted 
mechanism (Figure 15).55 In polar solvents such as methanol or water, the reaction proceeds 
via an ionic mechanism via protonation of the carbonyl component followed by nucleophilic 
addition of the isocyanide and carboxylate residue, respectively. The resultant intermediate 
undergoes acyl group transfer and amide tautomerization to give the α-acyloxyamide. In non-
polar solvents and at high concentrations a concerted mechanism is favorable: a trimolecular 
reaction between the isocyanide, the carboxylic acid, and the carbonyl in a sequence of 
nucleophilic additions has been proposed. The transition state [TS] is depicted as a 5-
membered ring with partial covalent or double bonding. The last step includes the acyl 
migration to the neighbouring hydroxyl group to give the desired ester.  
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Figure 15. Mechanism of the Passerini reaction 
Two different reaction pathways have been hypothesized: 
A) In polar solvents such as methanol or water, the reaction proceeds via an ionic mechanism. 
B) In non-polar solvents and at high concentrations a concerted mechanism is likely. 
 
There is some support that the Passerini reaction proceeds via the concerted mechanism 
where the reaction kinetics depend on all three reactants and the reaction usually takes place 
in relatively non-polar solvents (in line with the transition state). There are three main factors, 
which have an influence on the rate of the Passerini reaction: acidity of the medium, 
concentration of the reagents and the polarity of the solvents. Thus, in the presence of strong 
mineral acids the reaction was complete in 1 min.76 It was also established that the Passerini 
reaction is accelerated in aprotic solvents, supporting that the Passerini reaction proceeds via 
the concerted mechanism.77  
Another important factor is the concentration of reagents, because all MCRs including the 
Passerini reaction proceed better if the reactants are present in high concentration, that is 0.5-
1 M.76  
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1.8.5. The Ugi Reaction  
The Ugi-4CR usually refers to the reaction between an amine (usually a primary amine; 
less often ammonia or a secondary amine), a carbonyl compound (aldehyde or ketone), an 
isocyanide and a carboxylic acid to give α-amido amides (Figure 16).55 Thus, this reaction is 
an extension of the Passerini three- component reaction.  
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Figure 16. Ugi multicomponent reaction  
This reaction involves a four-component condensation between an aldehyde, an amine, a carboxylic acid and an 
isocyanide which allows the rapid preparation of α-aminoacyl amide derivatives. 
 
It was postulated that the reaction involves a sequence of four steps including: a) imine 
formation (step 1), b) protonation of the imine by acid, thus strongly increasing the 
electrophilicity of the C=N bond (step 2), c) α-addition of the electrophilic iminium cation 
and the nucleophilic carboxylate anion to isocyanide (step 3), and d) intramolecular acyl-
transfer (step 4) (Figure 17). The Ugi reaction is known to work in polar aprotic solvents, like 
DMF. However, methanol and ethanol have also been used successfully.78 
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Figure 17. Mechanism of the Ugi reaction 
The mechanism is believed to involve a prior formation of an iminium by condensation of the amine with the 
aldehyde, followed by addition of the carboxylic acid oxygen and the imino carbon across the isocyanide 
carbon; the resulting acylated isoamide rearranges by acyl transfer to generate the final product. 
 
Recent research has shown that the Passerini and Ugi reactions are accelerated in water.79
 
This acceleration has been attributed to many factors, such as the hydrophobic effect and 
enhanced hydrogen bonding in the transition state.80, 81 
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The objectives of this project 
Several attempts have been made to design and synthesize multifunctional agents able to 
recognize the various ingredients of OS in cells. Needless to say, the synthesis of such 
compounds encounters increasing difficulties when moving from just one or two to three or 
more redox sites, in particular if a rather complicated selenium and/or tellurium chemistry is 
involved. 
The aim of this study is to discover suitable synthetic avenues that could be used to 
generate multi-functional agents. These agents are designed in order to represent di-, tri-, and 
even tetra-functional redox agents with multiple chalcogen and quinone redox sites. 
The potency and selectivity of toxic compounds to inhibit cell proliferation is evaluated 
by using a range of cancer cell lines and healthy primary cells. Phenotypical changes, the 
induction of cell death, OS, cell cycle delay, and apoptosis are also intended to be explored as 
a part of this study.  
Several techniques, such as immunostaining and fluorescence activated cell sorting 
(FACS) are applied for exploring the mode of action of these multifunctional compounds.
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Chapter II: Materials and Methods 
2.1.  Synthetic strategies 
While there is a strong demand for multifunctional redox agents containing sulfur, 
selenium or tellurium, synthetic avenues leading to such agents are often marred by 
difficulties and low yields. We have therefore explored three different methods for the 
synthesis of agents combining one, two, three or even four redox/metal binding sites in one 
molecule. 
 
A.  Method 1 
This method relies on the direct attack of nucleophilic selenolate or tellurolate compounds 
at suitable bromoquinones. Several compounds combining two or three redox centres were 
generated by employing the heterogeneous solvent system (water and ethyl acetate (1:1)) and 
a phase transfer catalyst (PTC, tricaprylmethylammonium chloride).  
 
Multicomponent reactions (MCRs) 
Multicomponent reactions are convergent reactions, in which three or more starting 
materials react to form a product. This allows high synthetic efficiency, a minimization in the 
formation of by-products and simple synthetic procedures.  
 
B. Method 2 (the Passerini three-component reaction (P-3CR)) 
This reaction type allows the synthesis of α-acyloxy carboxamides from a carboxylic 
acid, an aldehyde and an isocyanide.  
 
C. Method 3 (the Ugi four component reaction (U-4CR)) 
This reaction type allows the synthesis of amide bonded α-aminoacyl amide structures 
from a carboxylic acid, an aldehyde, an amine and an isocyanide.  
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2.2. Chromatography 
 Thin layer chromatography (TLC) 
Silica gel 60 F254 (with fluorescent indicator) pre-coated sheets, 20 x 20 cm wide and 0.2 
mm thick (Merck, Germany), were used for TLC analysis, during synthesis and isolation. The 
solvent systems used for TLC were mixtures of methanol and dichloromethane, or ethyl 
acetate and petroleum ether (40-65 °C) in different proportions. 
Cerium Molybdate Stain (Hanessian's Stain) was applied to the TLC as a means to 
visualize compounds on the plate. For this stain, ammonium molybdate (12 g), ceric 
ammonium molybdate (0.5 g) and concentrated sulfuric acid (15 ml) were added to 235 ml of 
distilled water. This stain is a highly sensitive, multipurpose (multifunctional group) stain.  
 
Column Chromatography (CC) 
Silica gel 60 (0.063-0.200 mm) 70-230 mesh (Merck, Germany) was used as stationary 
phase for column chromatography. The solvent systems applied for the Silica gel column 
were mixtures of methanol and dichloromethane, or ethyl acetate and petroleum ether (40-65 
°C) in different proportions.  
 
Materials and analytical methods 
Chemical reagents for the synthesis of compounds were purchased from Sigma-Aldrich-
Fluka (Darmstadt,Germany) and used without further purification unless stated otherwise. 
CHCl3 and CH2Cl2 were refluxed with phosphorus pentoxide (P2O5) and freshly distilled 
before use. THF was stored for two days over Na and then refluxed using benzophenone as 
indicator, and freshly distilled before use. Diethyl ether was stored over KOH, for two days 
refluxed using benzophenone as indicator and freshly distilled before use.  
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3-(Phenylselanyl)propanoic acid 2a82, 3-(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-
2-ylthio)propanoic acid 2b83, 5-(4-carboxyphenyl)-10,15,20-triphenylporphyrin 2f 84, 2-
(phenylselanyl)acetaldehyde 1a85, 3-(phenyltellanyl)propan-1-amine86, 3-
(phenylselanyl)propan-1-amine86, 3-(phenylthio)propan-1-amine86, 1,2-bis(2,2-
diethoxyethyl)diselane85 and benzyl 6-isocyanohexanoate 3b were synthesized  according 
to the literature.85 Reactions were carried out under argon (99.996%) using standard Schlenk 
techniques. Reaction progress was monitored by TLC on Alugram SIL G UV254 (Macherey- 
Nagel).   
1
HNMR spectra were recorded at 500 MHz, and 
13
CNMR spectra at 125 MHz on a 
Bruker (Rheinstetten) DRX 500 or Avance 500 spectrometer. Chemical shifts are reported in 
δ (ppm), expressed relative to the solvent signal at 7.26 ppm (CDCl3, 
1
HNMR) and at 77.16 
ppm (CDCl3, 
13
CNMR), as well as 3.31 ppm (CD3OD, 
1
HNMR) and 49.00 ppm (CD3OD, 
13
CNMR). Coupling constants (J) are given in Hz. 
LC-MS/MS analysis was performed using a TSQ Quantum mass spectrometer equipped 
with an ESI source and a triple quadrupole mass detector (Thermo Finnigan, San Jose, CA). 
High-resolution mass spectrometry was performed on an Accela UHPLC-system (Thermo-
Fisher) coupled to a linear trap- FT-Orbitrap combination (LTQ-Orbitrap), operating in 
positive ionization mode.  
 
General synthetic procedure for Method 1 
As a general procedure, the appropriate diselenide/ditelluride (0.6 mmol) was dissolved in 
a 1:1 mixture of water and ethylacetate (50 ml) along with the phase transfer catalyst (PTC) 
tricaprylylmethylammonium chloride (200 mg, 0.45 mmol) under nitrogen gas. NaBH4 (60-
100 mg) was added (as thiophenol was used in case of sulfur analogues, NaBH4 was not 
required in this case). The mixture was stirred until the solution turned colourless (1-3 min) 
then acetaldehyde solution (2-3 ml) was added to destroy the remaining NaBH4. The reaction 
mixture was stirred for further 5 min. A solution of bromoquinone (1 mmol) in ethylacetate 
(5 ml) was then added trough the rubber septum without opening the reaction apparatus. The 
reaction mixture was stirred at room temperature and monitored via thin layer 
chromatography (TLC). Disappearance of the bromoquinone spot indicated that the reaction 
was complete (usually between 3 to 10 min).  
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Afterwards the solution was stirred for a further 30 min on air. The violet, dark red or 
orange coloured reaction mixture (depending upon the Te, Se or S counterpart of the product) 
was diluted with 50 ml of water and extracted with diethylether or ethylacetate.  
The combined organic extracts were dried over Na2SO4 and the solvent was evaporated 
under reduced pressure. The crude product was purified by silica gel chromatography using a 
mixture of petrol ether (40-65 
o
C) and ethyl acetate as specified for each compound below. 
Yields between 76 and 94% were obtained by this method. 
 
2.3. Synthesis of building blocks for multicomponent reactions 
Several building blocks were synthesized according to literature methods. Some building 
blocks, however, have not been reported to date and were synthesized as follows: 
 
Synthesis of the aldehyde building blocks 8n and 7n 
Compound 8n was synthesized via 2-(2,2-diethoxyethylselanyl)-3-methylnaphthalene-
1,4-dione. The latter was synthesized from 1,2-bis(2,2-diethoxyethyl)diselane (237 µl, 0.6 
mmol) dissolved in a 1:1 mixture of water and ethylacetate (50 ml) along with the phase 
transfer catalyst (PTC) tricarpylmethylammonium chloride (200 mg, 0.45 mmol) under 
nitrogen. NaBH4 (76 mg, 2 mmol) was added and the mixture was stirred until the 
solution turned colorless. Acetaldehyde solution (2-3 ml) was added and the reaction 
stirred for a further 5 min. A solution of 3-bromo-2-methyl-1,4-naphthoquinone (250 mg, 
1 mmol) in ethylacetate (5 ml) was added and the reaction mixture stirred at room 
temperature for 10 min under nitrogen and for a further 30 min on air. The orange 
coloured reaction mixture was diluted with 50 ml of water and extracted with 
diethylether. The combined organic extracts were dried over Na2SO4 and solvent was 
evaporated under reduced pressure. The resulting 2-(2,2-diethoxyethylselanyl)-3-
methylnaphthalene-1,4-dione (7n) was purified by column chromatography on silica gel 
with petrol ether: ethyl acetate = 10:1.  
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Compound 8n was then synthesized in a two-phase system consisting of a solution of 7n 
(386 µl, 1 mmol) in 500 ml of ether and 500 ml of 1 M HCl. The reaction mixture was 
vigorously stirred for 24 h. After separation of the phases, the aqueous layer was re-
extracted with ether (2x) and the organic layers were washed with water (2x) and brine 
(1x). The combined organic extracts were dried over Na2SO4 and the solvent was 
evaporated under reduced pressure. 8n was purified by column chromatography on silica 
gel with petrol ether: ethyl acetate = 7:1. 
 
General procedure for the preparation of chalcogen containing isocyanide building 
blocks  
For the Ugi and Passerini reactions, chalcogen bearing isocyanide building blocks 
suitable for multicomponent chemistry were devised, including the sulfur, selenium and 
tellurium containing isocyanides.  
A mixture of 1 g of appropriate amine, 1.0-1.2 equivalents of formic acid and 1.5-2.0 
equivalents of acetic anhydride were mixed and heated for 2h. The progress of the reaction 
was monitored by TLC, and after the starting material had disappeared, the solvent was 
evaporated from the reaction mixture to give the crude N-formyl compound, essentially as an 
oily product which could be purified by chromatography on silica gel, usually with 
dichloromethane: methanol (10: 1).  
The N-formyl compound (6.05 g, 50.0 mmol) and diisopropylamine (DIPA) (19 ml, 0.14 
mol) were dissolved in CH2Cl2 (50 ml) and cooled to 0 °C. POCl3 (5.0 ml, 55 mmol) was 
added slowly and stirring was continued at 0 °C for another 30 min. Sodium carbonate (10 g) 
in H2O (50 ml) was added at room temperature in a rate so that the temperature was 
maintained between 25 and 35 °C. The mixture was stirred for 90 min at room temperature. 
H2O and CH2Cl2 (25 ml each) were added. The organic layer was separated, washed with 
H2O (3x 25 ml), dried over MgSO4 and purified by chromatography on silica gel, with petrol 
ether: ethyl acetate (8: 1) as eluent. 
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General procedure for the preparation of α-acyloxy amide via the three-component 
Passerini reaction (Method 2) 
As a general procedure, a mixture of aldehyde (1 mmol), carboxylic acid (1.2 mmol) and 
isocyanide (1.5 mmol) in 5 ml solvent (H2O was used in most cases) was stirred at room 
temperature overnight. Upon completion (monitored by TLC), 10 ml CH2Cl2 were added to 
dissolve the sticky product.  
The water layer was extracted three times with CH2Cl2, the organic layers were 
combined, dried over Na2SO4 and concentrated to yield a sticky product which was purified 
by chromatography on silica gel, with petrol ether: ethyl acetate (4: 1) as eluent.  
 
General procedure for the preparation of α-aminoacyl amide via the four-component 
Ugi reaction (Method 3) 
As a general procedure, a mixture of aldehyde (1 mmol), amine (1 mmol), carboxylic acid 
(1.2 mmol), and isocyanide (1.5 mmol) in 5 ml solvent (H2O was used in most cases) was 
stirred at room temperature overnight. Upon completion (monitored by TLC), 10 ml CH2Cl2 
were added to dissolve the sticky product. The water layer was extracted three times with 
CH2Cl2, the organic layers were combined, dried over Na2SO4 and concentrated to yield a 
sticky product which was purified by chromatography on silica gel, with petrol ether: ethyl 
acetate (5: 2).  
The synthesis of individual products, including building blocks, yields and analytical data 
are provided in the Results section. 
 
2.4. Cell culture 
The effects of the tested compounds on cell proliferation were initially assayed in vitro 
with different mammalian cancer cell lines, i.e. MCF-7 (human breast adenocarcinoma), A-
498 (human kidney carcinoma), A-431 (human epidermoid carcinoma), A-549 (human lung 
carcinoma), SW-480 (human colon adenocarcinoma) and L-929 (mouse fibroblasts). The 
primary human fibroblasts (HF) and human umbilical vein endothelial cells (HUVEC) were 
used as normal controls. The metabolic activity at different incubation times was measured 
by means of an MTT cell survival colorimetric assay. 
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Furthermore, one-dose and five-dose screens were performed independently by the 
National Cancer Institute (Bethesda, MD, USA).  58 tumour cell lines representing leukemia, 
non-small cell lung cancer, colon cancer, cancer of the central nervous system, melanoma, 
ovarian cancer, renal cancer, prostate cancer and breast cancer were used to estimate 
selectivity and to identify possible cancer targets. 
 
Solutions and media used 
 Phosphate buffered saline (PBS) 
PBS solution (pH=7.45) was prepared by dissolving one PBS tablet (Gibco, U.K.) in 500 
ml distilled water. 
 Isopropanol/HCl 
  0.4 ml of concentrated HCl was added to 100 ml isopropanol. 
 [3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide] (MTT) solution 
 1 g of MTT (98%, Sigma Aldrich) powder was dissolved in 200 ml of PBS and used 
directly without dilution. This solution was stored below 4°C, in the dark and was used 
within two weeks. 
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Apparatus used for cell culture experiments 
Apparatus                       Details 
Incubator CO2-Auto-Zero, Thermo Scientific 
Sterile Workbench Heraeus LaminAir Instruments, HBB 2472 S 
Centrifuge Eppendorf Centrifuge 5810 R 
Microscope Axiovert 35, Zeiss, Germany 
Multi-plate reader Wallac, 1420 Victor Multilabel Counter 
Autoclave Autoklavi Spa, Fedegari (Italien) 
Vortex Heidolph, REAX 1 R, Germany 
Digital multichannel Pipette Matrix Technologies Corp, Thermo Scientific 
Pipette controller Pipetus, Hirschmann 
Pipettes Cellstar, Greiner bio-One 
Falcon Flasks Falcon, Becton Dickinson, USA 
96 well plates Falcon, Becton Dickinson, USA 
Scraper Nalge nunc international, nunc, USA 
Resevoir Carl Roth, Germany 
 
Cell culture 
Cell lines were purchased from DSMZ (Braunschweig, Germany) and grown at 37°C and 
10% CO2 in the following media: MCF-7 cells in DMEM supplemented with 1% L-
glutamine and 1% non essential amino acids, A-498 cells in MEM (Lonza),  A-431 cells in 
RPMI 1640 (Gibco), L-929 cells in DMEM medium (lonza), A-549 cells in DMEM medium 
(lonza), SW-480 cells in McCoy's medium (Gibco), HUVEC cells in EBM-2 (Lonza) and HF 
cells in MEM (Gibco) supplemented with 1% L-glutamine.  
All media were supplemented with 10 % fetal calf serum (Lonza or Gibco). In all 
experiments, exponentially growing cells were used. 
MTT dye was used to measure the metabolic activity of cells which are capable of 
reducing it by dehydrogenases to a violet formazan product. Briefly, 120 µl aliquots of a cell 
suspension (50,000 cells/ml) in 96-well microplates were incubated at 37°C and 10% CO2 
and allowed to grow for two days.  
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Then 60 µl of serial dilutions of the test compounds were added and incubated for further 
24h. After 24h incubation at 37°C and 10% CO2, 20 µl MTT in PBS were added to a final 
concentration of 0.5 mg/ml. After 2 h the precipitate of formazan crystals was centrifuged, 
and the supernatant discarded.  
The precipitate was washed two times with 100 µl PBS and dissolved in 100 µl 
isopropanol containing 0.4% hydrochloric acid. The resulting colour was measured at 590 nm 
using an ELISA plate reader. 
In another experiment, 60 µl of serial dilutions of the test compounds were added to 120 
µl aliquots of a cell suspension (50,000/ml) in 96-well microplates. After 5 days incubation at 
37°C and 10% CO2, the MTT assay was performed as described before.  
All investigations were carried out in two parallel experiments. The IC50 values were 
determined as the concentrations of tested compounds, at which cell samples developed 50% 
of the absorbance of untreated control cells as estimated from the dose–response curves. 
 
2.5.  Bioassays 
2.5.1. DCF assay  
One of the most commonly used methods for the detection of intracellular ROS 
formation. This assay is based on the oxidation of non fluorescent DCFH probe to the highly 
fluorescent DCF. Also it is considered as a general indicator of ROS, since this it reacts with 
H2O2, ONOO
-
, lipid hydroperoxides, and, to a lesser extent, O2
.-
. 
 
2´,7´-dichlorodihydrofluorescein diacetate stock solution (DCFH-DA) 
30 mM DCFH-DA stock solution was prepared by dissolving 2´,7´-
dichlorodihydrofluorescein diacetate (50 mg, 97%, Sigma Aldrich) in 3.4 ml DMSO. 
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Assay procedure 
A-431/HUVECs were seeded in a black-walled 96-well plate at a density of 10
5
 cells per 
well in RPMI 1640/ EBM-2 medium and treated with different concentrations of test 
compounds for 1 h. The cells were then stained with DCFH-DA (20 µl, 10 µM) and allowed 
to incubate for 30 min in the dark. The intensity of fluorescence was read immediately in a 
spectrofluorophotometer (DCF, λex = 485±20 nm; λem = 528±20 nm). Results were 
expressed as arbitrary units of fluorescence (Au) per 10
5
 cells.  
 
2.5.2. DHE assay  
 The intracellular ROS levels could also be assayed further spectrofluorimetrically by 
oxidation of the DHE probe. This assay is as close to being a “gold standard” for detecting 
only O2
•− 
in intact tissues or cells in the presence of other ROS. 
 
DHE stock solution 
30 mM stock DHE solution was prepared by dissolving DHE (10 mg, 95%, Sigma 
Aldrich) in 1 ml DMSO. 
 
Assay procedure 
A-431/HUVECs were seeded in a black-walled 96-well plate at a density of 10
5
 cells per 
well in RPMI 1640/ EBM-2 medium and treated with different concentrations of test 
compounds for 1 h. The cells were then stained with DHE (20 µl, 10 µM) and allowed to 
incubate for 30 min in the dark. The intensity of fluorescence was immediately read in a 
spectrofluorophotometer (DHE, λex =540±25nm; λem = 600±40 nm). Results were 
expressed as arbitrary units of fluorescence (Au) per 10
5
 cells.  
 
2.5.3. 5,5'-dithiobis(2-nitrobenzoate) assay (DTNB) 
Ellman‟s reagent (DTNB, 98%, Sigma Aldrich) was used to estimate the intracellular 
levels of thiols (primarily glutathione).  
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Preparation of stock solutions 
 Miller Phosphate buffer solution 
NaH2PO4 solution (5.3 ml, 0.2 M) and Na2HPO4 solution (94.7 ml, 0.2 M) were mixed 
together. The resulting buffer was then diluted to 0.1 M (pH=8) by adding an equal volume 
of distilled H2O (~ 100 ml).  
 L-Glutathione stock solution (GSH) 
A 10 mM stock solution of GSH was prepared by dissolving L-glutathione (50 mg, 98%, 
Sigma Aldrich) in 16 ml DMSO. 
 DTNB stock solution 
A 0.04 mM stock solution of DTNB was prepared by dissolving 5,5'-dithiobis(2-
nitrobenzoate) (50 mg, 98%, Sigma Aldrich) in 3 ml DMSO. 
 
Assay procedure 
MCF-7 cells (10
6 
cell/well) were treated with different concentrations of test compounds 
for 1 h at 37 
0
C. The cells were removed by mild trypsinization, centrifuged at 800 rpm for 5 
min, washed twice with cold PBS and lysed using 5% w/v chilled metaphosphoric acid at 4 
0
C for 2 h to extract cellular GSH.  
The suspension was then centrifuged at 13,000 rpm for 5 min and GSH was determined 
by the following method: The supernatant was mixed with 0.2 M sodium phosphate buffer 
(pH 8.0) and 0.04 mM DTNB and kept at room temperature for 10 min.  
The absorbance of the samples was recorded against reagent blank at λ=412 nm in an 
UV–Vis double beam spectrophotometer (Shimadzu-1640). The GSH levels were determined 
by comparison with a standard curve prepared with known concentrations of GSH under 
similar conditions.  
 
2.5.4. Thiophenol oxidation assay (PhSH assay) 
The GPx-like catalytic activity of the compounds was measured by monitoring the 
formation of PhSSPh formed during thiophenol oxidation in presence of H2O2. 
Reagents  
Ebselen and hydrogen peroxide (H2O2 35% in water) were purchased from Acros Organic 
(Germany). Thiophenol (PhSH) was purchased from Fluka (Germany). 
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All solvents were used dried and Millipore Direct-Q® 3 UV water was used. Spectra 
were recorded on a CARY 50Bio UV-Visible spectrophotometer (Varian). 
 
Assay procedure 
To 890 μL methanolic solution of PhSH (1 mM) containing Et3N (0,05 mM) was added 
10 μL of compound (100 μM) in DMSO. The reaction was initiated by adding 100 μL H2O2 
(2 mM) and monitored at 305 nm for 30 min at 25 °C. Negative control included compounds 
in the presence of H2O2 and compounds in the presence of PhSH. Ebselen was used as 
positive control in this assay. 
 
2.5.5. Thiobarbituric acid radcial scavenging assay (TBA assay) 
The thiobarbituric acid (TBA) assay was performed by measuring at 532 nm the 
formation of the adduct between malonaldehyde (MA) and TBA (MA-TBA). MA is 
produced by lipid oxidation.  
 
Reagents  
TBA, 2,6-di-tert-butyl-4-methylphenol (BHT), vitamin C, were purchased from Acros 
Organic (Germany). Sodium dodecyl sulphate (SDS) and glycine were purchased from Roth 
(Germany). Arachidonic acid was obtained from Sigma-Aldrich (Germany) and FeCl3.6H2O 
from Fluka (Germany). 
 
Assay procedure 
1.5 mL aqueous solution of TBA/SDS, 1.5 mL glycine-hydrochloric acid buffer (pH 2.5) , 
0.1 mL ethanolic solution of BHT, 0.1 mL aqueous solution of FeCl3.6H2O, 0.1 mL of 
sample in DMSO (0.3 mM) and 10 μL arachidonic acid in DMSO (0.5 mM) were mixed in a 
glass vial and heated in a water bath for 15 min. A pink colour developed. After cooling, 1 
mL of acetic acid and 2 mL of CHCl3 were added, the mixture was centrifuged and the 
absorbance of the supernatant was measured using a spectrophotometer at 532 nm. Vitamin C 
was used as positive control and benchmark antioxidant in this assay. 
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2.5.6. Caspase activity assay 
The caspase-3 and -7 activities were assessed using the homogeneous, luminescent 
caspase-Glo 3/7 kit (Promega, Germany).   
 
Assay procedure 
A-431 cells seeded in white-walled 384 well plates at a density of 20,000 cells per well 
were treated with 2.8 µM of different test compounds and allowed to incubate for 1, 2, 4, 6, 
12 and 24 h at 37 
0
C, in 5% CO2 and 95% air in the dark. Caspase-Glo 3/7 reagent was then 
added and the cells were incubated at room temperature for further 30 min in the dark. The 
luminescence was measured in a plate-reading Multi-plate luminometer (1420 Victor 
Multilabel Counter, Wallac). 
 
2.5.7. Cell cycle analysis 
 The cell cycle distribution was evaluated by flow cytometric analysis of MCF-7 cells 
stained with propidium iodide (PI). 
 
Reagents and stock solutions 
 PI staining solution 
PI (2 mg, 95%, Sigma Aldrich) dissolved in 1 ml PBS. 
 RNase A stock solution 
RNase (50 mg, Worthington Biochemicals) dissolved in 1 ml deionized H2O. 
 Ice-cold 70% ethanol 
Ethanol/H2O (70%) was prepared and stored in the freezer at -20 °C. 
 Saponin washing buffer (PBS-S) 
Saponin (1 mg, Sigma Aldrich) was dissolved in 10 ml PBS. 
 
Assay procedure 
MCF-7 cells (10
6
/experiment) were treated with different test compounds at their 
respective IC50 values for 24 h. They were subsequently fixed with ice-cold ethanol/H2O 
(70%) and kept at 4 
0
C for one day. Cells were then washed with PBS-S wash buffer.  
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A mixture of propidium iodide (500 µl, 20 µg/ml) and RNAse (1 mg/ml) were used for 
staining and after 30 min, samples were analyzed by FacScan. 
 
2.5.8. Apoptosis 
Apoptosis were assessed by flow cytometric analysis of A-431 cells treated for 12 h with 
different concentrations of test compounds using the FITC Annexin  V Apoptosis Detection 
Kit II (BD Pharmingen). 
 
Assay procedure 
A-431 cells (10
6
/experiment) were treated with different concentrations (0, 8, 11 and 13 
µM) of test compounds for 12 h. They were suspended in 1 ml binding buffer. 100 µl of the 
solution were stained with a mixture of 5 µl FITC Annexin  V and 5 µl PI. After 15 min of 
incubation, 400µl of binding buffer was added and the samples were analyzed after further 30 
min by FacScan. 
 
2.5.9. Immunocytochemistry (ICC) 
The phenotypical changes of cell shape and adhesion were investigated by the technique 
of immunofluorescence. Actin filaments, microtubules and the endoplasmic reticulum (ER) 
were investigated upon treatment of the potoroo cells (PtK2) cells with/without test 
compounds. 
 
Reagents  
 Fixation solutions 
  Ice cold MeOH/acetone (50:50) 
  Paraformaldehyde (3.7 %) 
 PBS 
 Triton X-100 (0.1 %) 
 4',6-diamidino-2-phenylindole stain (DAPI) 
 Anti-fade solution 
 Primary and secondary antibodies 
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Assay procedure 
PtK2 cells were grown on cover slips in 4-well plates. Test compounds were added after 
the cells became semi-confluent and incubated for 24 h. Cells were then fixed with 3.7% 
paraformaldehyde or cold methanol /acetone (50:50) for 10 min and washed with phosphate-
buffered saline (PBS). Primary antibodies were added and incubated for 45 min and washed 
with PBS. Secondary antibodies were then added to the cells and incubated for further 45 
min.  
After washing with PBS, DAPI was added and incubated at room temperature for 5 min. 
Cover slips were mounted in anti fade mounting medium. Images were taken with a CCD 
camera attached to a flourescence microscope.  The following antibodies were used: anti-
GRP94, anti- α-tubulin, anti-mouse Alexa Fluor 488 and anti-rat Alexa Fluor 488. The actin 
filaments were stained with phalloidin Alexa Fluor 594  
 
2.5.10. Chemogenomic assay 
A chemical Genetic Interaction Approach (CGI) has proven to be a powerful means to 
study and predict the mode of action of bioactive compounds. Chemogenomic assays using 
mutant libraries of Saccharomyces cerevisiae rely on comparing the growth of each gene 
deletion strain to the wild type strain in the presence and absence of the test compounds. The 
growth inhibition of deletion strains upon exposure to compounds allows the establishment of 
a chemical-genetic interaction profile. Analyzing such profiles provides valuable information 
about the possible pathways and targets of new compounds which are not revealed that easy 
by conventional methods. 
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Apparatus and materials used for establishment of chemical-genetic interaction profiles  
Apparatus and Materials Details 
S. cerevisiae mutants COMP-SET1-A (haploid MATa), EUROSCARF 
Automated pipetting system EpMotion 5070, Eppendorf 
Sterile Workbench Heraeus LaminAir Instruments, HBB 2472 S 
Multi-plate reader Wallac, 1420 Victor Multilabel Counter 
Autoclave Autoklavi Spa, Fedegari (Italien) 
96 well plates Falcon, Becton Dickinson, USA 
384 well plates Falcon, Becton Dickinson, USA 
Resevoir Carl Roth, Germany 
Incubator 30 
0
C, Memmert, Germany 
Spectrophotometer UV-vis. recording spectrophotometer, 2401PC Shimadzu 
 
Reagents  
  Yeast growth medium 
 YPD bRoth (65 g, Sigma Aldrich) was dissolved in 1 l deionized H2O. This solution 
was sterilized by autoclaving and stored below 4°C. 
  Yeast agar medium 90 
  A mixture of malt extract (30 g, BD), bacto peptone (3 g, BD) and bacto agar (18 g, 
BD) suspended in 1 l deionized H2O. The pH of the mixture was adjusted to 5.6 by adding 10 
% acetic acid. The mixture was then sterilized by autoclaving and stored below 4°C. 
Assay procedure 
  Agar diffusion assay 
Mutants of S. cerevisiae generated by the European Archive for functional Analysis ( 
(EUROSCARF) were grown on standard YPD medium and seeded into liquid agar medium 
90 to a final optical density of 0.1 AU. Paper discs of 6 mm diameter soaked with 20 µl of 
methanolic solution of the test compounds (1mg/ml) were added to the agar plates and 
incubated at 30°C. The yeast growth was observed after 1 and 2 days. The diameter of the 
resulting inhibition zones is given as a measure of antimicrobial activity. 
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 Minimal inhibitory concentration assay (MIC) 
MIC values were determined with serial dilutions of the compounds that were added to 
the suspended mutants in liquid media using 96-well microtiter plates. The concentration 
range of tested compounds was 0.36-50 µg/ml in methanol. The seeded plates were incubated 
at 30 °C for 24 h, and then the optical density at 620 nm was recorded on a VICTOR 1420 
micro plate reader. MIC was defined as the compound concentration that induces 90% 
inhibition of growth compared to control. 
 
 High-throughput screening (HTS)  
A mutant library of S. cerevisiae  consisting  of 4,800 deletion mutants were used to 
screen for chemical-genetic interactions. 5 µl of each mutant was seeded into wells of 384-
well plates with 40 µl/well YPD medium to which 5 µl of compound was added. Liquid 
handling was done by means of an automated pipetting system. The seeded plates were 
incubated at 30 °C for 24 h, and then the optical density of each well was recorded on a 
VICTOR 1420 micro plate reader at λ = 620 nm. 
 
2.5.11.  Antifungal assay 
The potential antifungal activity of the test compounds was assayed against 
Saccharomyces cerevisiae, Candida albicans and Aspergillus niger by means of an agar 
diffusion assay. 
 
Reagents  
 Yeast growth medium 
YPD bRoth (65 g, Sigma Aldrich) was dissolved in 1 l deionized H2O. This solution was 
sterilized by autoclaving and stored below 4°C. 
 Yeast agar medium 90 
A mixture of malt extract (30 g, BD), bacto peptone (3 g, BD) and bacto agar (18 g, BD) 
was suspended in 1 l deionized H2O. The pH of the mixture was adjusted to 5.6 by adding 10 
% acetic acid. The mixture was then sterilized by autoclaving and stored below 4°C. 
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Assay procedure 
The fungi were grown on standard YPD medium and seeded into liquid agar medium 
90 to a final optical density of 0.1 AU. Paper discs of 6 mm diameter soaked with 20 µl of 
methanolic solution of the test compounds (1mg/ml) were added to the agar plates and 
incubated at 30°C. The fungi growth was observed after 1 and 2 days. The diameter of the 
resulting inhibition zones is given as a measure of antifungal activity. 
 
2.5.12. Antibacterial assay 
The potential antibacterial activity of the test compounds was assayed against 
Mycobacterium phlei, Micrococcus luteus, Pseudomonas aeruginosa, Staphylococcus aureus, 
Klebsiella pneumonia and E. coli tolC by means of an agar diffusion assay. 
 
Reagents  
 Bacteria growth medium 
A mixture of proteose peptone (8 g, Roth), bacto peptone (5 g, BD), dry meat extract (1 g, 
Merck), Hepes buffer (10 g, Roth) and bacto yeast extract (1 g, BD) were suspended in 1 l 
deionized H2O. The pH was adjusted to 7 and the mixture was then sterilized by autoclaving 
and stored below 4°C. 
 
 Bacteria agar medium 
A mixture of proteose peptone (8 g, Roth), bacto peptone (5 g, BD), dry meat extract (1 g, 
Merck), Hepes buffer (10 g, Roth), bacto yeast extract (1 g, BD) and bacto agar (17 g, BD) 
were suspended in 1 l deionized H2O. The pH was adjusted to 7 and the mixture was then 
sterilized by autoclaving and stored below 4°C. 
 
Assay procedure 
The bacteria were grown on standard bacteria growth medium and seeded into liquid agar 
medium to a final optical density of 0.01AU. Paper discs of 6 mm diameter soaked with 20 µl 
of methanolic solution of the test compounds (1mg/ml) were added to the agar plates and 
incubated at 30°C. The bacteria growth was observed after 1 and 2 days. The diameter of the 
resulting inhibition zones is given as a measure for antibacterial activity. 
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2.5.13.  Lipophilicity measurements 
 Lipophilicity is one of the properties which influences the partition of a substance in 
(biological) media. It is also an essential parameter in the development of the QSARs. High 
performance liquid chromatography (HPLC) was used as a rapid method for the 
determination of lipophilicity. In order to correlate the measured HPLC data of a compound 
with its P value, a calibration graph of logP versus chromatographic data using at least six 
reference points has to be established.  
 
Equipments and Procedure 
The retention times (tR), of the compounds were determined using a Hewlett Packard 
series 1090 HPLC fitted with a diode array detector and UV detection with maximum 
absorbance at λ=230 and λ=245 nm. Chromatographic conditions were as follows: column 
EC 125/2 mm and precolumn, Nucleosil 120-5-C18; flow rate 0.5 ml/min. Isocratic elution 
was performed with water/methanol at a volume ratio of (3:1) as the mobile phase. The dead 
time (t0) of the system was determined using thiourea (as unretained substance) with a t0 
value of 0.728 min. 
 
Evaluation of Experimental Data 
The retention factors under isocratic conditions, k, were calculated according to the 
equation k= (tR – t0)/t0. The calibration lines for the RP-HPLC retention factors (Y=A + B*X, 
with Y= logk and X= logPow) were established by linear regression with the reference data.
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Chapter III: Results 
3.1.  Synthetic avenues for multifunctional redox agents containing sulfur, selenium and 
tellurium  
Several attempts have been made to design and synthesize multifunctional agents able to 
recognize the various ingredients of OS in cells. Unfortunately, the synthesis of such agents 
is far from trivial. This chemistry is frequently marred by decomposition of products, difficult 
purification processes and low yields. Furthermore, the synthesis of such compounds 
encounters increasing difficulties when moving from just one or two to three or more redox 
sites - in particular if a rather complicated selenium and/or tellurium chemistry is involved. In 
order to resolve this obstacle posed by synthetic chemistry, we describe here the use of three 
different methods for the synthesis of the multifunctional agents. 
 
3.1.1. Method 1 
Nucleophilic substitution by direct attack of a redox-active chalcogen moiety at a 
haloquinone core structure leads to the synthesis of seven multifunctional redox compounds 
(1n-8n) (Figure 18). Modifying the original method by employing a heterogeneous solvent 
system (water and ethyl acetate) and a phase transfer catalyst (PTC) significantly improved 
the yield. In the case of compound 3n, for instance, yields of 79% have been obtained with 
the two-phase-system, compared to a yield of just 9% in the original method.  
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Figure 18. The nucleophilic substitution reaction. 
The nucleophilic substitution reaction was used for the synthesis of mono- and di-chalcogenoquinone redox 
agents 1n – 8n containing quinone and sulfur, selenium, or tellurium chalcogen redox sites. 
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The synthesis of compounds 1n to 6n has previously been reported in the literature.36
 
These compounds were synthesized according to a more general procedure for yield 
improvement purpose. The synthesis of mono- and di-substituted chalcogenoquinone 
compounds was developed as part of this study and also applied for the synthesis of hitherto 
unknown compounds 7n and 8n. 
 
Compound 7n: 2-(2,2-diethoxyethylselanyl)-3-methylnaphthalene-1,4-dione 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 10:1. It was obtained as a yellow solid. Yield = 94 %.  
TLC (petroleum ether: ethyl acetate 9:1), Rf = 0.75. 
1
H-NMR (CDCl3, 500 MHz): 8.02 – 7.98 (m, 2H), 7.63 – 7.58 (m, 2H), 4.72 – 4.70 (t, 
1H), 3.63 – 3.56 (m, 2H), 3.48 – 2.42 (m, 2H), 3.28 (d, 2H), 2.30 (s, 3H), 1.08 (s, 3H), 
1.05 (s, 3H) ppm.  
13
C-NMR (CDCl3, 75.5 MHz): 181.6 (s), 181.4 (s), 148.0 (s), 146.8 (s), 133.5 (d), 133.2 
(d), 132.9 (s), 131.9 (s), 126.9 (d), 126.6 (d), 102.8 (d), 62.2 (t, 2C), 30.9 (t), 17.3 (q), 
15.2 (q, 2C) ppm. 
Compound 8n: 2-(1,4-dihydro-2-methyl-1,4-dioxonaphthalen-3-ylselanyl)acetaldehyde 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 7:1. It was obtained as yellow solid. Yield = 90 %. 
TLC (petroleum ether: ethyl acetate 9:1), Rf = 0.55. 
1
H-NMR (CDCl3, 500 MHz): 8.02 – 7.98 (m, 2H), 7.63–7.58 (m, 2H), 3.28(d, 2H), 2.30 
(s, 3H) ppm. 
13
C-NMR (CDCl3, 75.5 MHz): 181.9 (d), 181.6 (s), 181.2 (s), 148.0 (s), 146.8 (s), 133.5 
(d), 133.2 (d), 132.9 (s), 131.9 (s), 126.9 (d), 126.6 (d), 30.9 (t), 17.3 (q) ppm. 
 LC-MS (ESI): m/z calc. 293.98, Rt = 7.01 min, m/z found 295.79 [M+H]
+
. 
HRMS: [M+H] calc. 294.9873, [M+H] found 294.9868. 
 
Multicomponent reactions  
Multicomponent reactions enable the efficient synthesis of a vast number of redox-active 
multifunctional sulfur, selenium and tellurium compounds, of which some exhibit interesting 
biological activities. 
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3.1.2. Method 2 (the Passerini three-component reaction) 
A Passerini-type reaction has been employed for the synthesis of 15 representative sulfur 
and selenium multifunctional redox agents.  
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Figure 19. Building blocks used to synthesize multifunctional redox agents.  
Acid, aldehyde and isocyanide building blocks used in P-3CR were synthesized following literature procedures 
or, in case of hitherto unknown agents, could be synthesized in sufficient yield.  
 
The Passerini reaction described here has required a range of building blocks, which 
needed to be designed and synthesized first (Figure 19). Figures 20, 21 and 22 show the 
synthesis of the aldehyde, carboxylic acid and isocyanide building blocks used as part of P-
3CR. Details regarding the synthesis of these compounds are provided in the Materials and 
Methods section. 
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Figure 20. Synthesis of aldehyde building blocks required for the P-3CR. 
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Figure 21. Synthesis of carboxylic acid building blocks required for the P-3CR. 
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Figure 22. Synthesis of benzyl 6-isocyanohexanoate. 
 
 Figure 23 provide an overview of the chemical structures of the multifunctional 
compounds synthesized via P-3CR. For details regarding the synthesis of these compounds 
see the Materials and Methods section as well as Table 3. 
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Figure 23. Chemical structures of the multifunctional compounds synthesized via the P-
3CR.  
 
Table 3. Building blocks, solvents, and yields of the synthesized compounds 1p-15p.  
Cpd. 
Building 
blocks 
Solvent 
Yield 
[ %] 
Redox 
centres 
Cpd. 
Building 
blocks 
Solvent 
Yield 
[ %] 
Redox 
centres 
1p 1b, 2b, 3a H2O 62 3 9p 8n, 2d, 3b H2O 75 2 
2p 1a, 2b, 3a H2O 68 3 10p 8n, 2c, 3b H2O 66 2 
3p 1a, 2b, 3b H2O 71 3 11p 8n, 2e, 3b H2O 85 3 
4p 8n, 2b, 3a H2O 76 4 12p 8n, 2a, 3b H2O 79 3 
5p 1b, 2b, 3b H2O 75 3 13p 1d, 2f, 3a CHCl3 93 1 
6p 8n, 2b, 3b H2O 73 4 14p 1a, 2f, 3a CHCl3 89 2 
7p 8n, 2d, 3a H2O 76 2 15p 8n, 2f, 3a CHCl3 86 3 
8p 8n, 2e, 3a H2O 54 3      
Building blocks were designed to carry one or two relevant redox or metal binding sites, which could be combined 
to larger, highly functionalized molecules with four or more biologically interesting sites. The reaction was 
performed mostly in water at high concentrations and under mild condition. 
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Sulfur and selenium multifunctional redox compounds provided by P-3CR were 
synthesized as follows: 
 
Compound 1p: 1-(tert-butylcarbamoyl)-3-(phenylselanyl)propyl3-(1,4-dihydro-2-methyl-1,4-
dioxonaphthalen-3-ylthio)propanoate 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:1. It was obtained as yellow oil. Yield = 62 %.  
TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.63.  
1
H-NMR (CDCl3, 500 MHz): 8.03-7.97 (m, 2H),  7.66-7.61 (m, 2H), 7.41-7.38 (m, 2H), 
7.17-7.14 (m, 3H), 5.84 (br s, 1H), 5.08-5.06 (t, J = 5.4, 11.8 Hz, 1H), 3.37-3.34 (t, J = 7.3, 
13.9 Hz, 2H), 2.86-2.83 (t, J = 7.9, 15.5 Hz, 2H), 2.74-2.71 (m, 2H), 2.27 (s, 3H), 2.18-2.12 
(m, 2H), 1.27 (s, 9H) ppm.  
13
C-NMR (CDCl3, 125.79Hz): 182.0 (s), 181.3 (s), 170.2 (s), 167.7 (s), 147.5 (s), 145.3 (s), 
133.8 (d), 133.5 (d), 132.7 (d, 2C), 132.6 (s), 131.9 (s), 129.6 (s), 129.1 (d, 2C), 127.1 (d), 
126.8 (d), 126.7 (d), 74.2 (d), 51.5 (s), 35.6 (t), 32.5 (t), 29.1 (t), 28.6 (q, 3C), 22.5 (t), 15.4 
(q) ppm.  
LC-MS (ESI): m/z calc. 573.21, Rt = 14.76 min, m/z found 574.15 [M+H]
+
. 
HRMS: [M+H] calc. 574.1141, [M+H] found 574.1161, [M+Na] calc. 596.0130 [M+Na] 
found 596.0980. Isotopic pattern of selenium: m/z (relative abundance %) 574.1161 (100), 
575.1194 (30), 576.1163 (18), 577.1196 (7). 
Compound 2p: 1-(tert-butylcarbamoyl)-2-(phenylselanyl)ethyl3-(1,4-dihydro-2-methyl-
1,4-dioxonaphthalen-3-ylthio)propanoate 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:1. It was obtained as yellow oil. Yield = 68 %.  
TLC (petroleum ether: ethyl acetate 5:1), Rf = 0.67.  
1
H-NMR (CDCl3, 500 MHz): 8.03-7.98 (m, 2H),  7.66-7.62 (m, 2H), 7.45-7.52 (m, 2H), 
7.18-7.12 (m, 3H), 5.98 (br s, 1H), 5.25-5.22, (dd, J = 5.1, 7.0 Hz, 1H), 3.38-3.34 (m, 
1H), 3.30-3.20 (m, 3H), 2.58-2.52 (m, 1H), 2.49-2.43 (m, 1H), 2.27 (s, 3H), 1.29 (s, 9H) 
ppm.  
13
C-NMR (CDCl3, 125.79Hz): 182.0 (s), 181.2 (s), 169.6 (s), 167.0 (s), 147.5 (s), 145.4 
(s), 133.8 (d), 133.5 (d), 132.9 (d, 2C), 132.7 (s), 131.9 (s), 129.6 (s), 129.2 (d, 2C), 127.3 
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(d), 126.8 (d), 126.7 (d), 73.9 (d), 51.7 (s), 35.3 (t), 29.0 (t), 28.9 (t), 28.6 (q, 3C), 15.4 
(q) ppm. 
LC-MS (ESI) m/z calc. 559.09, Rt = 14.33 min, m/z found 560.08 [M+H]
+
. 
HRMS: [M+H] calc. 560.1009, [M+H] found 560.1004, [M+Na] calc. 582.0829 [M+Na] 
found 582.0824. Isotopic pattern of Se: m/z (relative abundance %) 554.1064 (2), 
556.1031(20), 558.1012 (48), 560.1004 (100), 561.1038 (31), 562.1006 (21), 563.1040 (6). 
Compound 3p: 1-(benzyl hexanoatecarbamoyl)-2-(phenylselanyl)ethyl 3-(1,4-dihydro-2-
methyl-1,4-dioxonaphthalen-3-ylthio)propanoate 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 3:1. It was obtained as yellow oil. Yield = 71 %.  
TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.35.  
1
H-NMR (CDCl3, 500 MHz): 8.02-7.97 (m, 2H),  7.65-7.61 (m, 2H), 7.45-7.41(m, 2H), 7.29-
7.21 (m, 5H), 7.17-7.12 (m, 3H), 6.41 (br t, 1H), 5.37-5.33 (dd, J = 4.4, 5.8 Hz, 1H), 5.00 (s, 
2H), 3.41-3.37 (dd, J = 4.4, 13.5 Hz, 1H), 3.28-3.11 (m, 5H), 2.56-2.50 (m, 1H), 2.46-2.40 
(m, 1H), 2.27-2.41 (m, 5H), 1.59-1.53 (m, 2H), 1.48-1.42(m, 2H), 1.31-1.25(m, 2H) ppm.  
13
C-NMR (CDCl3, 125.79Hz): 182.3 (s), 181.5 (s), 173.5 (s), 170.2 (s), 168.2 (s), 148.3 (s), 
145.5 (s), 136.3 (s), 134.1 (d), 133.7 (d), 133.1 (d, 2C), 132.9 (s), 132.2 (s), 129.8 (s), 129.4 
(d, 2C), 128.8 (d, 2C), 128.4 (d), 128.3 (d, 2C), 127,5 (d), 127.6 (d), 126.9 (d), 73.9 (d), 66.4 
(t), 39.5 (t), 35.4 (t), 34.2 (t), 29.3 (t, 2C), 29.1 (t), 26.5 (t), 24.6 (t), 15.7 (q) ppm.  
LC-MS (ESI): m/z calc. 707.146, Rt = 15.16 min, m/z found 708.08 [M+H]
+
. 
HRMS: [M+H] calc. 708.1456, [M+H] found 708.1529, [M+Na] calc. 730.1456 [M+Na] 
found 730.1348. Isotopic pattern of selenium: m/z (relative abundance %) 708.1529 (100), 
709.1562 (40), 710.1530 (20), 711.1564 (5), 730.1348 (100), 731.1382 (38), 732.1350 (20), 
733.1383 (5).        
Compound 4p: 1-(tert-butylcarbamoyl)-2-(1,4-dihydro-2-methyl-1,4-dioxonaphthalen-3-
ylselanyl)ethyl3-(1,4-dihydro-2-methyl-1,4-dioxonaphthalen-3-ylthio)propanoate 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 3:1. It was obtained as yellow oil. Yield = 76 %.  
TLC (petroleum ether: ethyl acetate 2.5:1), Rf = 0.57.  
1
H-NMR (CDCl3, 500 MHz): 8.01-7.96 (m, 4H),  7.65-7.58 (m, 4H), 6.01 (br s, 1H), 
5.37-5.35 (dd, J = 5.2, 7.1 Hz, 1H), 3.69-3.65 (dd, J = 5.2, 13.2 Hz, 1H), 3.46-3.42 (dd, J 
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= 6.6, 13.2 Hz, 1H), 3.31-3.28 (t, J = 6.6, 13.2 Hz, 2H), 2.69-2.66 (m, 2H), 2.30 (s, 3H), 
2.24 (s, 3H), 1.28 (s, 9H) ppm.  
13
C-NMR (CDCl3, 125.79 Hz): 182.1 (s), 181.7 (s), 181.3 (s), 181.2 (s), 170.1 (s), 166.8 
(s), 148.7 (s), 147.4 (s), 145.6 (s), 145.5 (s), 133.8 (d), 133.7 (d), 133.5 (d), 133.4 (d), 
132.7 (s, 2C), 132.0 (s), 131.8 (s), 126.9 (d), 126.8 (d), 126.7 (d), 126.6 (d), 74.4 (d), 51.7 
(s), 35.6 (t), 29.1 (t), 28.9 (t), 28.6 (q, 3C), 17.4 (q), 15.3 (q) ppm. 
LC-MS (ESI): m/z calc. 653.09, Rt = 14.68 min, m/z found 654.20 [M+H]
+
. 
 HRMS: [M+H] calc. 654.1064, [M+H] found 654.1059, [M+Na] calc. 676.0884 [M+Na] 
found 676.0879. Isotopic pattern of Se: m/z (relative abundance %) 648.1119 (2), 
650.1086 (20), 652.1067 (47), 654.1079 (100), 655.1093 (35), 656.1061 (18), 657.1095 (7). 
Compound 5p: 1-(benzyl hexanoatecarbamoyl)-3-(phenylselanyl)propyl 3-(1,4-dihydro-2-
methyl-1,4-dioxonaphthalen-3-ylthio)propanoate 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 2.5:1. It was obtained as yellow oil. Yield = 75 %.  
TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.33.  
1
H-NMR (CDCl3, 500 MHz): 7.99-7.93 (m, 2H), 7.63-7.57 (m, 2H), 7.39-7.35 (m, 2H), 7.27-
7.20 (m, 5H), 7.16-7.12 (m, 3H), 6.33 (br s, 1H), 5.19-5.16 (m, 1H), 4.96 (s, 2H), 3.71-3.69 
(t, J= 5.4 12.1 Hz, 2H), 3.34-3.30 (t, J = 5.7, 12.4 Hz, 2H), 2.86-2.81 (t, J = 8.0, 15.9 Hz, 
2H), 2.76-2.65 (m, 2H), 2.29-2.24 (m, 5H), 2.15-2.09 (m, 2H), 1.56-1.50 (q, J = 7.2, 15.25 
Hz, 2H), 1.44-1.38 (q, J = 7.2, 14.8 Hz, 2H), 1.26-1.19 (m, 2H) ppm.  
13
C-NMR (CDCl3, 125.79Hz): 181.9 (s), 181.3 (s), 173.2 (s), 170.1 (s), 168.6 (s), 147.9 (s), 
145.2 (s), 135.9 (s), 133.8 (d), 133.4 (d), 132.7 (d, 2C), 132.5 (s), 132.1 (s), 129.5 (s), 129.1 
(d, 2C), 128.4 (d, 2C), 128.1 (d), 128.0 (d, 2C), 127.0 (d), 127.7 (d), 126.6 (d), 73.9 (d), 66.0 
(t), 39.0 (t), 35.4 (t), 33.9 (t), 32.5 (t), 29.2 (t), 29.0 (t), 26.1 (t), 24.3 (t), 22.5 (t), 15.3 (q) 
ppm.  
LC-MS (ESI): m/z calc. 721.16, Rt = 15.10 min, m/z found 721.94 [M+H]
+
. 
HRMS: [M+H] calc. 722.1556, [M+H] found 722.1685, [M+Na] calc. 744.1456 [M+Na] 
found 744.1505. Isotopic pattern of selenium: m/z (relative abundance %) 722.1685 (100), 
723.1719 (39), 724.1687 (18), 725.1721 (6), 744.1505 (100), 745.1538 (36), 746.1506 (16), 
747.1540 (5).        
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Compound 6p: 1-(benzyl hexanoatecarbamoyl)-2-(1,4-dihydro-2-methyl-1,4-
dioxonaphthalen-3-ylselanyl)ethyl3-(1,4-dihydro-2-methyl-1,4-dioxonaphthalen-3-
ylthio)propanoate 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 2.5:1. It was obtained as yellow oil. Yield = 73 %.  
TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.30.  
1
H-NMR (CDCl3, 500 MHz): 8.02-7.95 (m, 4H), 7.66-7.56 (m, 4H), 7.30-7.21 (m, 5H), 6.48 
(br s, 1H), 5.49-5.46 (m, 1H), 5.01 (s, 2H), 3.69-3.65 (dd, J = 4.5, 13.0 Hz, 1H), 3.50-3.46 
(dd, J = 6.2, 13.0 Hz 1H), 3.31-3.23 (m, 2H), 3.19-3.15 (dt, J = 6.7, 13.0 Hz, 2H), 2.67-2.64 
(t, J = 6.2, 13.0 Hz, 2H), 2.29-2.24 (m, 8H), 1.58-1.52 (m, 2H), 1.48-1.42 (m, 2H), 1.30-1.18 
(m, 2H) ppm.  
13
C-NMR (CDCl3, 125.79Hz): 182.0 (s), 181.6 (s), 181.3 (s), 181.2 (s), 173.3 (s), 170.0 (s), 
167.7 (s), 148.9 (s), 148.0 (s), 145.5 (s), 145.2 (s), 135.9 (s), 133.8 (d), 133.7 (d), 133.5 (d), 
133.4 (d), 132.7 (s), 132.6 (s), 131.9 (s), 131.8 (s), 128.5 (d, 2C), 128.2 (d), 128.1 (d, 2C), 
127.0 (d), 126.7 (d), 126.6 (d, 2C), 74.1 (d), 66.1 (t), 39.2 (t), 35.4 (t), 34.0 (t), 29.1 (t), 29.0 
(t), 28.8 (t), 26.3 (t), 24.4 (t), 17.5 (q), 15.4 (q) ppm.  
LC-MS (ESI): m/z calc. 801.151, Rt = 17.44 min, m/z found 823.89 [M+Na]
+
. 
HRMS: [M+H] calc. 802.1576, [M+H] found 802.1584, [M+Na] calc. 824.1406 [M+Na] 
found 824.1403. Isotopic pattern of selenium: m/z (relative abundance %) 802.1584 (100), 
803.1617 (43), 804.1585 (17), 805.1619 (7), 808.1610 (2), 824.1403 (100), 825.1437 (41), 
826.1405 (5), 827.1438 (3). 
Compound 7p: tert-butyl(R)-1-((1-(tert-butylcarbamoyl)-2-(1,4-dihydro-2-methyl-1,4-
dioxonaphthalen-3-ylselanyl)ethoxy)carbonyl)-2-hydroxyethylcarbamate 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 2.5:1. It was obtained as yellow oil. Yield = 76 %.  
TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.54.  
1
H-NMR (CDCl3, 500 MHz): 8.05-8.02 (m, 1H),  7.99-7.97 (m, 1H), 7.68-7.62 (m, 2H), 6.64 
(br s, 1H), 5.37-5.30 (m, 2H), 4.28 (br d, 1H), 4.16 (br s, 1H), 3.74-3.66 (m, 2H), 3.50 (br t, 
1H), 3.31-3.26 (dd, J = 8.3, 13.5 Hz, 1H), 2.29 (s, 3H), 1.37 (s, 9H), 1.29 (s, 9H) ppm.  
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13
C-NMR (CDCl3, 125.79Hz): 182.6 (s), 181.2 (s), 170.3 (s), 167.5 (s), 148.9 (s), 144.8 (s), 
134.0 (d), 133.5 (d), 132.6 (s), 132.0 (s), 126.9 (d), 126.8 (d), 80.3 (s), 63.7 (t),56.1 (s), 52.0 
(s),75.3 (d) , 77.3 (d),28.9 (t), 28.6 (q, 3C), 28.3 (q, 3C), 17.3 (q) ppm.  
LC-MS (ESI): m/z calc. 582.148, Rt = 12.58 min, m/z found 583.04 [M+H]
+
. 
HRMS: [M+H] calc. 583.1523, [M+H] found 583.1553, [M+Na] calc. 605.1306 [M+Na] 
found 605.1373. Isotopic pattern of selenium: m/z (relative abundance %) 583.1553 (100), 
584.1587 (34), 585.1555 (20), 586.1588 (4), 605.1373 (100), 606.1406 (26), 607.1374 (16), 
608.1408 (4).        
Compound 8p: tert-butyl(S)-1-((1-(tert-butylcarbamoyl)-2-(1,4-dihydro-2-methyl-1,4-
dioxonaphthalen-3-ylselanyl)ethoxy)carbonyl)-2-(2-tert-butyldisulfanyl)ethylcarbamate 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 3:1. It was obtained as yellow oil. Yield = 54 %.  
TLC (petroleum ether: ethyl acetate 3:1), Rf = 0.45.  
1
H-NMR (CDCl3, 500 MHz): 8.02-7.99 (m, 2H), 7.65-7.60 (m, 2H), 6.54-6.47 (br s, 1H), 
5.41-5.11 (m, 1H), 4.45-4.25 (m, 1H), 3.75-3.65 (m, 1H), 3.55-3.45 (m, 1H), 3.13-2.90 
(m, 2H), 2.29 (s, 3H), 1.38 (s, 9H), 1.28 (s, 9H), 1.26 (s, 9H) ppm.  
13
C-NMR (CDCl3, 125.79Hz): 181.6 (s), 181.3 (s), 170.1 (s), 169.8 (s), 166.7 (s), 148.6 
(s), 133.6 (d), 132.8 (s), 131.9 (s), 127.0 (d), 126.8 (d), 126.7 (d), 75.1 (d), 53.9 (d), 53.8 
(s), 48.8 (s), 41.1 (t), 29.8 (q, 3C), 29.7 (s), 29.1 (t), 28.6 (q, 3C), 28.3 (s), 28.2 (q, 3C), 
17.5 (q) ppm.  
LC-MS (ESI): m/z calc. 686.16, Rt = 15.87 min, m/z found 687.02 [M+H]
+
. 
 HRMS: [M+H] calc. 687.1676, [M+H] found 687.1671, [M+Na] calc. 709.1496 [M+Na] 
found 709.1491. Isotopic pattern of selenium: m/z (relative abundance %) 687.1671 (100), 
688.1705 (32), 689.1673 (18), 690.1707 (8), 698.1732 (2).        
Compound 9p: tert-butyl (R)-1-((1-(benzyl hexanoatecarbamoyl)-2-(1,4-dihydro-2-methyl-
1,4-dioxonaphthalen-3-ylselanyl)ethoxy)carbonyl)-2-hydroxyethylcarbamate 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 2:1. It was obtained as yellow oil. Yield = 75 %.  
TLC (petroleum ether: ethyl acetate 2.5:1), Rf = 0.18.  
1
H-NMR (CDCl3, 500 MHz): 8.02-7.99 (m, 2H),  7.65-7.60 (m, 2H), 7.29-7.24 (m, 5H), 7.15 
(br s, 1H), 5.50-5.45 (m, 2H), 5.05 (s, 2H), 4.25-4.15 (m, 1H), 4.05-3.95 (m, 1H), 3.85-3.65 
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(m, 2H), 3.45-3.40 (m, 1H), 3.25- 3.15 (m, 2H), 2.31-2.38 (m, 5H), 1.57-1.39 (m, 4H), 1.35 
(s, 9H), 1.27-1.21 (m, 2H) ppm.  
13
C-NMR (CDCl3, 125.79Hz): 182.1 (s), 181.3 (s), 174.3 (s), 169.9 (s), 168.1 (s), 153.7 (s), 
145.0 (s), 133.8 (d), 133.5 (d), 132.6 (s), 132.0 (s), 130.8 (s), 128.8 (s), 128.6 (d, 2C), 128.3 
(d), 128.2 (d, 2C), 127.1 (d), 126.8 (d), 80.4 (s), 74.5 (d), 66.5 (t), 63.7 (t), 56.1 (d), 39.2 (t), 
33.9 (t), 28.8 (t), 28.5 (t), 28.3 (q, 3C), 26.0 (t), 24.2 (t), 17.5 (q) ppm.  
LC-MS (ESI): m/z calc. 730.20, Rt = 13.53 min, m/z found 730.96 [M+H]
+
. 
 HRMS: [M+H] calc. 731.2097, [M+H] found 731.2077, [M+Na] calc. 753.1807 [M+Na] 
found 753.1897. Isotopic pattern of selenium: m/z (relative abundance %) 731.2077 (100), 
732.2111 (37), 733.2079 (21), 734.2113 (4), 753.1897 (100), 754.1930 (28), 755.1899 (15), 
756.1932 (4).        
Compound 10p: tert-butyl ((1-(benzyl hexanoatecarbamoyl)-2-(1,4-dihydro-2-methyl-1,4-
dioxonaphthalen-3-ylselanyl)ethoxy)carbonyl)methylcarbamate 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 2:1. It was obtained as yellow oil. Yield = 66 %.  
TLC (petroleum ether: ethyl acetate 2.5:1), Rf = 0.54.  
1
H-NMR (CDCl3, 500 MHz): 8.03-8.00 (m, 2H),  7.66-7.60 (m, 2H), 7.30-7.23 (m, 5H), 6.79 
(br s, 1H), 5.53-5.51 (m, 1H), 5.03 (s, 2H), 4.79 (br t, 1H), 3.80-3.63 (m, 3H), 3.50-3.46 (dd, 
J = 6.9, 13.8 Hz, 1H), 3.21-3.07 (m, 2H), 2.30-2.28 (m, 5H), 1.61-1.55 (m, 2H), 1.50-1.44 
(m, 2H), 1.35 (s, 9H), 1.30-1.24 (m, 2H) ppm.  
13
C-NMR (CDCl3, 125.79Hz): 181.6 (s), 181.3 (s), 173.3 (s), 168.8 (s), 167.6 (s), 156.5 (s), 
148.9 (s), 136.4 (s), 133.7 (d), 133.5 (d, 2C), 132.7 (s), 131.9 (s), 128.5 (d, 2C), 128.2 (d, 
2C), 126.9 (d), 126.8 (d), 80.6 (s), 74.4 (d), 66.1 (t), 42.3 (t), 39.3 (t), 34.1 (t), 28.9 (t), 28.8 
(t), 28.2 (q, 3C), 26.2 (t), 24.4 (t), 17.5 (q) ppm.  
LC-MS (ESI): m/z calc. 700.19, Rt = 13.83 min, m/z found 701.15 [M+H]
+
. 
HRMS: [M+H] calc. 701.1976, [M+H] found 701.1972, [M+Na] calc. 723.1707 [M+Na] 
found 723.1791. Isotopic pattern of selenium: m/z (relative abundance %) 701.1972 (100), 
702.2005 (36), 703.1974 (19), 704.2007 (2), 723.1791 (100), 724.1825 (39), 725.1825 (20), 
726.1827 (2). 
 
Chapter III  Results 
63 
 
Compound 11p: (2S)-1-(benzyl hexanoatecarbamoyl)-2-(1,4-dihydro-2-methyl-1,4-
dioxonaphthalen-3-ylselanyl)ethyl 3-(2-tert-butyldisulfanyl)-2-(pivalamido)propanoate 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 2:1. It was obtained as yellow oil. Yield = 85 %.  
TLC (petroleum ether: ethyl acetate 2.5:1), Rf = 0.18.  
1
H-NMR (CDCl3, 500 MHz): 8.03-7.99 (m, 2H),  7.65-7.61 (m, 2H), 7.30-7.22 (m, 5H), 7.04 
(br s, 1H), 5.48-5.48 (m, 1H), 5.23 (s, 2H), 5.03 (s, 2H), 3.14-3.02 (m, 3H), 2.30-2.26 (m, 
6H), 1.60-1.54 (m, 2H), 1.50-1.43 (m, 3H), 1.37 (s, 3H), 1.33 (s, 9H), 1.24 (s, 9H) ppm.  
13
C-NMR (CDCl3, 125.79Hz): 181.46 (s), 181.3 (s), 170.1(s), 169.6 (s), 167.6 (s), 148.7 (s), 
136.1 (s), 133.7 (d), 133.5 (d), 133.6 (d), 132.8 (s), 132.7 (s), 131.9 (s), 128.5 (d, 2C), 128.2 
(d, 2C), 126.9 (d), 126.7 (d), 74.8 (d), 74.5 (d), 66.5 (t), 53.9 (s), 53.4 (s), 48.6 (s),  39.4 (t), 
33.3 (t), 34.1 (t), 29.8 (q, 3C), 28.9 (t), 28.3 (q, 3C), 26.3 (t), 24.5 (t, 2C), 17.5 (q) ppm.  
LC-MS (ESI): m/z calc. 818.20, Rt = 16.13 min, m/z found 835.02 [M+NH4]
+
. 
HRMS: [M+H] calc. 818.1196, [M+H] found 835.2196, [M+NH4] calc. 857.2017 [M+K] 
found 857.2015. Isotopic pattern of selenium: m/z (relative abundance %) 835.2196 (100), 
836.2229 (47), 837.2197 (20), 840.2189(2). 
Compound 12p: 1-(benzyl hexanoatecarbamoyl)-2-(1,4-dihydro-2-methyl-1,4-
dioxonaphthalen-3-ylselanyl)ethyl 3-(phenylselanyl)propanoate 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:1. It was obtained as yellow oil. Yield = 79 %.  
TLC (petroleum ether: ethyl acetate 2.5:1), Rf = 0.43.  
1
H-NMR (CDCl3, 500 MHz): 8.02-7.97 (m, 2H), 7.65-7.61 (m, 2H), 7.45-7.41(m, 2H), 7.29-
7.21 (m, 5H), 7.17-7.12 (m, 3H), 6.41 (br s, 1H), 5.37-5.33 (dd, J = 4.4, 5.8 Hz, 1H), 5.03 (s, 
2H), 3.31-3.23 (m, 2H), 3.19-3.15 (t, J = 6.2, 13.0 Hz, 2H), 3.01-2.95 (m, 2H), 2.66-2.64 (t, J 
= 7.1, 14.0 Hz, 2H), 2.46- 2.30 (m, 5H), 1.61-1.55 (m, 2H), 1.50-1.44 (m, 2H), 1.30-1.24 (m, 
2H) ppm.  
13
C-NMR (CDCl3, 125.79Hz): 182.3 (s), 181.5 (s), 173.5 (s), 170.2 (s), 168.2 (s), 148.3 (s), 
145.5 (s), 136.3 (s), 134.1 (d), 133.7 (d), 133.1 (d, 2C), 132.9 (s), 132.2 (s), 129.8 (s), 129.4 
(d, 2C), 128.8 (d, 2C), 128.4 (d), 128.3 (d, 2C), 127.6 (d), 127.5 (d), 126.9 (d), 73.9 (d), 66.4 
(t), 39.5 (t), 35.4 (t), 34.2 (t), 32.5 (t), 29.1 (t), 26.5 (t), 24.6 (t), 22.5 (t), 15.7 (q). 
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HRMS: [M+H] calc. 756.0978, [M+H] found 756.0973. Isotopic pattern of Se: m/z (relative 
abundance %) 746.1060 (1.5), 749.1034 (5), 750.1008 (20), 752.1000 (40), 756.0973 (100), 
757.1007 (41), 759.1009 (15), 760.0977 (7). 
Compound 13p: 21H,23H-Porphine, 5-(4- ((tert-butylcarbamoyl)methyl formate)phenyl)-
10,15,20-triphenyl  
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:2. It was obtained as yellow oil. Yield = 93 %.  
TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.39.  
1
H-NMR (DMSO-d
6
, 500 MHz): 8.90-8.88 (m, 6H),  8.80-8.75 (m, 2H), 8.53-8.49 (m, 2H), 
8.39-8.25 (m,2H), 8.24-8.19 (m, 6H), 7.79-7.71 (m, 9H), 6.12 (s, 1H), 4.92 (s, 2H), 1.50 (s, 
9H), -2.75 (s, 2H) ppm.  
13
C-NMR (DMSO-d
6
, 125.79 Hz): 167.44 (s), 166.0 (s), 149.60 (s), 148.19 (s), 145.72 (s), 
142.25(s, 8C), 134.81 (d), 134.53 (d, 10C), 128.02 (d, 2C), 127.87 (d, 2C), 126.73 (d, 10C), 
120.99 (s), 120.70 (s, 4C), 118.17 (s), 77.02 (d, 2C), 52.08 (s), 29.36 (t), 28.79 (q, 3C) ppm. 
LC-MS (ESI): m/z calc. 771.32, Rt = 16.99 min, m/z found 772.18 [M+H]
+
. 
HRMS: [M+H] calc. 772.3377, [M+H] found 772.3265.   
Compound 14p: 21H,23H-Porphine, 5-(4- (1-(tert-butylcarbamoyl)-2-(phenylselanyl)ethyl 
formate)phenyl)-10,15,20-triphenyl 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:2. It was obtained as yellow oil. Yield = 89 %.  
TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.51.  
1
H-NMR (DMSO-d
6
, 500 MHz): 8.98-8.90 (m, 6H), 8.85-8.75 (m, 2H), 8.20-8.35 (m, 10H), 
7.82-7.75 (m,10H), 7.68-7.60 (m, 2H), 7.29-7.35 (m, 2H), 6.15 (s, 1H), 5.75 (t, J = 5.7, 12.4 
Hz, 1H), 3.75-3.40(m, 2H), 1.45 (s, 9H), -2.85 (s, 2H) ppm.  
13
C-NMR (CDCl3, 125.79 Hz): 167.43 (s), 165.35 (s), 165.30 (s), 147.80 (s), 142.01 (s, 10C), 
134.66 (d, 4C), 134.53 (d, 10C), 132.99 (d, 2C), 129.74 (s), 129.29 (d, 6C), 128.02 (d), 
127.82 (d), 127.32 (s), 126.73 (d, 8C), 120.71 (s, 2C), 120.45 (s, 2C), 74.4 (d), 51.81 (s), 
29.08 (t), 28.79 (q, 3C) ppm.   
LC-MS (ESI): m/z calc. 941.28, Rt = 18.40 min, m/z found 942.43 [M+H]
+
. 
HRMS: [M+H] calc. 942.2937, [M+H] found 942.2917. Isotopic pattern of Se: m/z (relative 
abundance %) 942.2917 (100), 943.2950 (63), 944.2984 (20), 945.2952 (12). 
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Compound 15p: 21H,23H-Porphine, 5-(4- (1-(tert-butylcarbamoyl)-2-(1,4-dihydro-2-methyl-
1,4-dioxonaphthalen-3-ylselanyl)ethylformate)phenyl)-10,15,20-triphenyl 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:2. It was obtained as yellow solid. Yield = 86 %.  
TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.45.  
1
H-NMR (DMSO-d
6
, 500 MHz): 8.90-8.88 (d, J = 5.27 Hz, 2H),  8.85 (s, 3H), 8.73-8.72 (d, J 
= 4.52 Hz, 2H), 8.82-8.20 (m, 8H), 8.14-8.13 (m, 2H), 8.07-8.05 (m, 1H), 7.94-7.92 (m, 1H), 
7.78-7.73 (m, 8H), 7.57-7.54 (m, 1H), 7.41-7.38 (m, 1H), 6.28 (s, 1H), 5.85-5.83 (q, J = 4.35, 
6.40, 10.92 Hz, 1H), 4.03-3.83 (m, 3H),  2.44 (s, 3H), 1.47 (s, 9H), -2.8 (s, 2H) ppm. 
 
13
C-NMR (DMSO-d
6
, 125.79 Hz): 181.89 (s), 181.57 (s), 167.44 (s), 149.60 (s), 148.19 (s), 
145.72 (s), 142.25(s, 8C), 135.03 (d, 2C), 134.79 (d, 10C), 133.87(d), 133.59 (d), 132.95 (s), 
132.05 (s), 128.18 (s), 128.07 (d, 2C), 128.03 (d, 2C), 127.22 (d), 126.99 (d, 8C), 126.96 (d, 
2C), 126.91 (d, 2C), 120.99 (s), 120.70 (s, 4C), 118.17 (s, 2C), 75.37 (d), 60.61 (s), 52.08 (s), 
29.36 (t), 29.03 (q, 3C), 17.99 (q) ppm.  
LC-MS (ESI): m/z calc. 1035.00, Rt = 18.27 min, m/z found 1035.91 [M+H]
+
. 
HRMS: [M+H] calc. 1036.2977, [M+H] found 1036.2972. Isotopic pattern of Se: m/z 
(relative abundance %) 1030.3031 (3), 1032.2999 (19), 1034.2980 (49), 1036.2972 (100), 
1037.3005 (69.5), 1038.3039 (24), 1039.3007 (13). 
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3.1.3. Method 3 (the Ugi four-component reaction) 
An Ugi-type reaction has been employed for the synthesis of 15 representative sulfur, 
selenium and for the first time, (up to our knowledge), tellurium redox compounds. The Ugi 
reaction described here has required a range of building blocks, which needed to be designed 
and synthesized first (Figure 24).  
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Figure 24. Building blocks used to synthesize multifunctional redox agents. 
 Acid, aldehyde, isocyanide, and amine building blocks used in U-4CR reaction were synthesized following 
literature procedures or, in case of hitherto unknown agents, could be synthesized in sufficient yield. 
 
Figures 25 and 26 show the synthesis of the carboxylic acid and isocyanide building 
blocks used as part of U-4CR. Details regarding the synthesis of these compounds are 
provided in the Materials and Methods section. 
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Figure 25. Synthesis of tetracarboxytertaphenyl porphyrin. 
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Figure 26. Synthesis of sulfur, selenium, and tellurium isocyanides. 
 
Figure 27 provides an overview of the chemical structures of the redox compounds 
synthesized via U-4CR. For details regarding the synthesis of these compounds see the 
Materials and Methods section as well as Table 4.  
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Figure 27: Chemical structures of the multifunctional compounds synthesized via U-
4CR. 
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Table 4. Building blocks, solvents, and yieldsof the synthesized compounds 1u-15u. 
Cpd.  
Building 
Blocks 
Solvent 
Yield 
[ %] 
Redox 
centres 
Cpd.  
Building 
Blocks 
Solvent 
Yield 
% 
Redox 
centres 
1u 
1d, 2b, 
3c, 4a 
H2O 88 3 9u 
1d, 2g, 
3e, 4a 
CHCl3 69 1 
2u 
1d, 2b, 
3d, 4a 
H2O 94 3 10u 
1d, 2h, 
3c, 4a 
H2O 87 1 
3u 
1d, 2b, 
3e, 4a 
CHCl3 81 3 11u 
1d, 2h, 
3d, 4a 
H2O 92 1 
4u 
1d, 2c, 
3c, 4a 
H2O 77 1 12u 
1d, 2h, 
3e, 4a 
CHCl3 77 1 
5u 
1d, 2c, 
3d, 4a 
H2O 86 1 13u 
1d, 2i, 
3c, 4a 
H2O 86 1 
6u 
1d, 2c, 
3e, 4a 
CHCl3 70 1 14u 
1d, 2i, 
3d, 4a 
H2O 90 1 
7u 
1d, 2g, 
3c, 4a 
H2O 75 1 15u 
1d, 2j, 
3a, 4a 
CHCl3 85 1 
8u 
1d, 2g, 
3d, 4a 
H2O 79 1      
Building blocks were designed to carry one or two relevant redox or metal binding sites, which could be 
combined to larger, highly functionalized molecules with four or more biologically interesting sites. Reaction 
was mostly performed in water at high concentrations and under mild conditions. 
 
Taking advantage of the novel tellurium isocyanide, Passerini tellurium containing redox 
compounds were for the first time, up to our knowledge, also synthesized (Figure 28). For 
details regarding the synthesis of these compounds see the Materials and Methods section as 
well as Table 5. 
 
 
Figure 28. Chemical structures of the telluro compounds synthesized via P-3CR.  
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Table 5: Building blocks, solvents, and yields of the synthesized 
compounds of 16-19p.  
Cpd. Nr.  
Building 
Blocks 
Solvent Yield % Redox centres 
16p 1d, 2b, 3e CHCl3 96 3 
17p 1d, 2c, 3e CHCl3 83 1 
18p 1d, 2h, 3e CHCl3 90 1 
19p 1d, 2i, 3e CHCl3 86 1 
 
 
 
Compound 3c: (3-isocyanopropyl)(phenyl)sulfane 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:1. It was obtained as colorless oil. Yield = 77 %.  
TLC (petroleum ether: ethyl acetate 8:1), Rf = 0.69.  
1
H-NMR (CDCl3, 500 MHz): 7.30-7.28 (m, 2H), 7.25-7.22 (m, 2H), 7.17-7.13 (m, 1H), 
3.44-3.41 (m, 2H), 2.98-2.95 (t, J = 6.83, 13.66 Hz, 2H), 1.89-1.83 (m, 2H) ppm.  
13
C-NMR (CDCl3, 125.79 Hz): 156.65 (s), 134.68 (s), 129.45 (d, 2C), 128.76 (d, 2C), 
126.22 (d), 39.74 (t), 29.94 (t), 28.01 (t) ppm.  
LC-MS (ESI): m/z calc. 177.26, Rt = 15.26 min, m/z found 178.15 [M+H]
+
. 
HRMS: [M+H] calc. 178.0690, [M+H] found 178.0685. 
Compound 3d: (3-isocyanopropyl)(phenyl)selane 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:1. It was obtained as colorless oil. Yield = 82 %.  
TLC (petroleum ether: ethyl acetate 8:1), Rf = 0.66.  
1
H-NMR (CDCl3, 500 MHz): 7.51-7.49 (m, 2H), 7.30-7.28 (m, 3H), 3.48-3.46 (m, 2H), 2.95-
2.90 (m, 2H), 1.98-1.90 (m, 2H) ppm.  
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13
C-NMR (CDCl3, 125.79 Hz): 156.65 (s), 134.68 (s), 130.00 (d, 2C), 129.10 (d, 2C), 127.76 
(d,), 40.74 (t), 29.94 (t), 19.20 (t) ppm.  
LC-MS (ESI), m/z calc. 225.16, Rt = 1.65 min, m/z found 226.18 [M+H]
+
. 
 HRMS: [M+H+O] calc. 242.0134, [M+H+O] found 242.0243. Isotopic pattern of Se: m/z 
(relative abundance %) 244.0235 (100), 246.0237 (30), 247.0270 (10).  
Compound 3e: (3-isocyanopropyl)(phenyl)tellane 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:1. It was obtained as colorless oil. Yield = 62 %.  
TLC (petroleum ether: ethyl acetate 10:1), Rf = 0.41.  
1
H-NMR (CDCl3, 500 MHz): 7.76-7.74 (m, 2H), 7.34-7.30 (m, 1H), 7.27-7.22 (m, 2H), 
3.49-3.45 (m, 2H), 2.97-1.98 (t, J = 7.18, 14.67 Hz, 2H), 2.13-2.05 (m, 2H) ppm.  
13
C-NMR (CDCl3, 125.79Hz): 156.73 (s), 138.68 (d, 2C), 129.43 (d, 2C), 128.11 (d), 
110.69 (s), 43.25 (t), 31.00 (t), 3.64 (t) ppm.  
LC-MS (ESI): m/z calc. 274.99, Rt = 1.33 min, m/z found 276.1 [M+H]
+
. 
 HRMS: [M+H+O] calc. 291.9981, [M+H+O] found 291.9976. Isotopic pattern of Te: m/z 
(relative abundance %) 281.9954 (1), 283.9944 (8), 285.9942 (14.5), 286.9958 (21), 
287.9946 (55.5), 289.9958 (93.5), 291.9976 (100), 293.0009 (11), 294.0043 (05). 
 
Sulfur  and selenium and tellurium redox compounds provided by U-4CR and P-3CR were 
synthesized as follows: 
 
Compound 1u: N-((3-(phenylthio)propylcarbamoyl)methyl)-3-(1,4-dihydro-2-methyl-1,4-
dioxonaphthalen-3-ylthio)-N-(4-methoxyphenyl)propanamide 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:1. It was obtained as yellow oil. Yield = 88 %.  
TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.51.  
 
 
1
H-NMR (CDCl3, 500 MHz): 8.16-7.90 (m, 2H), 7.75-7.50 (m, 2H), 7.29-7.26 (m, 4H), 7.14-
7.00 (m, 2H), 6.77-6.70 (m, 2H), 6.56 (br s, 1H), 4.18 (s, 2H), 3.71 (s, 3H), 3.41-3.32 (t, J= 
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5.86, 12.48 Hz, 2H), 3.27-3.25 (t, J = 6.28, 10.47 Hz, 2H), 2.80-2.76 (t, J = 6.43, 12.28 Hz, 
2H), 2.50-2.46 (t, J = 6.87, 11.00 Hz, 2H), 2.28 (s, 3H), 1.88-1.82 (m, 2H) ppm.  
13
C-NMR (CDCl3, 125.79 Hz): 182.14 (s), 181.20 (s), 172.15 (s), 168.77 (s), 159.32 (s), 
147.06 (s), 146.40 (s), 136.12 (s), 134.92 (s), 133.62 (d), 133.32 (d), 132.73 (s), 131.96 (s), 
129.20 (d, 2C), 128.92 (d, 2C), 128.64 (d, 2C), 126.72 (d), 126.53 (d), 126.02 (d), 114.99 (d, 
2C), 55.41 (q), 54.48 (t), 38.45 (t), 35.04 (t), 31.07 (t), 30.02 (t), 28.84 (t), 15.29 (q) ppm.  
LC-MS (ESI): m/z calc. 588.18, Rt = 1.85 min, m/z found 589.85 [M+H]
+
. 
HRMS: [M+H] calc. 589.1830, [M+H] found 589.1825, [M+Na] calc. 611.1650 [M+Na] 
found 611.1645. Isotopic pattern of S: m/z (relative abundance %) 589.1825 (100), 
590.1859 (37), 591.1783 (10), 593.1850 (0.6). 
Compound 2u: N-((3-(phenylselanyl)propylcarbamoyl)methyl)-3-(1,4-dihydro-2-methyl-1,4-
dioxonaphthalen-3-ylthio)-N-(4-methoxyphenyl)propanamide 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:1. It was obtained as yellow oil. Yield = 94 %.  
TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.52.  
1
H-NMR (CDCl3, 500 MHz): 8.05-7.98 (m, 1H), 7.97-7.91 (m, 1H), 7.69-7.59 (m, 2H), 7.45-
7.37 (m, 2H), 7.20-7.10 (m, 3H), 7.09-7.02 (m, 2H), 6.71-6.68 (m, 2H), 6.48 (br s, 1H), 4.20 
(s, 2H), 3.70 (s, 3H), 3.29-3.26 (m, 4H), 2.80-2.75 (t, J = 7.30, 14.59 Hz, 2H), 2.50-2.45 (t, J 
= 6.78, 13.37 Hz, 2H), 2.20 (s, 3H), 1.98-1.76 (m, 2H) ppm.  
13
C-NMR (CDCl3, 125.79 Hz): 182.09 (s), 181.16 (s), 172.08 (s), 168.69 (s), 159.28 (s), 
155.16 (s), 153.19 (s), 146.98 (s), 146.39 (s), 134.91 (s), 133.59 (d), 133.29 (d), 132.55 (d), 
131.93 (s), 129.06 (d, 2C), 128.64 (d, 2C), 126.86 (d), 126.69 (d), 126.50 (d), 114.95 (d, 2C), 
114.30 (d) , 55.39 (q), 54.39 (t), 39.29 (t), 35.02 (t), 29.98 (t), 29.87 (t), 24.81 (t), 15.29 (q) 
ppm. 
 LC-MS (ESI): m/z calc. 636.12, Rt = 17.74 min, m/z found 637.10 [M+H]
+
. 
 HRMS: [M+H] calc. 637.1275, [M+H] found 637.1270, [M+Na] calc. 659.1094 [M+Na] 
found 659.1089. Isotopic pattern of Se: m/z (relative abundance %) 631.1329 (2), 633.1297 
(20), 635.1278 (49), 637.1270 (100), 638.1303 (36), 639.1272 (19), 640.1305 (9). 
Compound 3u: N-((3-(phenyltellanyl)propylcarbamoyl)methyl)-3-(1,4-dihydro-2-methyl-1,4-
dioxonaphthalen-3-ylthio)-N-(4-methoxyphenyl)propanamide 
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The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:1. It was obtained as yellow oil. Yield = 81 %.  
TLC (petroleum ether: ethyl acetate 5:2), Rf = 0.54.  
1
H-NMR (CDCl3, 500 MHz): 8.00-7.98 (m, 1H), 7.93-7.92 (m, 1H), 7.64-7.60 (m, 5H), 
7.12-7.09 (m, 2H), 7.03-7.01 (m, 2H), 6.71-6.69 (m, 2H), 6.39 (br s, 1H), 4.11 (s, 2H), 
3.65 (s, 3H), 3.29-3.24 (m, 4H), 2.80-2.77 (t, J = 7.43, 15.04 Hz, 2H), 2.44-2.41 (t, J = 
6.49, 12.98 Hz, 2H), 2.23 (s, 3H), 1.96-1.90 (m, 2H) ppm.  
13
C-NMR (CDCl3, 125.79 Hz): 182.14 (s), 181.21 (s), 172.12 (s), 170.80 (s), 168.72 (s), 
159.32 (s), 147.03 (s), 146.43 (s), 138.43 (d, 2C), 134.93 (s), 133.64 (d), 133.33 (d), 
132.74 (s), 131.98 (s), 129.23 (d, 2C), 128.67 (d), 127.69 (d, 2C), 126.74 (d), 126.55 (d), 
114.99 (d, 2C) , 55.43 (q), 54.45 (t), 41.18 (t), 35.05 (t), 31.56 (t), 30.03 (t), 15.33 (q), 
4.80 (t) ppm.  
LC-MS (ESI): m/z calc. 686.11, Rt = 1.63 min, m/z found 687.11 [M+H]
+
. 
 HRMS: [M+H] calc. 687.1172, [M+H] found 687.1167, [M+H+O] calc. 703.1121 
[M+H+O] found 703.1116. Isotopic pattern of Te: m/z (relative abundance %) 695.1084 
(8), 698.1098 (24), 699.1087 (57), 702 (94), 703.1116 (100), 704.1150 (36), 705.1183 (6). 
Compound 4u: tert-butyl ((2-(N-(4-methoxyphenyl)-N-amino)-N-(3-
(phenylthio)propyl)acetamide)carbonyl)methylcarbamate 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:1. It was obtained as colorless oil. Yield = 77 %.  
TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.63.  
1
H-NMR (CDCl3, 500 MHz): 7.31-7.24 (m, 6H), 7.17-7.14 (m, 1H), 6.99 (br s, 1H), 6.88-
6.86 (d, J = 8.90 Hz, 2H), 5.48 (s, 1H), 4.26 (s, 2H), 3.78 (s, 3H), 3.66-3.64 (d, J = 5.07 Hz, 
2H), 3.37-3.33 (q, J= 6.82, 13.00, 19.77 Hz, 2H), 2.92-2.89 (t, J = 7.24, 14.49 Hz, 2H), 1.86-
1.81 (p, J = 7.24, 13.96, 21.11, 28.00 Hz, 2H), 1.49 (s, 9H) ppm.  
13
C-NMR (CDCl3, 125.79Hz): 170.13 (s), 168.18 (s), 159.39 (s), 155.84 (s), 136.00 (s), 
133.46 (s), 128.82 (d, 2C), 128.69 (d, 2C), 128.54 (d), 125.71 (d, 2C), 114.94 (d, 2C), 79.44 
(s), 55.25 (q), 53.71 (t), 42.80 (t), 38.22 (t), 30.70 (t), 28.61 (t), 28.08 (q, 3C) ppm.  
LC-MS (ESI): m/z calc. 487.21, Rt = 1.61 min, m/z found 488.2 [M+ 1]
+
. 
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HRMS: [M+Na] calc. 510.2039, found 510.2033 [M+Na]. Isotopic pattern of S: m/z (relative 
abundance %) 488.2214 (100), 489.2247 (25), 490.2172 (5), 510.2033 (100), 511.2067 (25), 
512.1991 (5).                                  
Compound 5u: tert-butyl ((2-(N-(4-methoxyphenyl)-N-amino)-N-(3-
(phenylselanyl)propyl)acetamide)carbonyl)methylcarbamate 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:1. It was obtained as colorless oil. Yield = 86 %.  
TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.45.  
1
H-NMR (CDCl3, 500 MHz): 7.49-7.46 (m, 2H), 7.27-7.21 (m, 5H), 6.89-6.87 (d, J = 8.92 
Hz, 2H), 6.77 (br s, 1H), 5.40 (br s, 1H), 4.24 (s, 2H), 3.79 (s, 3H), 3.66-3.64 (d, J = 5 Hz, 
2H), 3.37-3.33 (q, J= 6.71, 12.71, 19.56 Hz, 2H), 2.89-2.87 (t, J = 7.37, 14.35 Hz, 2H), 1.93-
1.87 (p, J = 7.00, 13.73, 21.00, 27.95 Hz, 2H), 1.41 (s, 9H) ppm.  
13
C-NMR (CDCl3, 125.79Hz): 170.18 (s), 168.20 (s), 159.52 (s), 155.88 (s),  133.52 (s), 
132.39 (d, 2C), 129.89 (s), 128.95 (d, 2C), 128.61 (d), 126.73 (d, 2C), 115.07 (d, 2C), 79.59 
(s), 55.37 (q), 53.91 (t), 42.90 (t), 39.21 (t), 29.69 (t), 28.18 (q, 3C), 24.68 (t) ppm. 
 LC-MS (ESI): m/z calc. 535.16, Rt = 1.73 min, m/z found 558.10 [M+ Na]
+
. 
HRMS: [M+H] calc. 536.1585, [M+H] found 536.1658, [M+Na] calc. 558.1478 [M+Na] 
found 559.1511. Isotopic pattern of Se: m/z (relative abundance %) 536.1658 (100), 
537.1692 (26), 538.1660 (15), 539.1694 (5).                                                                                                                                                           
Compound 6u: tert-butyl ((2-(N-(4-methoxyphenyl)-N-amino)-N-(3-
(phenyltellanyl)propyl)acetamide)carbonyl)methylcarbamate 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:1. It was obtained as colorless oil. Yield = 70 %.  
TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.37.  
1
H-NMR (CDCl3, 500 MHz): 7.66-7.64 (m, 2H), 7.19 (s, 1H), 7.14-7.10 (m, 4H), 6.82-6.79 
(d, J = 8.9 Hz, 2H), 6.32 (br s, 1H), 5.20 (br s, 1H), 4.13 (s, 2H), 3.73 (s, 3H), 3.58-3.57 (d, J 
= 5.28 Hz, 2H), 3.28-3.24 (q, J= 6.55, 13.41, 19.32 Hz, 2H), 2.80-2.77 (t, J = 7.66, 15.15 Hz, 
2H), 1.97-1.91 (p, J = 6.95, 14.24, 21.66, 28.65 Hz, 2H), 1.43 (s, 9H) ppm.  
13
C-NMR (CDCl3, 125.79Hz): 170.25 (s), 168.30 (s), 159.72 (s), 155.92 (s), 138.45 (d, 2C), 
133.58 (s), 129.23 (d, 2C), 128.68 (d, 2C), 127.70 (d), 115.26 (d, 2C), 111.46 (s), 79.80 (s), 
55.25 (q), 54.22 (t), 43.05 (t), 41.22 (t), 31.52 (t), 28.30 (q, 3C), 4.75 (t) ppm.  
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LC-MS (ESI): m/z calc. 585.15, Rt = 1.54 min, m/z found 608.15 [M+Na]
+
. 
HRMS: [M+H] calc. 586.1482, [M+H] found 586.1555, [M+H+O] calc. 602.1431 [M+H+O] 
found 602.1504, [M+Na] calc. 608.1380 [M+Na] found 608.1656. Isotopic pattern of Te: m/z 
(relative abundance %) 586.1555 (100), 587.1589 (29), 588.1622 (5), 602.1504 (100), 
603.1538 (26), 604.1571 (5), 608.1656 (1).                                                                                                                                                           
Compound 7u: N-((3-(phenylthio)propylcarbamoyl)methyl)-N-(4-methoxyphenyl)benzamide 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:1. It was obtained as colorless oil. Yield = 75 %.  
TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.56.  
1
H-NMR (CDCl3, 500 MHz): 7.25-7.22 (m, 4H), 7.19-7.17 (m, 2H), 7.11-7.07 (m, 3H), 6.94-
6.91 (m, 2H), 6.64-6.61 (m, 3H), 4.38 (s, 2H), 3.63 (s, 3H), 3.36-3.32 (q, J = 6.48, 12.34, 
19.75 Hz, 2H),2.87-2.84 (t, J = 7.35, 18.85 Hz, 2H), 1.82-1.76 (p, J = 6.98, 13.85, 20.83, 
27.92 Hz, 2H) ppm.  
13
C-NMR (CDCl3, 125.79Hz): 171.49 (s), 168.18 (s), 158.52 (s), 136.70 (s), 136.30 (s), 
135.09 (s), 130.26 (d), 129.52 (d, 2C), 129.38 (d), 129.15 (d), 129.06 (d, 2C), 128.52 (d, 2C), 
128.04 (d, 2C), 126.28 (d), 114.70 (d, 2C), 55.57 (q), 38.62 (t), 31.32 (t), 29.06 (t) ppm. 
LC-MS (ESI): m/z calc. 434.17, Rt = 15.69 min, m/z found 435.2 [M+H]
+
. 
HRMS: [M+H] calc. 435.1764, [M+H] found 435.1737, [M+Na] calc. 457.1562 [M+Na] 
found 457.1556. Isotopic pattern of S: m/z (relative abundance %) 435.1737 (100), 436.1770 
(29), 437.1695 (5), 457.1556 (100), 458.1590 (25), 459.1514 (5).                                                                                                     
Compound 8u: N-((3-(phenylselanyl)propylcarbamoyl)methyl)-N-(4-
methoxyphenyl)benzamide 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:1. It was obtained as colorless oil. Yield = 79 %.  
TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.43.  
1
H-NMR (CDCl3, 500 MHz): 7.40-7.38 (m, 2H), 7.24-7.22 (m, 2H), 7.16-7.14 (m, 4H), 7.11-
7.07 (m, 2H), 6.94-6.91 (m, 2H), 6.64-6.61 (m, 2H), 4.36 (s, 2H), 3.63 (s, 3H), 3.33-3.29 (q, J 
= 6.57, 13.14, 19.41 Hz, 2H), 2.83-2.81 (t, J = 7.06, 14.52 Hz, 2H), 1.86-1.81 (p, J = 6.98, 
13.96, 21.31, 28.29 Hz, 2H) ppm.  
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13
C-NMR (CDCl3, 125.79Hz): 171.22 (s), 168.88 (s), 158.26 (s), 136.44 (s), 134.84 (s), 
132.60 (d, 2C), 130.00 (d), 129.86 (s),129.06 (d, 2C), 128.79 (d, 2C), 128.27 (d, 2C), 127.79 
(d, 2C), 126.89 (d), 114.44 (d, 2C), 55.31 (q), 55.28 (t), 39.23 (t), 29.78 (t), 24.78 ppm.  
HRMS: [M+H] calc. 483.1109, [M+H] found 483.1181, [M+Na] calc. 505.1007 [M+Na] 
found 505.1001. Isotopic pattern of Se: m/z (relative abundance %) 483.1181 (100), 
484.1215 (30), 485.1183 (20), 486.1217 (8), 505.1001 (100), 506.1034 (30), 507.1003 (20), 
508.1036 (5).                            
Compound 9u: N-((3-(phenyltellanyl)propylcarbamoyl)methyl)-N-(4-
methoxyphenyl)benzamide 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:1. It was obtained as colorless oil. Yield = 69 %.  
TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.31.  
1
H-NMR (CDCl3, 500 MHz): 7.78-7.75 (m, 2H), 7.38-7.30 (m, 5H), 7.24-7.22 (m, 3H), 7.06-
7.04 (m, 2H), 6.77-6.75 (m, 2H),  4.49 (s, 2H), 3.78 (s, 3H), 3.43-3.38 (p, J = 6.68, 13.09, 
19.56, 25.44 Hz, 2H), 2.93-2.90 (t, J = 7.52, 15.16 Hz, 2H), 2.08-2.03 (p, J = 6.84, 14.37, 
21.49, 28.74 Hz, 2H) ppm.  
13
C-NMR (CDCl3, 125.79Hz): 171.24 (s), 170.80 (s), 168.90 (s), 158.30 (s), 138.48 (d, 2C), 
136.46 (s), 134.85 (s), 130.04 (d), 129.22 (d, 2C), 128.82 (d, 2C), 128.27 (d, 2C), 127.82 (d, 
2C), 127.69 (d), 114.47 (d, 2C), 55.36 (t), 55.35 (q), 41.11 (t), 31.52 (t), 4.67 ppm.  
LC-MS (ESI): m/z calc. 532.10, Rt = 1.54 min, m/z found 533.0 [M+H]
+
. 
HRMS: [M+H+O] calc. 549.1006, [M+H+O] found 549.1028. Isotopic pattern of Te: m/z 
(relative abundance %) 549.1028 (100), 550.1061 (30), 551.1095 (6). 
Compound 10u: (E)-N-((3-(phenylthio)propylcarbamoyl)methyl)-N-(4-
methoxyphenyl)cinnamamide 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:1. It was obtained as colorless oil. Yield = 87 %.  
TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.48. 
1
H-NMR (CDCl3, 500 MHz): 7.61-7.58 (m, 1H), 7.24-7.04 (m, 11H), 6.88-6.71 (m, 3H), 
6.30-6.27 (m, 1H), 4.28 (s, 2H), 3.73 (s, 3H), 3.33-3.29 (q, J = 6.73, 12.95, 19.68 Hz, 2H), 
2.87-2.84 (t, J = 7.16, 14.50 Hz, 2H), 1.81-1.75 (p, J = 6.94, 13.99, 21.04, 27.98 Hz, 2H) 
ppm.  
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13
C-NMR (CDCl3, 125.79Hz): 169.02 (s), 167.10 (s), 159.11 (s), 142.92 (d), 136.08 (s), 
134.87 (s), 134.73 (s), 129.78 (d), 129.13 (d, 2C), 128.82 (d, 2C), 128.75(d, 2C), 128.64 (d, 
2C), 127.90 (d, 2C), 125.90 (d), 117.71 (d), 114.83 (d, 2C), 55.42 (q), 54.71 (t),  38.33 (t), 
30.99 (t), 28.82 (t) ppm.  
LC-MS (ESI): m/z calc. 460.18, Rt = 14.10 min, m/z found 461.2 [M+H]
+
. 
HRMS: [M+H] calc. 461.1821, [M+H] found 461.1893. Isotopic pattern of Se: m/z (relative 
abundance %) 461.1893 (100), 462.1927 (30), 463.1851 (5), 464.1885 (2).  
Compound 11u: (E)-N-((3-(phenylselanyl)propylcarbamoyl)methyl)-N-(4-
methoxyphenyl)cinnamamide 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:1. It was obtained as colorless oil. Yield = 92 %.  
TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.39. 
1
H-NMR (CDCl3, 500 MHz): 7.62-7.59 (m, 1H), 7.39-7.37 (m, 2H), 7.24-7.08 (m, 9 H), 
6.88-6.64 (m, 3H), 6.30-6.27 (m, 1H), 4.27 (s, 2H), 3.75 (s, 3H), 3.31-3.27 (q, J = 7.10, 
13.37, 20.20 Hz, 2H), 2.83-2.80 (t, J = 7.25, 14.87 Hz, 2H), 1.86-1.81 (p, J = 6.96, 14.21, 
21.31, 28.42 Hz, 2H) ppm.  
13
C-NMR (CDCl3, 125.79Hz): 169.03 (s), 167.14 (s), 159.15 (s), 142.96 (d), 134.88 (s), 
134.76 (s), 132.56 (d, 2C), 129.91 (s), 129.81 (d), 129.02(d, 2C), 128.76 (d, 2C), 128.67 (d, 
2C), 127.93 (d, 2C), 126.82 (d), 117.71 (d), 114.83 (d, 2C), 55.46 (q), 54.78 (t),  39.22 (t), 
29.82 (t), 24.78 (t) ppm.  
LC-MS (ESI): m/z calc. 508.13, Rt = 1.71 min, m/z found 509.10 [M+H]
+
. 
HRMS: [M+H] calc 509.1265, [M+H] found 509.1338. Isotopic pattern of Se: m/z (relative 
abundance %) 509.1338 (100), 510.1371 (30), 511.1340 (17), 512.1373 (7), 513.1407 (2).                                                                                                    
Compound 12u: (E)-N-((3-(phenyltellanyl)propylcarbamoyl)methyl)-N-(4-
methoxyphenyl)cinnamamide 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:1. It was obtained as colorless oil. Yield = 77 %.  
TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.33. 
1
H-NMR (CDCl3, 500 MHz): 7.64-7.61 (m, 3H), 7.40-7.3 (m, 5H), 7.25-7.2 (m, 3H), 6.71-
7.02 (m, 3H), 6.75 (br s, 1H), 6.30-6.27 (m, 1H), 4.26 (s, 2H), 3.76 (s, 3H), 3.28-3.24 (q, J = 
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6.42, 12.84, 19.69 Hz, 2H), 2.80-2.77 (t, J = 7.59, 15.19 Hz, 2H), 1.96-1.91 (p, J = 6.94, 
14.52, 21.47, 28.88 Hz, 2H) ppm.  
13
C-NMR (CDCl3, 125.79Hz): 169.30 (s), 167.42 (s), 159.43 (s), 143.25 (d), 138.64 (d, 2C), 
135.13 (s), 135.03 (s), 130.10 (d), 129.42 (d, 2C), 129.02 (d, 2C), 128.95 (d, 2C), 128.21 (d, 
2C), 127.87 (d), 117.97 (d), 115.15 (d, 2C), 111.66 (s), 55.74 (q), 55.06 (t), 41.33 (t), 31.78 
(t), 4.95 (t) ppm. 
 LC-MS (ESI): m/z calc. 558.12, Rt = 17.19 min, m/z found 558.80 [M+ H], 582.1, [M+ Na]. 
HRMS: [M+H+O] calc. 575.1162, [M+H+O] found 575.1184. Isotopic pattern of Te: m/z 
(relative abundance %) 575.1184 (100), 576.1218 (30), 577.1251 (5), 578.1285 (2).          
Compound 13u: N-((3-(phenylthio)propylcarbamoyl)methyl)-N-(4-methoxyphenyl)-3-
phenylpropiolamide 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:1. It was obtained as colorless oil. Yield = 86 %.  
TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.55. 
1
H-NMR (CDCl3, 500 MHz): 7.29-7.24 (m, 4H), 7.19-7.16 (m, 5H), 7.10-7.06 (m, 3H), 6.84-
6.81 (m, 2H), 6.47 (br s, 1H), 4.27 (s, 2H), 3.74 (s, 3H), 3.35-3.31 (q, J = 6.77, 12.89, 19.49 
Hz, 2H), 2.88-2.85 (t, J = 7.09, 14.34 Hz, 2H), 1.83-1.77 (p, J = 7.09, 13.86, 20.94, 27.71 Hz, 
2H) ppm.  
13
C-NMR (CDCl3, 125.79Hz): 168.15 (s),  159.44 (s), 155.33 (s), 136.02 (s), 134.81 (s), 
132.51 (d), 130.20 (d, 2C), 129.29 (d, 2C), 128.98 (d, 2C), 128.92 (d, 2C), 128.35 (d, 2C), 
126.03 (d), 120.03 (s), 114.39 (d, 2C), 92.68 (s), 81.96 (s), 55.53 (q), 53.62 (t),  38.51 (t), 
31.08 (t), 28.79 (t) ppm.  
LC-MS (ESI): m/z calc. 458.17, Rt = 1.56 min, m/z found 459.2 [M+H]
+
. 
HRMS: [M+H] calc. 459.1664, [M+H] found 459.1734, [M+Na] calc. 482.1590 [M+Na] 
found 481.1556. Isotopic pattern of S: m/z (relative abundance %) 459.1734 (100), 460.1770 
(30), 461.1695 (4), 481.1556 (100), 482.1590 (30), 483.1514 (5).                                                                                                     
Compound 14u: N-((3-(phenylselanyl)propylcarbamoyl)methyl)-N-(4-methoxyphenyl)-3-
phenylpropiolamide 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:1. It was obtained as colorless oil. Yield = 90 %.  
TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.46. 
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1
H-NMR (CDCl3, 500 MHz): 7.42-7.39 (m, 2H), 7.27-7.22 (m, 3H), 7.18-7.13 (m, 5H), 7.11-
7.07 (m, 2H), 6.84-6.82 (m, 2H), 6.46 (br s, 1H), 4.26 (s, 2H), 3.74 (s, 3H), 3.32-3.28 (q, J = 
6.94, 13.23, 19.84 Hz, 2H), 2.84-2.80 (t, J = 7.07, 14.40 Hz, 2H), 1.87-1.81 (p, J = 6.91, 
13.92, 20.72, 27.74 Hz, 2H) ppm.  
13
C-NMR (CDCl3, 125.79Hz): 168.08 (s),  159.40 (s), 155.28 (s), 134.79 (s), 132.61 (s), 
132.48 (d, 2C), 130.18 (d, 2C), 129.87 (d), 128.06 (d, 2C), 128.98 (d, 2C), 128.33 (d, 2C), 
126.86 (d), 120.01 (s), 114.36 (d, 2C), 92.62 (s), 81.97 (s), 55.51 (q), 53.54 (t),  39.34 (t),  
29.76 (t), 24.77 (t) ppm. 
 LC-MS (ESI): m/z calc. 506.11, Rt = 11.45 min, m/z found 507.54 [M+H]
+
. 
HRMS: [M+H] calc. 507.1109, [M+H] found 507.1181. Isotopic pattern of Se: m/z (relative 
abundance %) 507.1181 (100), 508.1215 (33), 509.1183 (18), 510.1217 (7), 511.1250 (1).         
Compound 15u: 4,4′,4′′,4′′′-(Porphine-5,10,15,20-tetrayl)tetrakis(((tert-
butylcarbamoyl)methyl)(4-methoxyphenyl)carbamic chloride) 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:2. It was obtained as colorless oil. Yield = 85 %.  
TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.38. 
1
H-NMR (DMSO-d
6
, 500 MHz): 8.50 (s, 7H), 8.00-7.85 (m, 8H), 7.70-6.65 (m, 8H), 7.20-
7.30 (m,9H), 7.80-7.75 (m, 9H), 6.30 (s, 4H), 4.50 (s, 8H), 3.75 (s, 12H), 1.45 (s, 35H), -3.10 
(s, 2H) ppm.  
13
C-NMR (DMSO-d
6
, 125.79 Hz): 171.21 (s, 4C), 167.90 (s, 4C), 158.70 (s, 6C), 143.60 (s, 
4C), 136.74 (s, 6C), 135.91 (s, 6C), 133.78 (d, 10C), 128.71 (d, 8C), 127.07 (d, 10C), 117.57 
(d, 2C), 119.24 (s, 6C), 116.98 (s, 4C), 114.56 (d, 10C), 55.57 (q, 4C), 56.36 (t, 4C), 28.88 
(q, 12C) ppm.  
HRMS: [M+H] calc. 1663.77, [M+H] found 1663.7784.  
Compound 16p: N-((3-(phenyltellanyl)propylcarbamoyl)methyl)-3-(1,4-dihydro-2-methyl-
1,4-dioxonaphthalen-3-ylthio)propanamide 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:1. It was obtained as yellow oil. Yield = 96 %.  
TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.62.  
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1
H-NMR (CDCl3, 500 MHz): 8.02-7.97 (m, 2H), 7.65-7.62 (m, 2H), 7.15-7.10 (m, 1H), 7.09-
7.04 (m, 2H), 6.79-6.70 (m, 2H), 6.5 (br s, 1H), 4.25 (s, 2H), 3.75-3.73 (m, 2H), 3.45-3.25 
(m, 2H), 2.95-2.80 (m, 2H), 2.50-2.48 (m, 2H), 2.27 (s, 3H), 1.85-1.75 (m, 2H) ppm.  
13
C-NMR (CDCl3, 125.79 Hz): 182.04 (s), 181.40 (s), 169.96 (s), 166.81 (s), 148.25 (s), 
145.18 (s), 138.33 (d, 2C), 133.86 (d), 133.52 (d), 132.54 (s), 131.92 (s), 129.19 (d, 2C), 
127.69 (d), 126.79 (d), 126.67 (d), 111.35 (s), 63.14 (t), 40.82 (t), 35.29 (t), 31.39 (t), 
29.22 (t), 15.43 (q), 4.64 (t) ppm.  
LC-MS (ESI): m/z calc. 580.07, Rt = 1.60 min, m/z found 581.12 [M+H]
+
. 
 HRMS: [M+H] calc. 580.0712, [M+H] found 582.0588, [M+H+O] calc. 598.0543 [M+H+O] 
found 598.0538. Isotopic pattern of Te: m/z (relative abundance %) 590.0506 (8), 593.0520 
(23), 594.0508 (58), 596 (93), 598.0538 (100), 599.0571 (29), 600.0496 (6). 
Compound 17p: tert-butyl (((3-
(phenyltellanyl)propylcarbamoyl)methoxy)carbonyl)methylcarbamate 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:1. It was obtained as colorless oil. Yield = 83 %.  
TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.54.  
1
H-NMR (CDCl3, 500 MHz): 7.66-7.63 (m, 2H), 7.23-7.20 (m, 1H), 7.15-7.11 (m, 2H), 6.70 
(br s, 1H), 5.05 (br s, 1H),  4.56 (s, 2H), 3.83-3.82 (d, 2H), 3.30-3.26 (q, J = 6.68, 12.91, 
19.81 Hz, 2H), 2.81-2.78 (t, J = 7.50, 15.11 Hz, 2H), 1.99-1.93 (p, J = 7.26, 14.53, 21.55, 
29.05 Hz, 2H), 1.37 (s, 9H) ppm.  
13
C-NMR (CDCl3, 125.79Hz): 168.99 (s), 166.87 (s), 156.48 (s), 138.42 (d, 2C), 129.21 (d, 
2C), 127.68 (d), 111.50 (s), 80.79 (s), 63.13 (t), 42.88 (t), 40.96 (t), 31.44 (t), 28.30 (q, 3C), 
4.70 (t) ppm.  
LC-MS (ESI): m/z calc. 480.09, Rt = 7.21 min, m/z found 497.59 [M+H+O], 497.44 
[M+H+O]
+
. 
HRMS: [M+H+O] calc. 497.0849, [M+H+O] found 497.0926, [M+Na] calc. 503.0904, 
[M+Na] found 503.1078. Isotopic pattern of Te: m/z (relative abundance %) 495.0908 (93), 
497.0926 (100), 498.0959 (22), 499.0993 (7), 503.1078 (2).      
Compound 18p: (E)-(3-(phenyltellanyl)propylcarbamoyl)methyl cinnamate 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:1. It was obtained as colorless oil. Yield = 90 %.  
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TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.37. 
1
H-NMR (CDCl3, 500 MHz): 7.73-7.64 (m, 3H), 7.57-7.45 (m, 2H), 7.37-7.33 (m, 2H), 7.22-
7.18 (m, 2H), 7.11-7.15 (m, 2H), 6.50-6.35 (m, 1H), 6.12 (br s, 1H), 4.60 (s, 2H), 3.35-3.31 
(q, J = 6.63, 13.07, 19.96 Hz, 2H), 2.82-2.79 (t, J = 7.28, 14.82 Hz, 2H), 2.00-1.95 (p, J = 
7.09, 14.27, 21.45, 28.81 Hz, 2H) ppm.  
13
C-NMR (CDCl3, 125.79Hz): 167.23 (s), 165.42 (s), 146.79 (d), 138.51 (d, 2C), 133.96 (d), 
130.87 (s), 129.28 (d, 2C), 129.02 (d, 2C), 128.28 (d, 2C), 127.81 (d), 116.38 (d), 111.33 (s), 
63.07 (t), 40.80 (t), 31.47 (t), 4.60 (t) ppm.  
LC-MS (ESI): m/z calc. 453.06, Rt = 9.01 min, m/z found 469.85 [M+O]
+
. 
HRMS: [M+H+O] calc. 470.0584, [M+H+O] found 470.0606. Isotopic pattern of Te: m/z 
(relative abundance %) 470.0606 (100), 471.0639 (23), 472.0673 (4).  
Compound 19p:N-((3-(phenyltellanyl)propylcarbamoyl)methyl)-3-phenylpropiolamide 
The compound was purified by column chromatography on silica gel with petrol ether: 
ethyl acetate = 5:1. It was obtained as colorless oil. Yield = 86 %.  
TLC (petroleum ether: ethyl acetate 4:1), Rf = 0.58. 
1
H-NMR (CDCl3, 500 MHz): 7.70-7.65 (m,2H), 7.55-7.51 (m, 2H), 7.36-7.31 (m, 3H), 7.22-
7.21 (m, 1H), 7.15-7.10 (m, 2H), 6.60 (br s, 1H), 4.65 (s, 1H), 4.60 (s, 2H), 3.64-3.61 (m, 
2H), 2.75-2.72 (m, 2H), 1.72-1.67 (m, 2H) ppm. 
13
C-NMR (CDCl3, 125.79Hz): 167.40 (s),  166.55 (s), 152.53 (s), 133.43 (d, 2C), 133.37 (d), 
131.44 (d), 131.39 (d, 2C), 128.97 (d), 128.93 (d, 2C), 126.85 (d), 119.28 (s), 88.87 (s),79.81 
(s), 63.97 (t), 43.75 (t),  36.63 (t), 32.89 (t) ppm. 
HRMS: [M+O] calc. 466.0427, [M+O] found 466.0449. Isotopic pattern of Te: m/z (relative 
abundance %) 468.0449 (100), 469.0483 (21), 470.0516 (5).  
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3.2.  Cell culture and biological studies 
3.2.1. Cytotoxicity 
The cytotoxic activity was assayed with MCF-7 (human breast adenocarcinoma), A-498 
(human kidney carcinoma), A-431 (human epidermoid carcinoma), L-929
1
 (mouse 
fibroblasts), A-549
1
 (human lung carcinoma), and SW-480
1 
(human colon adenocarcinoma), 
cancer cell lines as well as primary human fibroblasts (HF) and endothelium cells (HUVEC) 
by means of an MTT assay at different incubation times
1
 (Table 6).  
Furthermore, one-dose and five-dose screens of compounds 2p, 4p, 6p, 7p, 8p, 9p, 11p, 12p, 
15p, 16p, 3u, 6u, and 9u with 58 tumour cell lines were performed at the National Cancer 
Institute (see Appendix for details). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
1  The results shown here are only after one-day incubation with the multifunctional compounds. Results 
obtained after five-days incubation time as well as the IC50 values in case of L-929, A-549, and SW-480 cell 
lines are shown in the Appendix section. 
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Table 6. Influence of multifunctional redox compounds on the viability of human cancer 
and primary cell lines.  
Cpd. MCF-7 A-498 A-431 HUVEC HF Cpd.  MCF-7 A-498 A-431 HUVEC HF 
1p 26 >100 >100 13 11 18p 1 52 6 7 11 
2p 14 >100 7 34 26 19p 1 63 7 10 7 
3p 10 >100 >100 23 50 1u 16 >100 17 24 26 
4p 3 3 1 1 n.d. 2u 8 >100 17 21 24 
5p 19 >100 >100 17 21 3u 7 7 1 6 4 
6p 10 5 6 7 5 4u >100 >100 >100 >100 >100 
7p 3 5 2 3 7 5u >100 >100 >100 >100 >100 
8p 3 5 2 2 4 6u  >100 5 6 25 
9p 5 5 4 35 27 7u >100 >100 >100 >100 >100 
10p 4 7 5 36 6 8u >100 >100 >100 >100 >100 
11p 8 13 4 10 4 9u  2 5 5 7.5 
12p 9 4 4 3 6 10u >100 >100 >100 >100 >100 
13p >100 >100 >100 >100 >100 11u >100 >100 >100 >100 >100 
14p >100 >100 >100 >100 >100 12u 2 9 6 4.5 5 
15p >100 >100 >100 >100 >100 13u >100 >100 >100 >100 >100 
16p 12 1 1 4 13 14u >100 >100 >100 >100 >100 
17p  5 0 2.5 19 15u >100 >100 >100 >100 >100 
The metabolic activity of the cells was measured after one day of incubation with different concentrations of the test 
compounds by means of an MTT assay. The IC50 was determined from the dose-response curves as the mean of two 
parallel experiments. 
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a)       b) 
         
c)              d) 
  
 
 
 
 
 
3.2.2. Immunocytochemistry (ICC) 
Phenotypical changes in the cytoskeleton architecture, nucleus, and the morphology of 
the endoplasmic reticulum were monitored in potoroo cells (PtK2) treated with different 
multifunctional compounds (see Appendix for more results). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Immunofluorescence investigations of the ER (panel a and b) and the actin 
cytoskeleton (panel c and d) of PtK2 cells. 
PtK2 cells were incubated with 7p and 6p, respectively, in comparison with control cells. Treated cells show 
holes in the ER (panel b) and reduced Actin stress fibers (panel d). Cells are rounded and detached from each 
other. 
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Figure 29 shows that the ER structure is affected and the cell morphology in general is 
altered; cells are rounded and detached from each other. The adhesion of the cells seems to be 
reduced and actin stress fibers are barely detectable. On the other hand, no phenotypical 
changes were noticed in case of the microtubular network. 
 
3.2.3. Assessment of intracellular levels of oxidative stress 
Compounds possessing chalcogen(s) and quinone(s) redox centres were able to 
significantly increase the ROS levels in A-431 melanoma cells in a concentration dependent 
manner over 1 h treatment in both DCF (Figure 13, panel a) and DHE assays (Figure 30, 
panel b). 
a) 
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 b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. ROS levels were measured in A-431 using two different methods after 1 h of 
treatment with different concentrations of multifunctional compounds. 
a) A DCF assay was run after incubation with 2p, 5p, 6p, and 10p 
b) A DHE assay was performed after incubation with 1p, 3p, 6p, and 9p. 
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On the other hand, compounds with one redox centre (sulfur and selenium) were not able 
to disturb the ROS levels in A-431 melanoma cells over a 1 h treatment in the tested 
concentration range in the DCF assay (Figure 31). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. ROS levels were measured in A-431 using the DCF assay after 1 h of 
treatment with different concentrations of 7u, 8u, 11u, and 13u. 
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Interestingly, compounds with tellurium redox centres (only one redox centre) were able 
to decrease the ROS levels to some extent in A-431 melanoma cells in a concentration 
dependent manner over 1 h treatment in the DCF assay (Figure 32). 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 32. ROS levels were measured in A-431 using the DCF assay after 1 h of 
treatment with different concentrations of tellurium containing compounds 6u, 9u, 12u, 
17p, 18p,  and 19u. 
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Figure 33 (panel a and b) shows the levels of ROS monitored in both, A-431 melanoma 
cancer cells and primary HUVECs.  
 a) 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
   
   
 
 
 
 
 
 
 
 
 
Figure 33. Assessment of oxidative stress in melanoma and normal human umbilical 
vein endothelial cells. 
 Using two different methods ROS levels were measured in A-431 in comparison with HUVECs after 1 h of 
treatment with different concentrations of multifunctional compounds. 
a) A DCF assay was run after incubation with 5p, 6p, and 8p 
b) A DHE assay was performed after incubation with 1p and 6p. 
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The intracellular levels of reduced glutathione after a 1 h treatment of exponentially 
growing MCF-7 cells with different concentrations of test compounds were then estimated by 
the DTNB assay. A concentration of 5 µM of compounds 7p, 8p, 10p, and 12p causes a 
decrease of the intracellular GSH level in the breast cancer cell line up to 46%, 59%, 62%, 
and 76%, respectively (Figure 34). 
 
Figure 34. Assessment of the intracellular levels of reduced glutathione in breast cancer 
cells.  
Depletion of the intracellular levels of reduced GSH in MCF-7 cells treated with compounds 7p, 8p, 10p, and 
12p for 1 h were assessed employing the DTNB assay. This assay is not entirely specific for GSH, but DTNB 
reacts also with other thiols, including proteins and enzymes. 
 
3.2.4. Thiophenol oxidation assay (PhSH assay) 
 This assay was used as a predictor of activity in cell culture. The results shown in 
Table 7 confirm that all coumpounds enhance the oxidation of thiols in the presence of H2O2. 
Several compounds are even considerably more active than the benchmark compound 
ebselen (1.5-fold increase vs. DMSO), with tellurium compounds 16p and 3u being the most 
active.  
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Table 7. The thiophenol (PhSH) assay (normalized for 
DMSO). 
Product PhSH- Assay 
ebselen 1.5 
2p 1.32 
4p 1.81 
8p 2.09 
15p 1.95 
16p 5.09 
3u 4.73 
2u 1.23 
1u 1.14 
 
3.2.5. Thiobarbituric acid radcial scavenging assay (TBA assay) 
Most of the compounds were not particularly active in this assay. Only the tellurium 
compounds 16p and 3u showed some acitvity, probably due to the higher reducing power of 
tellurides compared to selenides. In contrast, most of the other (selenium) compounds were 
not active (Figure 35).  
 
 
 
  
 
 
 
 
 
 
 
 
Figure 35. Thiobarbituric acid radcial scavenging assay 
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3.2.6. Cell cycle analysis 
 Flow cytometric analysis of MCF-7 cells treated with 7p, 8p, 12p, 17p, 9u, and 3u at 
their respective IC50s for 24 h revealed a significant delay in cell cycle progression.  
 Figure 36 and Table 8 show a clear increase in the G0/G1 phase and reduction in 
G2/M phase compared to vehicle control (See Appendix for more results). 
 
Table 8. The distribution percentage of cell cycle phases with different 
multifunctional compounds compared to vehicle treated methanol 
  
Cell cycle Phase 
% 
G0/G1 S G2/M 
 
Methanol 
(negative control) 
 
68 
 
19 
 
1.6 
7p 80 7.7 12 
8p 95 3.9 1.6 
12p 87 6.8 6 
17p 92 6.2 8.8 
3u 89 5.5 5.8 
9u 85 6.2 8.8 
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a) 
 
b) 
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c) 
 
Figure 36. Cell cycle analysis of MCF-7 breast cancer cells. 
MCF-7 cells were treated with methanol (vehicle control; panel a), or with 8p (panel b), and 17p (panel c) at 
their respective IC50s for 24 h. The diagrams show the distribution of the cells according to their DNA content. 
The inserts give the percentages of cells in different cell cycle phases. 
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3.2.7. Caspase activity 
 The caspase-3/7 activity in A-431 cells was assessed in cells treated with 12p for 24 
hours employing the homogeneous, luminescent caspase-Glo 3/7 kit. 
 Figure 37 shows that caspase-3/7 activity increased significantly in a time dependent manner 
in case of the multifunctional compounds 12p with three redox centres (one quinone and two 
selenium atoms). 
Figure 37. The activity of caspase-3 and -7 in A-431 melanoma cells. 
A-431 cells were treated with compound 12p was monitored employing a homogeneous, luminescent caspase-
3/7 assay. 
 
On the other hand, there was no significant change in caspase-3/7 activity after 24 hr 
treatment with compounds possessing one redox centre (sulfur, selenium or even tellurium). 
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3.2.8.  Apoptosis  
 Flow cytometric analysis of FITC Annexin  V labeled A-431 cells treated with 
different concentrations (0, 8, 11 and 13 µM) of 12p for 12 h indicated a concentration 
dependent increase of apoptotic cells (Figure 38).  
 
 
Figure 38. Flow cytometric analysis of apoptosis. 
 A-431 melanoma cells were treated with 0, 8, 11, and 13 µM of compound 12p for 12 h, and stained with FITC 
Annexin  V and propidium iodide. Quadrant I contains the percentage of viable cells (stained neither with PI nor 
with FITC Annexin  V); quadrant III shows the percentage of late apoptotic cells (stained with both PI and FITC 
Annexin  V), and quadrant IV the percentage of early apoptotic cells (stained with FITC Annexin  V only).  
Chapter III  Results 
97 
 
3.2.9.  Chemogenomic assay 
 The compounds activity against S. cerevisiae wild type and other mutant strains was 
determined using agar diffusion assays. Diameters [mm] of inhibition zones of agar diffusion 
assays are given in Table 9.  
 
 
3.2.10.  Microbiological assays 
 The antifungal activity of was evaluated against Saccharomyces cerevisiae, Candida 
albicans and Aspergillus niger, and the antibacterial activity against Mycobacterium phlei, 
Micrococcus luteus, Staphylococcus aureus, Klebsiella pneumonia, Pseudomonas aeruginosa 
and Escherichia coli tolC using agar diffusion assays. Diameters [mm] of inhibition zones of 
agar diffusion assays are given in Table 10. 
  
 
Table 9. Activity of the multifunctional compounds against S. cerevisiae wild type and 
mutant strains. Diameters [mm] of inhibition zones of agar diffusion assays are given. 
 
BY4741 
Wild type 
YJR104C 
SOD1 
YHR008C 
SOD2 
YDR032C 
PST2 
YHL028W 
WSC4 
YLL060C 
GTT2 
YPL188W 
POS5 
YGL158W 
RCK1 
YOL049W 
GSH2 
YLL009C 
COX17 
YDL190C 
UFD2 
 
1p 
 
0 
 
10 
 
0 
 
12 
 
11 
 
0 
 
0 
 
0 
 
0 
 
10 
 
10 
2p 0 15 12 12 11 12 9 9 9 0 0 
3p 0 18 13 12 12 0 0 0 0 0 0 
5p 0 13 12 11 11 17 0 0 0 0 0 
6p 0 16 15 11 16 12 10 10 10 11 0 
7p 0 22 19 11 19 21 11 18 18 13 13 
8p 0 21 18 11 20 20 11 14 14 14 0 
9p 0 17 11 15 0 12 0 0 0 0 0 
10p 0 20 25 11 14 18 0 0 0 0 0 
11p 0 12 0 11 14 12 0 0 0 0 0 
12p 0 14 19 16 26 25 17 15 15 15 15 
Diameters (mm) of inhibition zones of an agar diffusion assay are given. In each case 6-mm disks with 20 µg 
of the test compounds were incubated. 
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Table 10. Diameters [mm] of inhibition zones of agar diffusion assays against a variety of 
fungi and bacteria, the fungal growth was observed after 1 and 2 days. 
 S. cerevisiae C. albicans As. niger M. phlei 
M. 
Luteus 
S. aureus K. pneumonia P. aeruginosa 
E. coli 
tolC 
1p 0 0 0 0 0 0 0 0 0 
3p 0 0 0 0 0 0 0 0 0 
5p 0 0 0 0 0 0 0 0 9 
6p 0 0 0 9 9 0 0 9 11 
7p 0 0 18 19 18 0 0 15 16 
8p 0 0 10 10 10 0 0 12 10 
9p 0 0 0 9 9 0 0 13 11 
10p 0 0 0 0 7 0 0 10 9 
11p 0 0 0 0 0 0 0 10 9 
12p 0 0 0 0 7 0 0 10 0 
16p 0 0 19 16 11 13 13 12 11 
1u 0 0 0 0 0 0 0 0 0 
2u 0 0 0 0 7 0 0 0 0 
3u 0 0 0 15 8 11 12 0 12 
13p 0 0 0 0 0 0 0 0 0 
14p 0 0 0 0 0 0 0 0 0 
15p 0 0 0 0 0 0 0 0 0 
15u 0 0 0 0 0 0 0 0 0 
 
Table 10: continued….. 
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 S. cerevisiae C. albicans As. niger M. phlei 
M. 
Luteus 
S. aureus K. pneumonia P. aeruginosa 
E. coli 
tolC 
4u 0 0 0 0 0 0 0 0 0 
5u 0 0 0 0 0 0 0 0 0 
6u 0 0 0 12 7 10 12 10 12 
7u 0 0 0 0 0 0 0 0 0 
8u 0 0 18 0 0 0 0 0 0 
9u 0 0 10 17 13 12 12 9 11 
10u 0 0 0 15 0 0 0 0 0 
11u 0 0 0 0 0 0 0 0 0 
12u 0 0 0 12 8 11 13 9 11 
13u 0 0 0 0 0 0 0 0 0 
14u 0 0 19 0 0 0 0 0 0 
17p 0 0 0 14 7 16 15 0 12 
18p 0 0 0 0 7 0 0 0 0 
19p 0 0 0 15 9 0 0 0 0 
Diameters (mm) of inhibition zones of an agar diffusion assay are given. In each case 6-mm disks with 20 µg of the 
test compounds were incubated. 
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3.2.11. The partition coefficient (logPow) measurements 
The experimental partition coefficient values (logPow) of the compounds in the 
octanol-water system were measured by the high performance liquid chromatography 
(HPLC) technique (Table 11) to check the compliance with Lipinski‟s rule. 
 
Table 11: Retention times, logK and logPow values for compounds and several reference 
standards.  
Cpd.  Retention time 
75% MeOH 
LogK LogPow Cpd.  Retention time 
75% MeOH 
LogK LogPow 
Thiourea 0.728 ----- ---- 7u 1.407 -0.03 3.10 
Acetanilide 0.811 -0.94 1 8u 1.412 -0.03 3.10 
Benzene 0.941 -0.53 2.1 9u 0.890 -0.65 1.72 
Toluene 1.508 0.03 2.7 10u 2.514 0.39 4.00 
Thymol 1.285 -0.12 3.3 11u 2.088 0.27 3.70 
Naphthalene 1.894 0.20 3.6 12u 0.834 -0.84 1.31 
Phenanthrene 3.615 0.60 4.5 13u 1.698 0.12 3.40 
1u 2.940 0.48 4.20 14u 1.134 -0.25 2.60 
2u 3.297 0.55 4.23 16p 0,928 -0.56 1.92 
3u 0.938 -0.54 1.97 17p 2.247 0.32 3.83 
4u 2.170 0.3 3.80 18p 1.356 -0.06 3.01 
5u 1.434 -0.01 3.12 19p 0.794 -1.04 0.90 
6u 1.548 0.05 3.30  
In essence, these values point towards a lipophilicity which is in compliance with Lipinski‟s rule requiring a logPow 
value of below 5 (and above -0.4). 
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Chapter IV: Discussion 
As introduced before, the aim of this study was to serve three major, interdependent, 
purposes; namely the synthesis of multifunctional catalytic agents potentially able to 
recognize the biochemical signature of OS in cancer cells, the subsequent evaluation of this 
potential in both primary and malignant cells, and the characterisation of the underlying mode 
of action(s) by which these agents exert their activity. 
 
4.1. Selection and Synthesis of Suitable Redox Agents 
The synthesis of multifunctional redox agents encounters many challenges by moving 
from just one or two to three or even more redox centres- in particular if a rather complicated 
selenium and/or tellurium chemistry is involved.43 Many synthetic avenues have been 
described for the synthesis of multifunctional redox agents. Such avenues, however, have 
often been marred by low yields, decomposition of the products, and difficulties to generate 
compounds in sufficient quantities and purities.36, 39 
Although the most basic „nucleophilc substitution‟ approach appears to be a simple one-
step procedure (Figure 10), it is ultimately limited in scope, mainly, by the low yield. Indeed, 
the attraction of one-step synthesis is lost once rather complex starting materials have to be 
synthesized  first. 
Furthermore, the aminoalkylation method, which works rather well in case of sulfur and 
selenium compounds (Figure 11), seems to be unsuccessful in case of the corresponding 
tellurium analogues. Even more, the yields obtained are usually only up to 35%, which is still 
considered low, in principle. 
The amide coupling approach is capable of overcoming the previous difficulties. It allows 
the successfull synthesis of various selenium and tellurium compounds (Figure 12) in rather 
good yield (50-60 %). Higher functionalized or more diverse compounds, however, may 
become difficult. This is due to the fact that generally just two building blocks are assembled 
via amide coupling, and additional groups would have to be introduced via more complex 
building blocks. Ultimately, the issue of generating highly functionalized molecules would 
simply shift from the synthesis of the final product to the synthesis of the individual building 
blocks. All these obstacles in addition to the strong demand for multifunctional redox agents 
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compelled me to look for and develop new synthetic avenues that are able to overcome the 
previous mentioned drawbacks and to generate a wide range of tailor-made multi-functional 
agents. 
In 2005, Fry et al.36 have shown that compounds integrating two redox sites, i.e. a redox 
active quinone and a chalcogen moiety, are able to discriminate between oxidatively stressed 
and unstressed cells in culture. The potential selective anticancer activities of such agents 
were also established to occur at submicromolar and low micromolar concentrations. At that 
time, the ability of such catalysts to effectively and selectively kill cells under OS was only 
demonstrated for rat PC12, human Jurkat and human Daudi cells.39, 41 Moreover, the precise 
redox behaviour and mode of action of these compounds were not fully explored. 
 From the perspective of synthetic chemistry, the synthesis of such compounds provides 
interesting challenges since they were prepared in quite low yield, for instance, in case of 
compound 3n, yields of just 9% have been obtained, emphasising the urgent need to develop 
more efficient methods for the preparation. 
The synthesis of 2-methyl-3-(phenyltellanyl)naphthalene-1,4-dione (3n) has already been 
described in literature with dramatic variation in the yield.36 Sodium borohydride (NaBH4) 
was used for the reduction of the corresponding ditelluride employing ethanol as the solvent.  
 
 
Figure 39. Reaction mechanism for the synthesis of quinone-chalcogen compounds by 
nucleophilic substitution. 
 
In order to increase the yield, other procedures (metal-catalyzed), quoted from literature, 
have been explored including; samarium (II) iodide (SmI2), indium (I) iodide (InI), 
triphenylphosphine (C6H5)3P, and tributylphosphine [CH3(CH2)3]3P based reactions.45, 87-89 
Chapter IV  Discussion 
103 
 
Unfortunately, such strategies turn out to be low yielding or ineffective with our starting 
materials.  
This impelled us to reconsider the reaction employing NaBH4 as it is a cheap and shelf 
chemical reagent. During the initial studies we observed that: The ethanolic, colourless, 
solution of ditelluride/NaBH4 turns to a deep violet colour upon adding the bromoquinone. 
This colour disappears immediately. We thought that the violet colour is due to the product 
formation i.e. violet crystals, and the disappearance is due to the reduction by excess NaBH4, 
which is always used in excess (2-5 equivalents). The excess NaBH4 was then reduced either 
by decreasing the amount of NBH4 to 1 equivalent, or by adding acetaldehyde to the reaction 
mixture. As the preliminary trials showed little improvement in the yield, we looked for other 
possible strategies. Back et al.
 
reported a method for the preparation of sodium diselenide 
(Na2Se2) in „water‟ from selenium and NaBH4.90
 
  
This directed us to think of using mixed organic-aqueous solvent systems, since some of 
the starting materials are not soluble in water or organic solvents. 
 Theoretically, a two phase system and phase transfer catalyst (PTC) would be 
appropriate for this type of reaction. The sodium salt (resulting from the reduction of the 
ditelluride by NaBH4) would be soluble in water, and the bromoquinone would be soluble in 
organic solvent (e.g. ethyl acetate). The role of the PTC is to facilitate the migration of the 
salt from the aqueous phase into the ethyl acetate phase, where the reaction ultimately takes 
place. Owing to the fact that the reactant in this case is anionic, the quaternary ammonium 
salt „tricaprylylmethylammonium chloride‟ was used as the PTC. 
This coupling method enabled the synthesis of a range of mono- and di-substituted 
quinones in a simple one-step synthetic method. Good yields, for instance, in the case of 
compound 3n yields of 79%, have been obtained with the two-phase-system, compared to a 
yield of just 9% for 3n by the original method. Nonetheless, this method is ultimately limited 
by the number of achievable compounds, chemical diversity, and the availability of suitable 
quinones and chalcogen-derivatives. It is also questionable if higher substitutions, such as 
three- or four-substituted quinones, may be accessible by this method or stable in aqueous 
media, especially in the case of tellurium.43, 91  
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A bolder approach has therefore been investigated. The use of a simple Passerini three 
component reaction has elegantly cleared the way for tri- and even tetra-functional redox 
agents containing multiple chalcogen and quinone redox sites. Apart from being able to 
deliver the complicated multifunctional redox catalysts, the Passerini reaction employed here 
is characterized by the utilization of the same building blocks which were used previously as 
part of the less sophisticated synthetic avenues (namely aminoalkylation and amide 
coupling). 
Initial experiments showed that the classical volatile organic solvents usually used for the 
Passerini reaction, such as CH2Cl2 and CHCl3, were associated with several disadvantages 
such as long reaction times, low yields, undesired side reactions and the formation of by-
products (monitored by TLC). A significant enhancement of reaction rate and yields has been 
achieved upon using water as solvent instead of the classical organic solvents. This 
acceleration could be attributed to many factors, including the hydrophobic effect and 
enhanced hydrogen bonding in the transition state. As described above, not only does the use 
of water as solvent permit the reaction to be conducted rapidly, the products are often 
insoluble, facilitating their ready isolation as precipitates. 
Since the last 10 to 15 years have seen an increased interest in both, quinone and 
chalcogen chemistry, a wide range of building blocks for the Passerini reaction are now 
available and can be synthesized with comparable ease following well-established literature 
methods (see Materials and Methods section).
†
 
 
The bifunctionalized quinone-selenium 
bearing an aldehyde (8n) and the quinone-sulfur bearing an acid (2b) are of particular 
importance since they were used for the construction of three- and four-functional molecules. 
Other building blocks were chosen to incorporate the amino acid residues of glycine, L-
serine, and cysteine to the product backbone for biological and pharmacological purposes 
(2c-2e).
 
In case of the isocyanide building blocks, 3b was used in addition to the 
commercially available, frequently used, but expensive tert-butyl isocyanide (3a). In most 
cases 3b offers superior reactivity compared to the 3a.
 
                                                          
† A range of such compounds have now been reported by us in the literature.43, 91 
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Furthermore, 3b adducts could be used for further derivatization. According to the design 
criteria „mix and match‟ compounds were synthesized in order to combine diverse redox 
centres. For example, if one building block were to carry just one function, three- to four-
functional molecules may become accessible. 
The Passerini reaction described here has been employed to synthesize a total of 15 
compounds (1p-15p), whose chemical structures are shown in Figure 23. These compounds 
contain different number of redox centres: A) compounds posses two redox centres of which 
one is quinone and the other is selenium (7p, 9p, 10p); B) compounds with three redox 
centres, either with one quinone, one selenium and one sulfur  (1p, 2p, 3p, 5p); with one 
quinone and two selenium (12p); or with one quinone, one selenium and one disulfide (8p, 
11p); and even C) compounds containing four redox centres with two quinones, one 
selenium, and one sulfur  as the redox centres (4p, 6p).43, 91 
Furthermore, SOD mimics (containing a porphyrin metal binding centre) with/without 
chalcogen and quinone redox sites were also synthesized. These compounds contain: A) only 
a metal binding porphyrin centre (13p); B) a metal binding porphyrin centre and a selenium 
redox centre (14p); and C) a metal binding porphyrin centre, one quinone and selenium redox 
centre (15p).91 
The Passerini chemistry described here is rather straightforward: It can be carried out 
under mild conditions in solvents such as water, and yields are high when compared to the 
other methods evaluated in this study. Furthermore, it could also be used to generate 
molecules bearing four redox sites in one molecule. Nevertheless, the Passerini reaction may 
not always be the method of choice. The reasons for this are associated with the fact that a 
Passerini reaction introduces a low degree of diversity, since three components are only 
available to mix and match. Finally, the Passerini reaction leads to an α-acyloxy amide, i.e. a 
compound containing an ester bond, which is not particularly stable and may be cleaved 
chemically or enzymatically. It is possible that such compounds are readily modified in vivo, 
either for the benefit of activation or, less desirable, in conjunction with a loss of activity.  
A versatile version of multicomponent reaction was therefore employed for the next 
generation of multifunctional redox agents. The utilization of the Ugi reaction, in general, 
offers superior advantages over the Passerini reaction.  
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Owing to the fact that the Ugi reaction is an extension of the Passerini three-component 
reaction, both of them share almost the same building blocks. Furthermore, a four-component 
condensation (Ugi reaction) introduces a higher degree of diversity than a three-component 
one (Passerini reaction). Finally, the two amide bonds which link the components of the Ugi 
adduct are more stable and also suitable for the synthesis of peptidomimetics than the 
combination of one ester and one amide bond produced in the Passerini reaction.  
While the Ugi reaction is an excellent tool for a library synthesis of this core structure, it 
also suffers from a lack of commercially available isocyanides. Unlike the other three readily 
available components, fewer than two dozen isocyanides can be purchased. One possible 
solution is the creation of a sub-library of isocyanides as input into the Ugi four component 
condensations (Ugi-4CC) library. The isocyanides are the most difficult building blocks to 
functionalise, since they are typically not simple to prepare, volatile, and have quite offensive 
odours. This smell has been described by Hofmann and Gautier as „highly specific, almost 
overpowering‟, „horrible‟, and „extremely distressing‟. In order to turn this apparent 
limitation of the isocyanide building blocks into an advantage, we have devised chalcogen 
bearing isocyanides suitable for multicomponent chemistry, including the tellurium 
containing isocyanide. This is considered the first example where tellurium participates in 
both Passerini and Ugi IMCRs, according to the best of our knowledge.91  
The most effective reported isocyanide preparation method is based on the dehydration of 
formamides with the dangerous reagent phosgene. While some alternative syntheses have 
been reported, they are not considered a general method of preparation. In our case, the 
dehydration of the formamide was carried out using the less dangerous phosphoryl chloride 
(POCl3) within only 2 hours in a good yield (up to 82 %). The newly synthesized  isocyanides 
allowed the synthesis of a total of 19 compounds (1u-15u and 16p-19p).91 
In general, this approach has two major benefits. Firstly, we are now able to generate 
selenium and tellurium containing molecules, which combine two, three or even four redox 
sites in one molecule at will. Secondly, the synthetically more accessible acid, aldehyde, and 
amine building blocks remain variable and can be used to contribute further functionalities to 
the multicomponent reaction products. 
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To conclude, the reaction conditions not only place the Passerini and Ugi reactions within 
the realm of „green‟ chemistry, but also enable the use of a wide range of sensitive building 
blocks, which may decompose otherwise (e.g. at elevated temperatures) - ultimately allowing 
the employment of a range of redox active aldehydes, acids and isocyanides containing 
quinones, selenium and similar redox centres. The individual building blocks required can 
now be synthesized with comparable ease (including functionalized isocyanides) and one 
may „mix and match‟ them according to individual design criteria. Multicomponent 
chemistry ultimately was used to generate molecules bearing one, two, three, or even four 
redox and/or metal binding sites in one molecule. Analytical data for these compounds (
1
H-
NMR, 
13
C-NMR, LC-MS) were in accordance with the calculated/predicted values. 
 
4.2. Cytotoxic Activity of Redox Compounds in Cancer and Healthy Cells 
Initial screens for antiproliferative activity against different cancer cell lines revealed two 
distinct groups, separating multifunctional agents into toxic and non-toxic compounds. On 
the one hand, compounds possessing only one redox centre (sulfur or selenium) 4u, 5u, 7u, 
8u, 10u, 11u, 13u, and 14u were not able to reduce the cell survival of cancer cells. The same 
behaviour was also noticed in case of porphyrin containing compounds, 13p, 14p, 15p, and 
15u, regardless if these compounds were combined with one additional redox centre (such as 
the selenium in the case of compound 14p) or with two redox centres (for example compound 
15p which contains a selenium and quinone redox sites) besides the porphyrin moiety.
‡
 
 
  
 
 
 
 
 
 
                                                          
‡ Since this group of compounds was not toxic against cancer cell lines, the compounds were considered of less 
importance to us, and will be less considered thereafter. 
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On the other hand, compounds with tellurium comprising one redox centre, such as 
compounds 6u, 9u, 12u, 17p, 18p, and 19p, exhibited a significant toxic effect, compared to 
the sulfur and selenium analogues, against the same cancer cell lines. Indeed, compounds 
incorporating two, three, and four redox centres (with sulfur, selenium, and /or tellurium 
besides the quinone moiety) were also able to inhibit the proliferation of different cancer cell 
lines, as expected, in a moderate to high toxicity range. A closer look at the synthesized 
compounds revealed a certain correlation between chemical structure and toxic activity. 
Including, but not limited to: Tellurium compounds, in general, show higher toxic effects 
than the other synthesized agents (sulfur and selenium analogues). Moreover, compounds 4p 
and 6p with four redox centres were more cytotoxic than their homologues with three redox 
centres (1p, 2p, 3p, and 12p) as was expected. Nevertheless, there were exceptions: 
Compounds 7p, 9p, and 10p with just two redox centres were among the most toxic 
compounds, while compound 11p with four redox centres showed only modest toxicity. 
These observations were in excellent agreement with the one- and five-dose screens 
performed as a part of this study at the National Cancer Institute (Bethesda, MD, USA) for  
compounds 2p, 4p, 6p, 7p, 8p, 9p, 11p, 12p, 15p, 16p, 3u, 6u, and 9u.
§
 Their corresponding 
GI50 (50% growth inhibition) values were in the low to sub-micromolar range (see Appendix 
for details).  
  
 
 
 
 
 
 
 
 
 
                                                          
§ These compounds were selected by the National Cancer Institute according to their defined guidelines. 
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COMPARE analyses were performed using the correlation coefficient method. The 
compounds' pattern of activities correlates with cisplatin, which is used to treat various types 
of cancers, including sarcomas, lymphomas, and germ cell tumours. It also correlates with 
redox-activated methyl mitomycin C, which has an antitumour antibiotic activity against 
breast cancer, and last but not least, with anthracycline-based redox compounds such as 
menogaril, deoxydoxorubicin, and MX2 HCl, which are used in the treatment of prostate 
cancer and leukemia (see Appendix for details). 
Interestingly, when incubated with primary human fibroblasts (HF) and human umbilical 
vascular endothelial cells (HUVEC), some of the test compounds showed low toxicity (Table 
6).  Compound 9p clearly showed five to seven times lower cytotoxicity against primary cells 
than against the cancer cells. The same holds true for 10p with the exception that it was also 
toxic to primary fibroblasts. Compound 6u was five times more toxic to breast and 
epidermoid cancer cells (but not against the kidney cancer cells), than in case of the primary 
fibroblasts. In case of 16p, a toxic effect was only noticed in case of kidney and epidermoid 
cancer cells and not against the breast cancer cells. The IC50 value of 16p in killing cancer 
cells were thirteen fold lower than the one measured for the primary fibroblasts. 
Importantly, compounds 3p, 18p, and 19p point to a different type of selectivity. These 
compounds were only toxic to breast cancer cells (and not toxic to kidney and epidermoid 
cancer cells). Even though one can only speculate about the compounds' mode(s) of action, 
the various redox sites in these molecules point towards a modulation of the intracellular 
redox state. Quinones are known to increase ROS production in cells, while chalcogen 
compounds may „use‟ ROS to oxidize and hence impair redox-sensitive proteins and 
enzymes.  
It is likely that a combination of a „ROS generator‟ and a „ROS user‟ will be effective in 
increasing levels and severity of OS in cells and, in the case of cancer cells, push them over 
the critical ROS threshold. In contrast, normal cells with comparably low intrinsic levels of 
OS may be less affected. 
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4.3. Induction of  Oxidative Stress  
Mounting evidence suggests that, compared to their normal counterparts, many types of 
cancer cells have increased levels of ROS.3, 31, 32 In turn, ROS are considered to be responsible 
for the maintenance of the cancer phenotype. The enhanced ROS generation is described in 
several in vitro and in vivo cancer models. For instance, cell lines from melanoma, colon, and 
pancreatic carcinoma, breast and ovarian cancer, and neuroblastoma produce more H2O2 than 
normal, non-transformed cells. Likewise, chronic lymphocytic leukemia cells obtained from 
patients show an increased ROS production when compared to normal lymphocytes. 
Furthermore, elevated oxidative modifications in DNA, proteins, and lipids have been 
detected in various primary cancer tissues including renal cell carcinoma, mammary invasive 
ductal carcinoma, and colorectal adenocarcinomas, further suggesting that cancer cells are 
inherently under OS.92 
The disparities in ROS generation in cancer versus normal cells may provide a 
biochemical basis for the development of new therapeutic strategies to selectively kill the 
malignant cells. Our studies have demonstrated that it may be possible to take advantage of 
this biochemical difference between cancer cells and normal cells to preferentially increase 
ROS to a toxic level in cancer cells, consequently leading to death of the malignant cells. 
According to our results, multifunctional redox agents are able to enhance the ROS levels 
(in a concentration-dependent manner) in melanoma cells (Figure 30) assessed by DCF and 
DHE assays (see Materials and Methods for more details). This effect is likely to be the result 
of quinone redox cycling (Figure 9). Quinones are able to perform a redox cyclization 
process with triplet oxygen, to yield semiquinone and hydroquinone, which readily auto-
oxidize back to the parent quinone, with concomitant production of O2
.-
, which could be 
detected by DHE and DCF assays. The O2
.- 
formed is then rapidly metabolised by superoxide 
dismutase enzymes to dioxygen and H2O2, which is detected by the DCF assay.  
The physiological impact of H2O2 is thereafter enhanced by the peroxidation catalysis 
process which takes place at the chalcogen redox sites. Chalcogens are able, for instance, to 
catalyze the oxidation of thiols such as GSH (Figure 8, panel B) as well as cysteine residues 
in proteins and enzymes. 
Primary cells have a low basal level of ROS compared to cancer cells and can tolerate 
exogenous ROS stress to a certain degree owing to their antioxidative „reserve‟ capacity, 
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which can be mobilized to prevent the ROS levels from reaching the cell-death threshold. In 
order to determine if any of the synthesized compounds may be useful for further biological 
investigations, the ROS levels in A-431 melanoma and HUVECs were monitored. The results 
obtained clearly show that: 
A) HUVECs have lower basal intracellular ROS levels compared to melanoma cells. This is 
considered a further support for our hypothesis.  
B) Multifunctional agents were able to significantly increase ROS levels in melanoma cells 
to higher level compared to HUVECs. This may be due to the fact that primary cells have 
full antioxidant capacity that renders them less vulnerable to the kind of ROS stress that is 
induced by multifunctional redox agents. 
 
Although it is too early to speculate about possible uses of such catalytic, multifunctional 
redox agents in therapy, their rather high activity and selective toxicity against selected 
cancer cells encourages further in vivo investigations of such agents as potential anticancer 
drugs. Furthermore, it had previously been reported that the ROS-mediated cytotoxicity 
induced by various drugs also caused a depletion of endogenous levels of GSH.12, 13 To 
determine whether a similar phenomenon occurred in cells treated with the multifunctional 
agents used as part of this study, levels of reduced glutathione were estimated in these cells 
by the DTNB assay. The intracellular GSH is the most important biomolecule in protecting 
cells against chemically induced cytotoxicity. It acts by removal of free radicals by direct 
quenching, by hydroperoxide reduction or by elimination of reactive intermediates via 
conjugation.  
Upregulation of glutathione levels is an important factor in the protection against 
apoptosis and it is associated with resistance development in cancer therapy.
 
Consequently, 
low glutathione levels are sometimes linked to mitochondrial dysfunction and induction of 
apoptosis, thus decreasing the chemoresistance of cancer cells. Figure 34 points towards a 
rapid decline in levels of endogenous, cellular GSH upon treatment of MCF-7 cells with 
different doses of redox agents, confirming the induction of OS. These results were consistent 
with a recent report, in which the anticancer-based redox drugs anthracycline, juglone, 
plumbagin, and menadione were shown to cause OS in various malignant cells via depletion 
of GSH.12  
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In order to rule out any major antioxidant activity (which may be counter-productive), the 
thiobarbituric acid (TBA) assay has also been performed (see Results for more details). This 
assay measures the ability of compounds to sequester oxygen-based radicals. Most of the 
compounds studied here were not particularly active in this assay (Figure 35). 
 Only the tellurium compounds 3u and 16p showed some activity, probably due to the 
higher reducing power of tellurides compared to selenides. These results confirm that 
tellurides (and some) selenides can scavenge oxygen-based radicals - likely by forming 
telluroxides and selenoxides, respectively. Interestingly, HRMS also gave signals for 
telluroxides, but not for selenoxides, pointing towards ready oxidation of the tellurium 
compounds to telluroxides.  
The comparably straightforward synthesis of such multifunctional agents does not, of 
course, address the question whether such rather complex agents are at all useful in cancer 
therapy. We have therefore performed the thiophenol assay, which measures catalytic activity 
of compounds in the presence of thiols and H2O2. This assay has been used as a predictor of 
activity in cell culture. The results shown in Table 7 confirm that the multifunctional 
compounds were able to enhance the oxidation of thiols in the presence of H2O2. Several 
compounds are even considerably more active than the benchmark compound ebselen (1.5-
fold increase vs. DMSO), with tellurium compounds 3u and 16p being the most active ones. 
These findings are in excellent agreement with previous studies emphasizing the activity of 
tellurium agents in this assay. In cell culture, this apparent „antioxidant‟ reactivity is 
dominated by the catalytic activity demonstrated by the PhSH assay. 
 
4.4.  Cell Cycle Delay 
Upadhyay et al. 25 recently reported that a sublethal dose of H2O2 prevents progression of 
cell cycle by causing delay in the G0/G1 phase. We observed that multifunctional redox 
agents 7p, 8p, 12p, and 3u manifested the same behaviour (Figure 36). For example, cell 
cycle analysis of MCF-7 cells treated with 8p for 24h revealed 95 % cells were in G0/G1, 
with 3.9 % in S, and 1.6 % in G2/M, compared to methanol treated cells  with 68 % in 
G0/G1, 19 % in S, and 13 % in G2/M phase (see Appendix for more details).  
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Interestingly, the same results were also obtained with the tellurium compounds 9u and 
17p. These compounds were able to induce cell cycle delay in G0/G1 phase (85 % and 92 %, 
respectively). These results were consistent with a recent report from the patent literature, 
showing that the tellurium immunomodulating compound ammoniumtrichloro[1,2-
ethanediolato-O,O']-tellurate (AS101) is able to cause G0/G1 cell cycle delay.93 
 
4.5. Phenotypical changes in Cellular Morphology and Cytoskeleton 
As shown in the results section, alterations of cell morphology and the microfilament 
network were also observed, upon treatment with the redox compounds together with the 
perturbation of the ER. The cause was obviously OS. Previous reports have shown that such 
OS can cause damage to all types of biological molecules, including DNA, proteins, and 
lipids. The primary cellular target of OS can vary depending on the cell type, the nature of 
stress imposed (e.g., radical vs. non-radical oxidants), its site of generation (e.g., intra- vs. 
extracellular), the proximity of the oxidant to a specific cellular substrate, and how severe the 
stress is.94 
Cytoskeletal proteins are particularly abundant within the cell and several protein 
constituents of the cytoskeleton display highly reactive residues that can be oxidized easily. 
Owing to this reason, the cytoskeleton may represent one of the preferential targets of ROS 
whatever kind of OS is applied.  
 
4.6.  Induction of apoptosis 
Overwhelming evidence shows that the production of ROS is an early event that initiates 
mitochondria-mediated apoptotic pathways by triggering mitochondrial permeability 
transition pore opening, release of proapoptotic factors and activation of the caspase 
cascade.95 On the other hand, the role of ER stress in ROS-induced apoptosis has seldom 
been reported in cancer cells. A recent report from Seung-Ki Min et al. 94suggests that ER 
stress-mediated apoptosis occurres in human immortalized and malignant oral keratinocytes 
treated with H2O2. In general, most apoptosis pathways depend on the activation of caspases, 
in particular effector caspase 3 and 7, for the final execution of apoptosis. Therefore, it might 
be reasonable to first investigate these two caspases as a sign of apoptosis.  
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Our findings confirm the activation of caspase-3 / 7 in a time dependent manner after A-
431 cells were treated with compound 12p for 24h. This result is considered to be a first 
proof that these compounds act as inducers of apoptosis. 
The apoptosis induction was further investigated by flow cytometry after staining the 
cells with Annexin V and PI. Externalization of phosphotidylserine (PS) from the inner 
leaflet to the outer one of the plasma membrane is a hallmark of early apoptosis. 
 FITC labelled Annexin V binds to PS in the presence of calcium ions, resulting in green 
fluorescence of apoptotic cells. In later stages of apoptosis, PI enters the cells and binds to 
cellular DNA, resulting in red fluorescence. As shown in the Figure 38, treatment of A-431 
cells with 12p for 12 h resulted in an increase in FITC Annexin  V (+) (lower right quadrant) 
and PI (+) (upper right quadrant) fluorescence also indicating that apoptosis is induced. The 
appearance of late apoptotic cells was predominantly (12.9- 29.3 %) seen at the higher 
concentrations (13 μM) of 12p. These results were similar to the findings of Kalyanaraman et 
al.95 where adriamycin (an anthracycline drug used in cancer chemotherapy) induced cell 
death by induction of apoptosis. 
  
4.7. Chemical Genetic Interaction Approach 
Chemogenomic assays using a mutant library of S. cerevisiae have proven to be a 
powerful means to study and predict the mode of action of bioactive compounds. These 
assays rely on comparing the growth of each gene deletion strain to the wild type strain in the 
absence and presence of test compounds.  
The growth inhibition of deletion strains upon exposure to compounds is resulting in a 
chemical-genetic interaction profile. Analyzing such profiles provides information about the 
targets and pathways that are affected by compounds. Such information cann not be obtained 
easily by conventional methods96. We have applied a five-step strategy to possibly link the 
multifunctional compounds used in this study to their target pathways:  
i. We screened all the multifunctional compounds using an agar diffusion assay against S. 
cerevisiae wild type (BY4741) and four mutants (YJR104C, YHR008C, YHR106W and 
YLR011W), which were chosen based on a literature survey because the genes knocked out 
might be important to counterbalance OS. 
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 ii. The IC50 values of compounds 7p and 12p (the most active compounds) were 
determined using a serial-dilution assay against the sensitive mutants YJR104C and 
YHR008C.  
iii. Compounds 7p and 12p were then screened against a set of ~ 4,800 viable S. 
cerevisiae deletion strains using the IC50 concentration found in step (ii).   
iv. We identified a set of mutants which were sensitive in two chemical-genetic 
interaction screening procedures (step iii).  
v. The results from the chemical-genetic interaction profiling were evaluated and 
confirmed using an agar diffusion assay in a second round of analysis. 
 
At the concentrations applied the compounds under investigation had no effect on the 
wild type strain, BY4741, but striking effects were observed with 10 mutants (Table 3). 
Superoxide dismutase (mitochondrial and cytosolic copper-zinc SOD), glutathione synthetase 
(GSH2) and transferase (GTT2), and cytochrome c oxidase (COX17) deficient strains were 
among the mutants most sensitive to the test compounds.  
These enzymes play a major role in the antioxidant defence system and are pivotal for the 
removal of toxic oxidants. Deletion of the respective genes therefore might cause an OS 
sensitive phenotype of the mutant. These observations are in excellent agreement with the 
other cell-based assays performed as a part of this study, all of which unambiguously point 
towards a link between the redox compounds and a redox modulated cellular mode of action. 
 
4.8. Antimicrobial Activity 
The antimicrobial activity of the synthesized compounds was evaluated against three 
fungal strains namely Saccharomyces cerevisiae, Candida albicans and Aspergillus niger and 
six bacterial strains including Mycobacterium phlei, Micrococcus luteus, Staphylococcus 
aureus, Klebsiella pneumonia, Pseudomonas aeruginosa and Escherichia coli tol C using 
agar diffusion assays (Table 10). 
In general, almost all the compounds were nontoxic against S. cerevisiae, C. albicans and 
A. niger. Interestingly, compounds 7p and 16p showed a striking toxic effect against A. niger 
(the inhibition zone diameter was 18 and 19 mm, respectively).  
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On the other hand, most of the compounds show low to moderate toxicity against 
Mycobacterium phlei and Micrococcus luteus. Tellurium compounds were rather toxic to 
Staphylococcus aureus and Klebsiella pneumonia, while the quinone-containing compounds 
were not. The reverse effect was noticed in case of Pseudomonas aeruginosa and Escherichia 
coli tol C. Finally, compounds with one redox centre (sulfur and selenium) were not toxic at 
all to the tested organisms. 
 
4.9. QSAR studies 
Computer simulation techniques potentially offer further means to probe inhibition 
mechanisms. The quantitative structure−activity relationships (QSAR) represent one of the 
most effective computational approaches in drug design. While QSAR is largely used to 
predict activities and to define pharmacophore models, it was not useful or reliable in our 
case due to the small number of compounds available and the potential diversity of cellular 
targets involved (see Appendix for details)  
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Concluding Remarks and Future Perspectives 
This study has developed a promising synthetic avenue able to generate, with comparable 
ease, a wide range of tailor-made multi-functional catalysts designed to target cancer cells 
under OS. The use of a simple, straight forward, yet effective multi-component reactions 
have elegantly cleared the way for the synthesis of tri- and tetra-functional redox agents 
containing multiple chalcogen, porphyrin metal binding and quinone redox sites. In addition, 
the implementation of all combinations of P-3CR and U-4CR even with rather flexible 
building blocks supports the great potential of this concept towards the diversity-oriented 
synthesis of multifunctional agents.  
In cancer cells, such agents inhibit proliferation and induce cell death via multifactorial 
mechanisms such as induction of OS, cell cycle delay, and apoptosis. Although one can only 
speculate about the exact mode(s) of biochemical action of these compounds, the presence of 
several redox sites in these molecules points towards a modulation of the intracellular redox 
state in these cells. Quinones are known to increase ROS production in cells, while chalcogen 
compounds may „use‟ ROS to oxidize and hence impair or inhibit proteins and enzymes. It is 
therefore likely that a combination of a „ROS generator‟ and a „ROS user‟ will be effective in 
increasing levels and severity of OS in cells and, in the case of cancer cells, push them over 
the critical ROS threshold. In contrast, normal cells with comparably low intrinsic levels of 
OS may be less affected. Interestingly, some of the compounds studied here showed no 
apparent reduction in cell survival when incubated with normal healthy cells, and it is 
possible that such compounds may have a selective anticancer activity. 
 As far as synthetic chemistry is concerned, future studies may refine and expand the 
method proposed here, building upon more -and more diverse- building blocks, most of 
which will be easily accessible. At the same time, there is a need for more chemically diverse 
catalytic compounds. Here, the development of such multifunctional catalysts is not just 
dictated by an interest in anticancer drugs. It also poses a real challenge to synthetic organic 
chemistry, which needs to employ a sophisticated arsenal of modern synthesis to deal with 
the relevant quinone and chalcogen chemistry. The synthesis of organoselenium and 
organotellurium compounds has never been an easy task, and this area of research provides 
ample opportunities for further development and expansion. 
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This opens the door to a range of follow-up studies in the area of synthetic chemistry, 
redox chemistry, biochemistry and, ultimately, drug development.  
Preliminary cell based studies point towards a reasonably selective activity of some of 
these compounds, which needs to be investigated further by using a considerably wider 
arsenal of cells. Furthermore, in order to establish the complete picture of redox catalysts as 
possible therapeutics, this line of investigation will then need to move on to studies in animal 
models.  
In any case, there is plenty of scope for further, multi-disciplinary studies involving 
chemistry, biochemistry, cell biology, and pharmacology in order to develop a strategy to 
treat cancer by applying redox active compounds. 
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Appendix 
Appendix 1. Influence of different multifunctional redox compounds on the viability and 
proliferation of different cell lines. The IC50 [µg/ml] was measured in two different sets of 
experiments using an MTT reduction assay after five days. 
Cpd. Nr. L-929 A-549 SW-480 MCF-7 A-431 A-498 
1p 7 22 11 4 8 22 
2p 6 10 10 8 6 28 
3p 10 >100 8 5 8 23 
4p 22 1 1 1 1 1 
5p 8 >100 9 5 9 >100 
6p 8 3 6 5 5 4 
7p 1 1 1 1 1 2 
8p 1 1 1 1 1 1 
9p 15 4 >100 5 2 2 
10p 8 2 11 4 5 2 
11p 6 2 3 1 2 1 
12p 1 1 1 1 1 1 
13p >100 >100 >100 >100 65 >100 
14p >100 >100 >100 >100 >100 >100 
15p >100 >100 >100 >100 >100 >100 
 
       Appendix 1 :continued….. 
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Cpd. Nr. L-929 A-549 SW-480 MCF-7 A-431 A-498 
17p 1 1 1 1 2 1 
18p 3  1 1   
19p 8  4 1   
1u 7 35 >100 6  19 
2u 8 >100 >100 3 14  
3u 1 1 1 1 1  
4u >100 >100 3 18 >100 10 
5u >100 10 >100 31 >100 >100 
6u 29 2 2 3 3 6 
7u >100 >100 28 >100  46 
8u 1 >100  15 70 12 
9u 3 1 2 1 4 2 
10u >100 >100 >100  17 9 
11u >100 >100 >100  >100 >100 
12u 4 1 2 1 5 4 
13u  >100 >100 3 5 >100 
14u 6 14     
15u >100 >100 >100 >100 >100 >100 
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58 CANCER CELL LINE SCREEN 
The 58 cancer cell line screen for was performed at the National Cancer Institute 
(NCI) at the NIH (US). These single dose tests (at 10 μM) were performed for cell lines 
clustered in cells representing leukemia, non-small cell lung cancer, colon cancer, cancer of 
the central nervous system, melanoma, ovarian cancer, renal cancer, prostate cancer and 
breast cancer. All compounds were selected for 5-dose testing. All tests follow a standard 
protocol for cytotoxicity screens, details of which can be obtained from the NCI website at 
http://dtp.nci.nih.gov. 
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Appendix 2. Assay data obtained for compound 2p in different cancer cell lines. 
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Appendix 3. Assay data obtained for compound 4p in different cancer cell lines. 
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Appendix 4. Assay data obtained for compound 6p in different cancer cell lines. 
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Appendix 5. Assay data obtained for compound 7p in different cancer cell lines. 
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Appendix 6. Assay data obtained for compound 8p in different cancer cell lines. 
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Appendix 7. Assay data obtained for compound 9p in different cancer cell lines. 
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Appendix 8. Assay data obtained for compound 11p in different cancer cell lines. 
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Appendix 9. Assay data obtained for compound 12p in different cancer cell lines. 
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Appendix 10. Assay data obtained for compound 3u in different cancer cell lines. 
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Appendix 11. Assay data obtained for compound 6u in different cancer cell lines. 
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Appendix 12. Assay data obtained for compound 9u in different cancer cell lines. 
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Appendix 13. Assay data obtained for compound 16p in different cancer cell lines. 
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Appendix 14. Assay data obtained for compound 15p in different cancer cell lines. 
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Appendix 15. COMPARE analysis for compound 2p.  
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Appendix 16. COMPARE analysis for compound 4p.  
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Appendix 17. COMPARE analysis for compound 6p.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 18. COMPARE analysis for compound 7p.  
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Appendix 19. COMPARE analysis for compound 8p.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 20. COMPARE analysis for compound 9p.  
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Appendix 21. COMPARE analysis for compound 11p.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 22. COMPARE analysis for compound 12p. 
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Appendix 23. COMPARE analysis for compound 3u. 
 
 
 
 
 
 
 
 
 
Appendix 24. COMPARE analysis for compound 6u. 
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Appendix 25. COMPARE analysis for compound 9u. 
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Appendix 26. COMPARE analysis for compound 15p. 
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Appendix 27. Name and description of the S. cerevisiae mutants identified by the chemogenomic assay. 
Mutant Name 
(Systematic name) 
Description 
YPL188W 
 (POS5) 
Mitochondrial NADH kinase, phosphorylates NADH; also phosphorylates NAD(+) 
with lower specificity; required for the response to OS. 
YDR032C 
(PST2) 
Protein with similarity to members of a family of flavodoxin-like proteins; induced 
by OS in a Yap1p dependent manner; the authentic, non-tagged protein is detected 
in highly purified mitochondria in high-throughput studies. 
YHL028W 
(WSC4) 
 ER membrane protein involved in the translocation of soluble secretory proteins 
and insertion of membrane proteins into the ER membrane; may also have a role in 
the stress response but has only partial functional overlap with WSC1-3. 
YLL060C 
(GTT2) 
Glutathione S-transferase capable of homodimerization; functional overlap with 
Gtt2p, Grx1p, and Grx2p. 
YGL158W 
(RCK1) 
Protein kinase involved in the response to OS; identified as suppressor of S. pombe 
cell cycle checkpoint mutations. 
YOL049W 
(GSH2) 
Glutathione synthetase, catalyzes the ATP-dependent synthesis of glutathione 
(GSH) from gamma-glutamylcysteine and glycine; induced by OS and heat shock. 
YLL009C 
(COX17) 
Copper metallochaperone that transfers copper to Sco1p and Cox11p for eventual 
delivery to cytochrome c oxidase; contains twin cysteine-x9-cysteine motifs 
YDL190C 
(UFD2) 
Ubiquitin chain assembly factor (E4) that cooperates with a ubiquitin-activating 
enzyme (E1), a ubiquitin-conjugating enzyme (E2), and a ubiquitin protein ligase 
(E3) to conjugate ubiquitin to substrates; also functions as an E3. 
YJR104C 
(SOD1) 
 Cytosolic copper-zinc superoxide dismutase; some mutations are analogous to 
those that cause ALS (amyotrophic lateral sclerosis) in humans. 
YHR008C 
(SOD2) 
Mitochondrial superoxide dismutase, protects cells against oxygen toxicity. 
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Appendix 28. Immunofluorescence investigations of the ER (panel a and b) and the 
actin cytoskeleton (panel c and d) of PtK2 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
PtK2 cells were incubated with 17p in comparison with control cells. Treated cells show that the ER is affected 
in general (panel b) and Actin stress fibers are barely detectable (panel d). Adhesion seems to be reduced and 
cells become rounded and detached from each other. 
 
 
 
a)      b) 
                
 c)      d) 
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Appendix 29. Cell cycle analysis of MCF-7 breast cancer cells. 
 
a) 
 
b) 
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c) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
d) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MCF-7 cells were treated with 7p (panel a), 12p (panel b), 3u (panel c), and 9u (panel d) at their respective 
IC50s for 24 h. The diagrams show the distribution of the cells according to their DNA content. The inserts give 
the percentages of cells in different cell cycle phases. 
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Quantitative structure-activity relationship studies (QSAR) 
QSAR studies were performed in order to quantitatively correlate the chemical structure of 
the synthesized compounds to its biological activity (or chemical reactivity). The IC50 (µM)
 
values were converted into activities (log 1/C, where C is the IC50 in molar concentration) 
and used as dependent variables for the QSAR models. All the QSAR models were 
developed by multi-regression analyses (MRA) using the C-QSAR program.
1
 The details 
about this program can be found in earlier publications.
2,3
 Compounds were deemed to be an 
outlier on the basis of their deviation between the observed and predicted activities obtained 
from the individual QSAR model (obsd – pred > 2s, where s is the standard deviation).4 
QSARs were validated using statistical diagnostics and internal validation. In statistical 
diagnostics, QSARs were filtered through a number of specific conditions such as  (i) n/p ≥ 4 
(ii) r
2 
> 0.6 (iii) q
2 
> 0.5 (iv) F > F(lit) at 95% level (vi) high Q value, and (vii) low s value.
5,6
 
The internal validation was carried out using cross-validation and Y-randomization tests.
7,8
 
The poor values of r
2
 and q
2
 in Y-randomization tests (average of the five runs for QSARs; 
r
2
/q
2
: 0.406/-1.021, 0.422/-0.479, 0.259/-0.915, 0.738/0.401, and 0.188/-3.448) ensure the 
robustness of the QSAR models and also the lack of over fitting. Due to the small data sets, 
the external validation test was not performed. 
 
Refrences 
1. C-QSAR Program, BioByte Corp., 201W. 4th st., Suit 204, Claremont, USA. 2003, CA 
91711, www.biobyte.com. 
2. Hansch, C.; Hoekman, D.; Leo, A.; Weininger, D.; Selassie, C.D. Chem-Bioinformatics: 
Comparative QSAR at the interface between chemistry and biology. Chem. Rev. 2002, 
102, 783–812. 
3. Verma, R. P.; Hansch, C. Development of QSAR models using C-QSAR program: a 
regression program that has dual databases of over 21,000 QSAR models. Nat. Protoc. 
2007. 
4. Selassie, C. D.; Kapur, S.; Verma, R. P.; Rosario, M. Cellular apoptosis and cytotoxicity 
of phenolic compounds: a quantitative structure-activity relationship study. J. Med. 
Chem. 2005, 48, 7234–7242. 
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5. Bennett, C. A.; Franklin, N. L. Statistical Analysis in Chemistry and the Chemical 
Industry. John Wiley & Sons: New York. 1967; 708–709; 5th printing. 
6. Hansch, C.; Verma, R. P. 20-(S)-Camptothecin analogues as DNA Topoisomerase I 
inhibitors: A QSAR study. Chem. Med. Chem. 2007, 2, 1807-1813. 
7. Tropsha, A.; Gramatica, P.; Gombar, V. K. The importance of being earnest: Validation 
is the absolute essential for successful application and interpretation of QSPR models. 
QSAR Comb. Sci. 2003, 22, 69–77. 
8. Wold, S.; Eriksson, L. Statistical validation of QSAR results. Validation tools. In: van de 
Waterbeemd H., editor. Chemometrics Methods in Molecular Design (Methods and 
Principles in Medicinal Chemistry, Vol 2). Weinheim, Germany: VCH, 1995; 309–318. 
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Appendix  30.Terms and abbreviations used as in the development of QSAR models 
Abbreviations Details 
QSAR Quantitative structure activity relationship 
Activity log1/C, where C is the IC50 in molar concentration 
MRA Multi-regression analyses 
n Number of data points 
r
2
 Square of the correlation coefficient 
q
2
 Cross-validated r
2
 
s Standard deviation 
Q Quality factor 
F Fischer ratio 
Pow, Experimental partition coefficient of the compound in 
octanol-water system 
logPow Measure of hydrophobicity 
HBA Number of hydrogen bond acceptors 
NOR  Number of rings 
RC Number of redox centres 
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Appendix 20. Biological, Physicochemical, and structural parameters used to derive 
QSARs 1-5. 
Cpd. 
Nr. 
log 1/C (QSAR 
1) 
log 1/C (QSAR 
2) 
log 1/C (QSAR 
3) 
log 1/C (QSAR 
4) 
log 1/C (QSAR 
5) log Pow HBA NOR RC 
Obsd. Pred. Obsd. Pred. Obsd. Pred. Obsd. Pred. Obsd. Pred. 
1p 4.34 4.33 NA 5.48 NA 5.35 4.64 4.39 4.72a 4.32 4.50 6 3 3 
2p 4.60a 5.03 NA 5.48 4.90a 5.35 4.22a 5.23 4.33 4.32 1.94 6 3 3 
3p 4.85 4.86 NA 5.29 NA 5.23 4.49 4.74 4.15a 5.11 3.42 8 4 3 
4p 5.34 5.27 5.34 5.29 5.81a 5.23 5.81 5.61 NA 5.11 1.92 8 4 4 
5p 4.58 4.84 NA 5.29 NA 5.23 4.63 4.72 4.54a 5.11 3.50 8 4 3 
6p 4.90 5.06 5.20 5.11 5.13 5.11 5.06 5.06 5.20 5.17 3.60 10 5 4 
7p 5.29 5.03 5.07 5.11 5.46 5.47 5.29a 4.28 4.92 5.17 3.70 10 2 2 
8p 5.36 5.38 5.14 5.20 5.54 5.47 5.54 5.58 5.23 5.23 1.99 9 2 4 
9p 5.16 5.27 5.16a 4.92 5.26 5.35 4.32 4.28 4.43 4.50 3.70 12 3 2 
10p 5.24 5.15 5.00 5.01 5.15a 5.35 4.29 4.28 5.07 4.92 3.70 11 3 2 
11p 5.01 5.03 4.80a 5.11 5.31 5.35 4.91 5.03 5.31 5.17 3.70 10 3 4 
12p 4.92 4.79 5.28 5.29 5.28 5.23 5.40a 4.65 5.10 5.11 3.70 8 4 3 
a
Not included in the derivation of QSAR models; C = IC50 [mol/l] 
 
Appendix 19. QSAR models for the multifunctional redox compounds on the viability and 
proliferation of human cancer cell lines and primary human endothelium cell lines. 
QSAR 
Nr. 
Cell lines QSAR Models [C = IC50 (mol/L)] 
 
Statistics Outliers 
(Cpd.Nr.) 
n r2 q2 s Q F 
1 MCF-7 log 1/C = – 0.27(±0.15)log Pow + 0.12(±0.07)HBA + 
4.84(±0.81)        
11 0.808 0.715 0.159 5.654 16.834 2p 
2 A-498 log 1/C = – 0.09(±0.07)HBA + 6.04(±0.64) 6 0.783 0.603 0.066 13.409 14.433 9p and 11p 
3 A-431 log 1/C = – 0.12(±0.07)NOR + 5.70(±0.22) 6 0.855 0.727 0.063 14.682 23.586 2p, 4p  and  
10p 
4 HUVEC log 1/C = – 0.33(±0.22)log Pow + 0.37(±0.22)RC + 
4.74(±1.25) 
9 0.913 0.798 0.182 5.247 31.483 2p, 7p  and  
12p 
5 HF log 1/C = 1.68(±0.69)HBA – 0.09(±0.04)HBA2 – 
2.45(±3.03) 
Optimum HBA = 9.16(8.73-9.68) 
8 0.887 0.738 0.147 6.408 19.624 1p, 3p  and  
5p 
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Appendix 21. High resolution mass, 
1
HNMR, 
13
C NMR and 
13
C DEPT-135 spectra of 
novel compounds. 
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Compound 1p 
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Compound2p
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Compound 3p 
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Compound 4p 
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.4
5
5
3
5
.0
4
3
3
1
.0
7
6
3
0
.0
2
5
2
8
.8
4
4
1
5
.3
0
1
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Compound 2u 
 
Appendix 
199 
 
ppm (t1)
0255075100125150175
182.103
181.169
172.092
168.702
159.286
146.986
146.396
134.915
133.599
133.298
132.705
132.656
132.563
131.940
129.945
129.064
128.648
126.872
126.697
126.507
114.954
114.312
77.254
77.000
76.746
55.395
54.403
39.298
35.025
29.992
29.815
24.819
15.276
 
ppm (t1)
0255075100125
1
3
3
.6
0
2
1
3
3
.2
9
9
1
3
2
.5
6
3
1
2
9
.0
6
5
1
2
8
.6
4
9
1
2
6
.8
7
3
1
2
6
.6
9
7
1
2
6
.5
0
8
1
1
4
.9
5
4
5
5
.3
9
5
5
4
.4
0
2
3
9
.2
9
6
3
5
.0
2
3
2
9
.9
9
1
2
9
.8
1
4
2
4
.8
1
9
1
5
.2
7
7
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Compound 3u 
 
Appendix 
201 
 
ppm (t1)
0255075100125150175200
182.152
181.219
172.130
168.732
159.329
147.037
138.434
134.939
133.646
133.343
132.746
131.984
129.239
128.677
127.696
126.746
126.558
114.997
111.483
77.274
77.020
76.766
55.438
54.455
41.190
35.061
31.566
30.037
15.335
4.806
 
ppm (t1)
0255075100125
1
3
8
.4
3
4
1
3
3
.6
4
8
1
3
3
.3
4
5
1
2
9
.2
4
0
1
2
8
.6
7
9
1
2
7
.6
9
7
1
2
6
.7
4
8
1
2
6
.5
5
9
1
1
4
.9
9
8
5
5
.4
3
9
5
4
.4
5
5
4
1
.1
9
0
3
5
.0
6
0
3
1
.5
6
6
3
0
.0
3
6
1
5
.3
3
6
4
.8
0
5
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Compound4u
 
Appendix 
203 
 
ppm (t1)
255075100125150175
170.139
168.191
159.399
155.851
136.007
133.468
128.830
128.698
128.548
125.721
114.952
79.453
77.255
77.000
76.745
55.257
53.719
53.281
42.807
38.233
30.706
28.620
28.088
 
ppm (t1)
255075100125
1
2
8
.8
2
6
1
2
8
.6
9
9
1
2
8
.5
4
9
1
2
5
.7
2
1
1
1
4
.9
5
1
5
5
.2
5
7
5
3
.7
1
5
4
2
.8
0
5
3
8
.2
3
1
3
0
.7
0
1
2
8
.6
1
5
2
8
.0
8
5
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Compound 5u 
 
ppm (t1)
1.502.002.503.003.504.004.505.005.506.006.507.007.50
2
.0
0
4
.8
9
1
.8
7
1
.1
0
0
.8
7
1
.9
4
3
.2
9
1
.9
1
2
.1
1
2
.0
5
2
.1
3
8
.9
0
 
Appendix 
205 
 
ppm (t1)
255075100125150
1
7
0
.1
8
6
1
6
8
.2
1
4
1
5
9
.5
2
9
1
5
5
.8
8
5
1
3
3
.5
2
4
1
3
2
.3
9
9
1
2
9
.8
9
7
1
2
8
.9
5
9
1
2
8
.6
1
5
1
2
6
.7
4
3
1
1
5
.0
7
8
7
9
.5
9
5
7
7
.2
5
5
7
7
.0
0
0
7
6
.7
4
5
5
5
.3
7
4
5
3
.9
1
9
5
3
.3
2
7
4
2
.9
1
2
3
9
.2
2
2
2
9
.6
9
8
2
8
.1
8
4
2
4
.6
8
6
 
ppm (t1)
255075100125
1
3
2
.3
9
8
1
2
8
.9
6
0
1
2
8
.6
1
6
1
2
6
.7
4
4
1
1
5
.0
7
7
5
5
.3
7
5
5
3
.9
1
5
4
2
.9
0
9
3
9
.2
1
9
2
9
.6
9
6
2
8
.1
8
1
2
4
.6
8
4
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Compound 6u 
 
 
Appendix 
207 
 
ppm (t1)
0255075100125150
170.255
168.305
159.728
138.463
133.591
129.239
128.686
127.710
115.268
111.471
79.809
77.254
77.000
76.746
55.525
54.233
43.058
41.226
31.528
28.310
4.756
 
ppm (t1)
0255075100125
1
3
8
.4
6
3
1
2
9
.2
4
0
1
2
8
.6
8
7
1
2
7
.7
1
1
1
1
5
.2
6
7
5
5
.5
2
5
5
4
.2
3
0
4
3
.0
5
6
4
1
.2
2
5
3
1
.5
2
6
2
8
.3
0
8
4
.7
5
5
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Compound7u
 
ppm (t1)
2.002.503.003.504.004.505.005.506.006.507.007.50
4
.0
0
3
.0
9
2
.2
3
2
.0
9
3
.1
8
2
.1
2
3
.2
5
2
.1
6
2
.1
7
2
.1
1
 
Appendix 
209 
 
ppm (t1)
255075100125150175
171.502
169.185
158.534
136.706
136.304
135.096
130.266
129.529
129.159
129.065
128.532
128.051
126.287
114.712
77.507
77.254
77.000
55.577
38.632
31.327
29.073
 
ppm (t1)
255075100125
1
3
0
.2
6
7
1
2
9
.5
2
9
1
2
9
.1
5
9
1
2
9
.0
6
5
1
2
8
.5
3
2
1
2
8
.0
5
2
1
2
6
.2
8
8
1
1
4
.7
1
2
5
5
.5
7
7
3
8
.6
3
1
3
1
.3
2
4
2
9
.0
7
2
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Compound 8u 
 
ppm (t1)
2.002.503.003.504.004.505.005.506.006.507.007.50
2
.0
0
4
.1
8
2
.0
0
1
.9
7
1
.9
1
1
.9
2
2
.0
3
3
.3
1
2
.1
0
2
.1
6
2
.3
1
 
Appendix 
211 
 
ppm (t1)
255075100125150175
171.232
168.890
158.272
136.452
134.851
132.643
130.005
129.867
129.065
128.800
128.279
127.794
126.895
114.445
77.254
77.000
76.746
55.322
55.291
39.240
29.788
24.790
 
ppm (t1)
255075100125
1
3
2
.6
4
3
1
3
0
.0
0
6
1
2
9
.0
6
6
1
2
8
.8
0
1
1
2
8
.2
8
0
1
2
7
.7
9
6
1
2
6
.8
9
5
1
1
4
.4
4
5
5
5
.3
2
2
5
5
.2
8
8
3
9
.2
3
8
2
9
.7
8
7
2
4
.7
8
9
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Compound 9u 
 
 
Appendix 
213 
 
ppm (t1)
255075100125150175
171.245
168.907
158.305
138.489
136.464
134.862
130.045
129.226
128.830
128.282
127.825
127.699
114.980
114.483
114.343
111.367
77.254
77.000
76.746
76.653
55.728
55.356
41.115
31.526
4.682
4.630
 
ppm (t1)
0255075100125
1
3
8
.4
9
0
1
3
0
.0
4
5
1
2
9
.2
2
8
1
2
8
.8
3
1
1
2
8
.2
8
2
1
2
7
.8
2
6
1
2
7
.7
0
0
1
1
4
.4
8
3
5
5
.3
5
5
4
1
.1
1
4
3
1
.5
2
4
4
.6
8
0
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Compound 10u 
 
ppm (t1)
2.002.503.003.504.004.505.005.506.006.507.007.50
1
.0
0
1
1
.2
8
3
.0
9
1
.0
0
1
.9
8
3
.0
6
2
.0
5
2
.0
1
2
.0
7
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ppm (t1)
255075100125150
169.025
167.113
159.122
142.924
136.086
134.878
134.743
129.788
129.135
128.831
128.757
128.648
127.912
125.909
117.709
114.843
77.254
77.000
76.746
55.430
54.722
38.341
31.001
28.824
 
ppm (t1)
255075100125
1
4
2
.9
2
6
1
2
9
.7
9
1
1
2
9
.1
3
2
1
2
8
.8
3
1
1
2
8
.7
5
7
1
2
8
.6
4
9
1
2
7
.9
1
2
1
2
5
.9
0
9
1
1
7
.7
0
7
1
1
4
.8
4
3
5
5
.4
3
0
5
4
.7
2
0
3
8
.3
4
0
3
0
.9
9
6
2
8
.8
1
9
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Compound 11u 
 
ppm (t1)
2.002.503.003.504.004.505.005.506.006.507.007.50
1
.0
3
2
.0
0
9
.5
4
1
.0
1
3
.1
4
2
.0
0
3
.1
0
2
.0
6
2
.0
7
2
.3
7
 
Appendix 
217 
 
ppm (t1)
255075100125
142.970
132.568
129.825
129.026
128.769
128.682
127.940
126.828
117.720
114.878
55.465
54.786
39.223
29.827
24.783
ppm (t1)
255075100125150
1
6
9
.0
3
4
1
6
7
.1
4
8
1
5
9
.1
5
7
1
4
2
.9
6
9
1
3
4
.8
9
0
1
3
4
.7
7
0
1
3
2
.5
6
8
1
2
9
.9
1
4
1
2
9
.8
2
3
1
2
9
.0
2
5
1
2
8
.7
6
8
1
2
8
.6
8
1
1
2
7
.9
3
9
1
2
6
.8
2
6
1
1
7
.7
2
2
1
1
4
.8
7
8
7
7
.2
5
4
7
7
.0
0
0
7
6
.7
4
6
5
5
.4
6
5
5
4
.7
8
7
3
9
.2
2
5
2
9
.8
2
9
2
4
.7
8
5
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Compound 12u 
 
 
Appendix 
219 
 
ppm (t1)
255075100125150
169.309
167.429
159.434
143.256
138.653
135.142
135.037
130.104
129.433
129.030
128.955
128.214
127.882
117.975
115.156
111.666
77.508
77.254
77.000
55.744
55.067
41.339
31.793
4.959
 
ppm (t1)
0255075100125150
1
4
3
.2
5
7
1
3
8
.6
5
4
1
3
0
.1
0
5
1
2
9
.4
3
5
1
2
9
.0
3
1
1
2
8
.9
5
5
1
2
8
.2
1
7
1
2
7
.8
8
3
1
1
7
.9
7
5
1
1
5
.1
5
6
5
5
.7
4
4
5
5
.0
6
6
4
1
.3
3
7
3
1
.7
9
1
4
.9
5
8
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Compound 13u 
ppm (t1)
2.002.503.003.504.004.505.005.506.006.507.007.50
2
.0
0
2
.9
9
4
.9
6
3
.8
4
1
.0
2
1
.9
3
2
.9
7
2
.1
5
2
.0
4
2
.1
4
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221 
 
ppm (t1)
5075100125150
168.159
159.444
155.337
136.033
134.814
132.514
130.211
129.300
128.986
128.925
128.360
126.037
120.035
114.401
92.693
81.968
77.254
77.000
76.746
55.536
53.631
38.517
31.092
28.796
 
ppm (t1)
255075100125
1
3
2
.5
1
5
1
3
0
.2
1
3
1
2
9
.2
9
9
1
2
8
.9
8
6
1
2
8
.9
2
7
1
2
8
.3
6
0
1
2
6
.0
3
7
1
1
4
.4
0
1
5
5
.5
3
5
5
3
.6
2
9
3
8
.5
1
6
3
1
.0
8
7
2
8
.7
9
2
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Compound 14u 
 
ppm (t1)
2.002.503.003.504.004.505.005.506.006.507.007.50
2
.0
0
2
.9
4
2
.0
4
1
.0
0
1
.8
6
5
.0
7
1
.9
2
3
.0
8
2
.1
1
2
.1
3
2
.1
5
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ppm (t1)
255075100125150
159.413
155.287
134.801
132.620
132.487
130.187
129.875
129.066
128.986
128.343
126.872
120.018
114.364
92.632
81.974
77.254
77.000
76.746
55.517
53.545
39.344
29.764
24.779
 
ppm (t1)
255075100125
1
3
2
.6
2
1
1
3
2
.4
8
8
1
3
0
.1
8
9
1
2
9
.0
6
8
1
2
8
.9
8
8
1
2
8
.3
4
4
1
2
6
.8
7
3
1
1
4
.3
6
4
5
5
.5
1
6
5
3
.5
4
4
3
9
.3
4
1
2
9
.7
6
2
2
4
.7
7
7
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Compound 15u 
 
Appendix 
225 
 
ppm (t1)
255075100125150175
171.213
167.905
158.702
143.432
136.743
134.924
133.788
128.719
127.065
119.247
114.561
56.113
55.572
51.520
28.884
 
ppm (t1)
255075100125
1
3
3
.7
9
0
1
2
8
.7
1
6
1
2
7
.0
6
9
1
1
4
.5
6
3
5
6
.1
0
8
5
5
.5
7
0
2
8
.8
8
4
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Compound 3c 
 
 
Appendix 
227 
 
ppm (t1)
255075100125150
156.617
134.694
129.454
128.765
126.227
39.694
29.953
28.022
 
ppm (t1)
255075100125
1
2
9
.4
5
3
1
2
8
.7
6
8
1
2
6
.2
2
7
3
9
.6
9
3
2
9
.9
4
9
2
8
.0
2
0
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Compound 3d 
 
 
Appendix 
229 
 
ppm (t1)
5075100125150
161.170
133.128
132.883
129.252
129.158
127.133
77.254
77.000
76.746
37.932
29.800
24.839
 
ppm (t1)
255075100125
1
3
2
.8
8
4
1
2
9
.1
5
8
1
2
7
.1
3
3
3
7
.9
3
1
2
9
.7
9
8
2
9
.6
7
5
2
4
.8
3
8
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Compound 3e 
 
 
Appendix 
231 
 
 
ppm (t1)
0255075100125
1
3
8
.7
8
0
1
2
9
.4
4
2
1
2
8
.1
1
9
4
3
.2
0
8
4
3
.1
5
6
3
1
.0
0
7
3
.6
5
3
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